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Hypertension and other risk factors in peripheral arterial disease
(PAD). Study of 403 cases. R. MarIn, F. Fernández-J/ega, P. Escalada, E.
Gómez, J.M Estevan, and J. Alvarez, Hypertension Unit, Division of
Nephrology, Covadonga Hospital, Oviedo, Spain. Among the clinical man-
ifestations of atherosclerosis, PAD has received the least attention;
however, it's a strong predictor of subsequent mortality. Methods: Vascu-
lar risk factors and other associated cardiovascular diseases (coronary
artery disease and stroke) were evaluated by means of univariate analysis
and multiple logistic regression in a group of 403 patients (321 men and 82
women; mean ages 65.4 12 and 72.6 12 years, respectively), with
clinically and angiographically demonstrated EAP. All patients needed
hospitalization and were studied in the period from January 1st to
December 31st, 1991. The control group consisted 126 age- and sex-
matched individuals. Results: By univariate analysis in men, the prevalent
risk factors were cigarette smoking (51% of smokers vs. 31% in control
group, P < 0.001), diabetes mellitus (27% vs. 7%, P < 0.001), total
cholesterol (214 48 vs. 196 45, P < 0.01) and age. They remained
significant after multiple logistic regression. In women, only smoking (10%
vs. 0%, P < 0.05) and diabetes were found highly significant and
independent in relation with PAD. The prevalence of arterial hyperten-
sion was similar to control group for both sexes. Stroke and coronary
artery disease was more frequent in the case group, but had statistical
significance only in men. Smoking and hypercholesterolemia were the risk
factors associated in 58 patients with abdominal aortic aneurysm (AAA).
Neither hypertension nor diabetes could be related with AAA. Conclu-
sions: PAD afflicts mainly older men, who also have another associated
cardiovascular pathology. PAD isn't related to arterial hypertension.
Smoking and diabetes mellitus are the most important risk factors,
together with total serum cholesterol in males.
Hypertension in pregnancy: New clinical features. R. Manmn, E. Gonzd-
lez, P. Escalada, A. Lernos, F. Fernández-Vega, andJ. Alvarez, Hypertension
Unit, Division of Nephrology, Covadonga Hospital, Oviedo, Spain. Objec-
tives: To study 267 pregnant women with hypertension recently reviewed
(1983—1990) and compare the results with those obtained in a similar
group of 319 hypertensive pregnant women previously studied (1973—
1982). Methods: From 1983 to 1990, 267 pregnant women with hyperten-
sion were admitted to our hospital. Sixty-five were diagnosed as pre-
eclampsia (PCP), 57 as gestational hypertension (GH), 53 as chronic
hypertension (CH), 5 as eclampsia, and 87 were unclassifiable. The
following parameters were analyzed: age, mean blood pressure (MBP),
hematocrit, platelet count, creatinine and uric acid levels, antihypertensive
drugs used, early labor percentage, number of Caesarean births, newborn
weight, and fetal mortality. Results: The CH group showed the highest age
(33.6 7 years), multiparity (76%), the earliest hypertension diagnosis
and higher MBP than that of all cases (122 13 vs. 116 13,P < 0.01).
The PCP group showed the highest creatinine (0.8 0.2 vs. 0.7 0.1
mgjdl in CH and OH, P < 0.05) and uric acid levels (6.7 2.3 vs. 4.5
2.1 and 4.9 1.4 mg/dl, in CH and GH, respectively, P < 0.001).
Ninety-eight (40%) patients received antihypertensive drugs; they were
cases with GH the least treated (18 vs. 45 and 75%, PCP and GH
respectively, P < 0.001). The Caesarean rate was high (77%), especially in
PCP (91%, P < 0.001). Newborn weight was also lower in PCP. Overall
fetal mortality was 4.1%, being the highest in eclampsia (20%) and CH
complicated with PCP (20%). No maternal mortality was observed. When
comparing the results from both periods, we observed in the most recent
a decrease in eclampsia prevalence (2 vs. 10%, P < 0.001) and fetal
mortality (4.1% vs. 9.4%, P < 0.05), as well as an increase in the
Caesarean rate (77% vs. 38%, P < 0.001) and prevalence of CH.
Conclusions: (1) Hypertension in pregnancy remains an important cause
of fetal morbidity and mortality. (2) GH represents a benign condition of
pregnancy hypertension. (3) Fetal mortality and eclampsia incidence have
dramatically decreased in the last years. (4) Caesarean section has become
the most common method of ending hypertension-complicated pregnan-
cies.
Na/Li contratransport is a good marker of hypertension in IDDM
patients. f.M Mallafré, MA. Ortiz, LA. Oliva, J. CaniO, and J.M. Pou, Dept.
of Nephrology Hospital Creu Roja, and Dept. of Endocrinology, Hospital
Sant Pau, Barcelona, Spain. Hypertension is one of the major problems in
the development of diabetic nephropathy in IDDM patients. Markers of
risk factors are important tools for preventing nephropathy in patients
who can develop idiopathic hypertension. We studied 20 IDDM patients
(14 microalbuminuric and 6 macroalbuminuric), all of whom were nor-
motensive. Microalbuminuria, basal and stimulated plasma renin, plasma
and urinary aldosterone were measured and correlated with Na/Li con-
tratransport. Contratransport was determined in packed erythrocytes after
incubation with Li for 3 hours and reincubation in medium with and
without Na plus ouabain. Na/Li contratransport did not correlate with
renin, plasma and urinary aldosterone at basal and after stimulation.
Levels of in the controls contratransport were: 92.18 33.3; microalbu-
minuric group: 153.33 40.5; and macroalbuminuric group: 241.66 46.1
.tmol packed erythrocytes (N = 1). Na/Li contratransport was higher in
microalbuminuric IDDM patients than in controls (P < 0.0032) and in
macroalbuminuric patients was more significant than in microalbuminuric
(P < 0.004). Conclusion: Na/Li contratransport is a good marker of risk
factors in diabetic nephropathy, but not of risk factors of idiopathic
hypertension in normotensive microalbuminuric and macroalbuminuric
IDDM patients.
Effects of the HTA over the glomerular-tubular condition. J.A. Oliva, L.
Vives, J. Carrió, R. Lafuente, and f.M. Mallafre Dept. of Nephrology and
Dept. of Laboratory, Hospital Creu Roja, Barcelona, Spain. The renal
damage to the HTA is a demonstrable fact. We studied the possible
relationship between the rate and duration of the HTA and the beginning
of the glomerular and/or tubular damage. We determined the presence of
proteinuria (PN; NV < 0.10 g/24 hr) and the localization of glomerular
(GP, microalbuminuria) and tubular (TP; a1 microglobulin, 12 micro-
globulin and light chain, Lambda-Kappa free) damage in 33 patients, with
essential HTA (slight to moderate) without treatment or other associated
pathologies. The patients are classified in four groups: Group A: GP/TP
negative, 14 patients, 10 females and 4 males, aged 38—68 years (X = 56.7
8.8), HTA with 2—17 months (X = 9.78 4.3). All the patients are
classified with slight HTA; the PN levels were <0.10 g124 hr and the
creatinine levels were < 1.2mgIlOO ml. Group B: GP+TP—, 4 patients, 3
females and 1 male, aged 51—62 years (X = 57.2 4.5), HTA 60—120
months (X = 90.2 15.7). All the patients showed slight HTA and
creatinine levels below 1.2. In one patient we detected PN 0.7 g/24 hr.
Group C: OP—/TP+, 5 patients, 3 females and 2 males, aged 51—67 years
(X = 57.2 6.4), HTA 10—20 months (X = 13.2 4.1). In all the patients
we observed moderate HTA, PN < 0.10 and creatinine levels below 1.2.
Group D: GP+/TP+, 10 patients, 4 females and 6 males, aged 53—86 years
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(X = 69.0 11.5), HTA 48—360 months (X = 164.4 98.6). We detected
moderate HTA in 6/10 patients, PT >0.10 in 7/10 patients (0.4—2.8 g/24
hr; X = 1.28 0.7), and creatinine >1.2 in 9/10 patients (1.3—4.9; X = 2.9
1.3). We detected significant differences (P <0.05) between Group D
and the others groups. Conclusions: The long duration of the HTA is
responsible for the glomerular proteinuria, and the severity of the HTA is
in relation with the tubular proteinuria. The combination of these factors
is responsible for the renal disease. The absence of proteinuria does not
exclude the glomerular or tubular specific affectation.
Left ventricular hypertrophy (LVII) in essential arterial hypertension
(EHT): Possible involvement of hyperinsulinism. L. Orte, C. Quereda, M
Bermejo, J. Sabater, J. Pascual, M Rivera, J.J. Villafruela, and J. Ortuño,
Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain. LVH is a
known visceral marker and prognostic factor in EHT. Multifactorial and
controversial in origin, its development is mediated by growth and
hormonal factors, arterial blood pressure per Se, and recently implicated
are metabolic factors like hyperinsulinism and peripheral insulin resis-
tance. We evaluated in 203 EHT patients, prospectively studied in our
outpatient clinic, the possible relationship between LVH, defined by strict
ECG criteria, routine clinico-analytical parameters (age, sex, systolic and
diastolic blood pressure, heart rate, known evolution time of HT, body
mass index, lipids and antihypertensive treatment), and plasma insulin and
glucose levels after a 75 g oral glucose test. We detected 42 hypertensive
patients with LVH (24%). Similar in blood pressure levels and percent
distribution according to glucose tolerance test, they were less obese than
those without LVH (37% vs. 19%; P <
.05). Fasting insulinemia was
paradoxically lower (12.4 1.1 vs. 16.8 1.1 1tU/ml; P < .01) without
statistical differences at 120 minutes. Previous treatment with CEI bears a
lesser incidence of LVH (P <
.05). We did not find differences in the other
parameters analyzed. In our experience, LVH—defined by ECG crite-
ria—does not have a direct correlation with easily detected clinico-
analytical parameters used in the routine clinical evaluation of outpatient
EHT, including hyperinsulinemia.
Antihypertensive effects of acidic fibroblast growth factor in spontane-
ously hypertensive rats (SHR). L. Orte, P. Cuevas, F. Carceller, G.
Gimenez-Gallego, B. Cuevas, I. Muñoz, and J. Ortuño, Departments of
Nephrology and Histology, Hospital Ramón y Cajal, CSIC, Madrid, Spain.
Fibroblast growth factors (FGFs) are a group of several polypeptides,
extensively distributed in the organism and endothelium expressed, with
broad-spectrum functions in vitro. A growing body of experimental data
suggests that FGFs have non-mitogenic functions in several organs and
tissues. Recently, we have demonstrated that systemic administration of
FGFs in vivo decreased mean arterial blood pressure (MAP) in normo-
tensive experimental animals; this finding promoted our interest to
investigate its acute and long-term effects on SHR. We injected acidic
FGF, as a single iv. bolus (1 sg in 50 1id PBS, 0.1% Heparin), into adult
SHR (N = 30; mean weight 250 g), through right jugular vein; control
SHR group (N = 10) received only 50 .d of vehicle solution. We registered
immediate MAP, directly obtained by means of a femoral catheter
connected to a pressure transducer (acute experiment; anesthetized
animals); in the same conscious rats, on standard feeding and free access
to water, we determined in the next 10 days (long-term experiment)
indirect MAP (mean of three readings; cuff-tail method). All treated
animals with acidic FGF showed in the acute experiment a rapid decrease
in MAP (basal: 190 12.6 mm Hg; immediate post-bolus: 159.3 12.3
mm Hg; P <
.001), maintained throughout 2 days (26.6 4 mm Hg), and
followed by a slow recovery (9% SHR with MAP below basal values at
tenth day). We did not observe changes in control SHR. Acidic FGFs,
administered as intravenous bolus, induce in spontaneously hypertensive
rats a rapid and maintained MAP decrease. Present evidence suggests that
FGFs are potent antihypertensive peptides with a long-term action, and
their study opens new expectations in the knowledge of arterial hyperten-
sion pathogenia and treatment.
Hyperinsulinism in the young adult essential arterial hypertension
(HTAE). L. Orte, C. Quereda, M. Bermejo, J.J. J/illafruela, J. Pascual, M.
Rivera, J. Sabater, and J. Ortuno, Nephrology Department, Hospital Ramón
y Cajal, Madrid, Spain. Hyperinsulinism and insulin resistance are deter-
minant factors in HTAE. Their real incidence and clinical significance in
HTAE subpopulations are still to be defined, and they are the aim of our
study in the young adult. We analyzed the possible relationship of all
routine clinico-analytical parameters larterial blood pressure (BP) and
heart rate, body mass index (BMI), lipids, left ventricular hypertrophy and
hypertensive treatment], with the plasma insulin and glucose response to
75 g oral glucose overload, in 36 mild HTAE patients (BP = 143 3.2/96
2.1 mm Hg), treated or not, with age range between 18—40 years, and
a short evolution time of known HTA (x = 4.5 months). All data were
compared with those obtained from a normotensive control group (N =
30; BP = 109 2.4/68 1.9 mm Hg), with identical age and sex
distribution. Hypertensive patients, with a greater incidence of obesity (48
vs. 22%; P <
.05), and a distribution attending to glucose tolerance test
similar to controls (intolerance or diabetic curve, 11 vs. 9%, respectively;
NS), had fasting (15.7 2 vs. 10.2 0.6 ltU/ml; P < 0.05) and 120 minutes
(64.6 7.9 vs. 29.1 3.6 sU/ml; P < .001) insulin levels significantly
elevated with respect to normotensive ones, with a direct correlation with
BMI (r = 0.38). Only previous treatment with converting enzyme inhibi-
tors (CEI) was associated with lower basal insulin levels (8.04 1.6 vs.
18.4 2.9 LU/ml; P < 0.01), and the metabolic effect was not detected
with other drugs. We did not observe significant findings in other
comparisons. Hyperinsulinism is already present in the young adult with
essential and short evolution hypertension. Its ethiopathogenic and prog-
nostic significance are still to be defined. The correlation with obesity and
improvement with CEI would recommend weight loss and priority in the
use of these drugs in the management of this group of hypertensive
patients.
Von Recldinghausen disease (YRD) and hypertension: presence of
renal vascular lesions. L. Carreras, H. Rama, R. Poveda, R. Garcia-Osuna,
J.M. Cruzado, X Sarrias, A.M Amenós, and M Can-era, Servicios de
Nefrologla y Anatomla Patológica, Hospital de Bellvitge, Barcelona, Spain.
Hypertension in association with VRD has been related to great vessel
stenosis or pheochromocytoma. We have studied a group of 31 patients
diagnosed with VRD. Ten of them were hypertensive: 5 males and 5
females aged 12 to 60 (mean age 34). In seven, large vessel lesions were
found: coarctation of the aorta, 1 case; coarctation of the aorta and renal
artery stenosis (uni- or bilateral), 3 cases; and renal artery stenosis
(unilateral), 3 cases. In two patients renal biopsy was performed during
surgical revascularization showing small-sized vascular lesions. We found
the three histologic patterns previously described: intimal, aneurismatic
and nodular lesions. Interestingly enough, unlike previous reports, we
have found the coexistence of the three kinds of lesions in the same biopsy
specimen. After revascularization, both biopsied patients remain hyper-
tensive. In conclusion, microscopic renal vascular lesions can be found in
association with great vessel stenosis in VRD. Their presence could
explain the persistence of hypertension that is observed in some cases after
revascularization or dilation procedures.
Prevalence and characteristics of resistant hypertension (RH) in the
hospital environment. F. Fernandez-Vega, R. Mann, P. Escalada, E.
Gómez, and J. Alvarez-Grande, Hypertension Unit, Division of Nephrology,
Covadonga Hospital, Oviedo, Asturias, Spain. True RH (TRH), (that is,
hypertension without cause which cannot be corrected and with difficult
control despite the adequate dietary and pharmacological measures
taken) does not happen very often. It is, however, troublesome in essential
hypertension (EH). Methods: Out of 1,013 patients with EH examined in
our unit for 12 consecutive months, 40 (4%) fulfilled the following
requirements: age <60, followed for at least a year and treated with three
or more antihypertensive drugs (one of them diuretic) at adequate dosage
for a minimum of six months. Twenty-seven (67%) of them had their
casual blood pressure (CBP) persistently >160/95 mm Hg and were
catalogued as RH and represented the problem group (P). CBP in the
other 13 patients (33%) was adequately controlled and they were known
as the control group (C). In both groups the blood pressure (BP) was
studied by 24 hour ambulatory monitoring (BPAM, Spacelab 92020), a day
time average <135/85 was considered as normal. Besides, we performed
an Oster's maneuver and a survey on the dietetic and therapeutic
compliance. We analyzed as well the body mass index (BMI, weight/size
2), metabolic profile (cholesterol, HDL, triglycerides, glucose) and car-
diovascular complications (coronary heart disease, cerebrovascular acci-
dent, cardiac failure and peripheral arterial disease). Results: Out of the
27 in group P, 6 (22%) had normal BP measured with BPAM. In the other
21(78%) there was no dietetic and/or pharmacological compliance: two
admitted they had not taken the drugs regularly; one had been taking over
60 g alcohol/day and 11 were obese (BMI >28). For the other 7, the
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noncompliance was multiple. P and C were homogeneous in age (57 6
vs. 55 10), sex, smoking and alcoholic habits and presence of hypertro-
phy of the left ventricle. In group P the BMI was higher (P < 0.01) and the
therapeutic compliance lower (P < 0.001). Moreover, in this group the
prevalence of the cardiovascular complications globally considered was
higher (P = 0.002). Conclusions: TRH does not exist among our popula-
tion. Dietetic noncompliance is the major cause of false RH. At least one
out of five cases of false RH can be detected by BPAM.
Ambulatory blood pressure monitoring (ABPM) in chronic renal
failure secondary to chronic glomerulonephritis (GN) or chronic inter-
stitial nephritis (IN). J. Herrera, V. Peral, C. Rodriguez, P. Vidau, and R.
Tome, Servicio de Nefrologia, Hospital General de Asturias, Oviedo, Spain.
ABMP in chronic renal failure shows an absence or attenuation in the
nocturnal blood pressure (BP) decline, probably related to a permanent
sympathetic overactivity that has been described in these patients. Con-
sequently, this may have important clinical significance. If BP remains high
during the night, adjustments in dosage or frequency of administration of
antihypertensive drugs might be required. In order to assess differences in
BP, cardiac rhythm and nocturnal BP drop, between patients with chronic
GN and chronic IN, 32 patients on chronic hemodialysis (HD) were
studied. In 21 of them (13 men, 8 women, mean age 40 12 years, mean
on dialysis time 84 41 months) histological diagnosis was chronic GN. In
11 patients (4 men, 7 women, mean age 46 16 years, mean on dialysis
time 71 43 months), the diagnosis by clinical, radiological and/or
histological criteria was chronic IN. BP was recorded non-invasively using
a Spacelabs 90202 oscillometric BP monitor. Measurements were started
at the end of the HD session and continued during the first 24 hours of










SBP 138 30 137 28C 139 33
DBP 84 20 84 20 83 21'
HR 82 18b 83 20C 80 13b
IN
SBP 133 2P' 133 16 134 23b
DBP 75 16 76 14 74 16a
HR 14b 80 15C 7 11b
Abbreviations are: SBP, systolic BP; DBP, diastolic BP; HR,
By Student's t-test: a P < 0.001; b P < 0.01; P < 0.05.
heart rate.
Conclusions: Patients with chronic GN showed a statistically significant
increase in BP and heart rate in relation to patients with chronic IN,
during the 24 hours of observation. Neither group showed nocturnal
reduction in BP; otherwise, we observed a light increase in nocturnal BP.
Both groups showed a light decrease in heart rate during the night.
Atherosclerotic renovascular disease: Clinical outcome after angio-
plasty and usefulness of captopril renography. P. Ruiz, J.L. Tovar, A.
Segarra, S. Quiroga, M. Fraile, .1. Castell, and L. Piera, Hospital General
"Vall d'Hebron," Barcelona, Spain. Patients and methods: Twenty-seven
severely hypertensive patients (15 male) with a mean age of 52.9 8.7
years (±sD) and uni- or bilateral renal artery stenosis underwent percu-
taneous transluminal angioplasty (PCT) between 1982 and 1991. They
were on platelet antiaggregant therapy. Renography using 99mTc DTPA
one hour after 50 mg of captopril p.o. was obtained in 20 patients (pts).
Two subgroups were established according to the pre-PCT serum level of
creatinine (Scr): Group A (Se. <1.5 mg/dl) included 16 pts (12 females)
aged 51.3 9.5 (mean so). In 14, PCT was performed as the only
procedure and was followed by surgery in two additional pts. Group B (Se.
1.5 mg/dl) included 11 male patients. PCT alone was carried out in 8 and
was followed by surgery in 3. In group B, there were two diabetics and six
pts with a history of peripheral vascular disease. Results: Good BP control
without medication was achieved in 8 pts of group A and in one of group
B. Renal function remained within normal limits in Group A pts, whereas
it further deteriorated in 6 Group B pts, all of whom finally required
dialysis. Captopril renography predicted renal artery stenosis in 18 of the
pts. In the two missed cases bilateral disease was present. Comments:
Females with Scr <1.5 mgldl prior to PCT and no clinical history of
peripheral vascular disease showed better BP control over time than males
with Sr 1.5 mg/dl and vascular disease. More than 50% of such pts had
severe renal function loss after PCT. Captopril renography seems a useful
predictive test in these patients.
Antibodies (Ab) directed against hepatitis C virus (HCV) in patients
with chronic renal failure and other patients with impaired immunity. J.
Garcia-Valdecasas, M.C. Bemal, J.G. Hervas, M. Megia, P. Rodriguez, and
S. Cerezo, Hospital Universitario de Granada, Granada, Spain. Prevalence
of Ab directed against HCV was previously found to be higher in patients
with chronic renal failure than in the normal population. This high
prevalence correlated with age (>50 years) and inversely with renal
function (Ccr >30 mI/mm), suggesting the possibility of a relationship with
the immunological status of these patients. To study this hypothesis,
prevalence of HCV Ab in this population was further differentiated by
specific renal pathology based on kidney biopsy. Additionally, these
patients were compared to nonrenal patients with impaired immunity,
such as a group of patients under chemotherapy, patients with autoim-
mune diseases, and the elderly normals. We studied 414 patients (226 with
chronic renal failure, 85 oncology patients with chemotherapy, 39 patients
with autoimmune diseases, and 64 normals aged over 65 years). Ab
directed against HCV were measured by second generation ELISA and
RIBA tests. We found Ab against HCV in 7.9% of the renal patients,
versus none in the oncology patients, 23.1% in patients with autoimmune
diseases (P < 0.01) and 7.8% in normals aged over 65 years (NS). Of
patients with chronic renal failure, 12/72 (16.7%) with glomerulonephritis
were Ab positive (NS between those patients and patients with autoim-
mune diseases). Positive Ab were found in 2/51 (3.9%) with interstitial
nephritis (P < 0.01), 2/49 (4.1%) with nephroangiosclerosis (P < 0.01),
1/34 (2.9%) with diabetic nephropathy (P < 0.01), and 1/20 (5%) with
polycystic kidneys (P < 0.01). Of the patients with autoimmune diseases,
2/7 (28.6%) with SLE were positive and 7/32 (21.9%) with rheumatoid
arthritis were positive. Conclusions: (1) The highest prevalence of Ab
directed against HCV was found in patients with autoimmune diseases
(SLE, rheumatoid arthritis); (2) Prevalence was high among the elderly
(>65 years), but absent in immunosuppressed oncology patients; (3) In
patients with chronic renal disease, prevalence was highest among patients
with glomerulonephritis. These findings support a relationship between
HCV Ab and immunity.
Antibodies (Ab) directed against hepatitis C virus (HCV) in non-
dialyzed patients with chronic renal failure. J. Garcia-Valdecasas, MC.
Berna4 M Manjon, A. Navas-Parejo, F. Martinez, and S. Cerezo, Hospital
Universitario de Granada, Granada, Spain. The prevalence of Ab directed
against HCV is higher in hemodialysis patients than in the normal
population. The aim of the present study was to explore the prevalence of
these Ab and the epidemiological factors involved in this infection in
patients with chronic renal failure before dialysis. We studied (in 226
patients with chronic renal failure) the Ab directed against HCV by
second generation ELISA and RIBA tests. The following epidemiological
factors were evaluated: age, sex, renal function [creatinine clearance,
(Ccr)I, blood transfusions, and history of invasive procedures (biopsies,
intravenous catheters, arteriovenous fistulas, etc). We found 18 (7.9%)
patients with Ab directed against HCV. Age: from 24 to 72 years (mean
value 48 9 years). We found 11.2% positive patients older than 50 years
versus 4.5% positive patients younger than 50 years (P < 0.1). Renal
function: 13.0% positive patients with Cr less than 30 mI/mm versus 2.7%
with Cr more than 30 mI/mm (P < 0.01). Blood transfusions: 15.8%
positive patients with blood transfusions versus 7.2% positive patients with
no blood transfusions (NS) Invasive procedures: 17.3% positive patients
with biopsies versus 5.2% with no biopsies (P < 0.05). 11.4% positive
patients with a-v fistulas versus 7.1% without fistulas (NS). 10.6% positive
patients with intravenous catheters versus 6.1% without them (NS).
Conclusions: (1) There was a high prevalence of Ab directed against HCV
in our patients with chronic renal failure (7.9%). (2) There were no
relationships among positive Ab against HCV and sex, blood transfusions
and therapeutic acts. (3) There was a higher prevalence of Ab directed
against HCV in patients older than 50 years. (4) There was a higher
prevalence of Ab against HCV in patients with renal function less than 30
mI/mm of Ccr.
Glomerulonephritis associated with hepatitis C virus infection. R.
Sanchez, M Praga, T Ortuno, A. Mazuecos, A. Araque, C. Alamo, A.
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Andrés, and J.L. Rodicio, Hospital "12 de Octubre," Madrid, Spain. The
association between hepatitis C virus (HCV) infection and mixed cryo-
globulinemia has been recently described. On the other hand, several
cases of membranoproliferative glomerulonephritis (MPGN) and mem-
branous (MGN) have been reported in patients with HVC. We have
identified 6 patients with chronic liver disease by HCV and GN (4 MPGN
and 2 MGN); four of them had mixed cryoglobulinemia. Mean age was 52
17 (33—73) years, including 3 males and 3 females. Mean proteinuria
was 4.4 3.6 g/24 hr (1.3—10 g/24 hr) and serum creatinine 2.1 1.1 mg/dl
(1.3—4.3). The patients with MPGN had type I MPGN in 3 cases and type
III in 1; three of them had chronic hypocomplementemia. Every case with
MPGN had repeatedly positive cryoglobulins. In the patients with MGN,
complement was normal and cryoglobulins negative. Every patient showed
abnormal values of serum hepatic transaminases. Liver biopsies showed
chronic active hepatitis in 4. Two patients (one with MGN, the other with
MPGN) had been treated with interferon-alpha for 6 and 12 months,
respectively. The patient with MPGN showed normalization of transami-
nases and disappearance of ciyoglobulins. However, proteinuria did not
decrease. The patient with MGN did not show proteinuria decrease nor
improvement of liver enzymes. In conclusion, the association between
HCV and GN may not be an uncommon clinical observation; in our
experience interferon-alpha did not show favorable effects on proteinuria,
although more clinical experience is needed.
Multicentric study about HCV antibodies prevalence in predialysis
patients. G. Barril and J.A. Traver, et al. We consider predialysis patients
to be those whose creatinine clearance is <20 mI/mm. We have studied
194 patients from 11 centers in Spain, finding 16 HCV+, which means a
prevalence of 5.79%, clearly above the prevalence in the healthy popula-
tion. In these centers the prevalence varies from 0 to 12%. There is no
relationship between the number of HCV+ and the total number of
predialysis patients; however, the centers with more patients have more
seropositives in absolute values. We have studied age, sex, time of
evolution, antecedents of surgery, biopsies and catheterization, number of
blood transfusions, history of acute hepatitis, and presence of HB core.
The mean age (61 males, 28 females) was 59 + 15 years (23—89), and 40%
of the 13 patients HCV have received at least one transfusion compared
to 24% of the HCV—. We don't think that the time of progression of the
disease by itself is a risk factor, as the HCV+ patients had a mean time of
74.27 68.7 months (74.27; 14—216) compared to that of the HCV—,
(87.78 86; 4—216). All the 18 patients with renal biopsy were HCV—.
We didn't find any link between the rest of the parameters that we have
analyzed. Conclusions: (1) It seems that the predialysis population has a
prevalence rate clearly above the healthy population. (2) It is necessary to
carry Out further studies in order to determine which factors are important
in the presence of anti-HCV antibodies.
Synthetic peptide versus third generation ELISA as a method of
screening for HCV. To find a good screening method of hepatitis C virus
(HCV) antibodies is getting more important every day, as the confirmation
tests are not always available, and because of that we sometimes consider
patients to be HCV+ who are not. We have made determinations in 25
patients with two routine methods of screening; afterwards, we used a
confirmation test, comparing specificity and sensitivity of both methods in
the discordant cases. In 20 patients with serology done 12 months
previously by ELISA 2, we checked the possible variation with other
methods and then we proved the usefulness of the confirmation test. We
studied 25 patients for HCV antibodies by ELISA 3 (ORTHO), and
considering C22-3, C200 and NS5, 15 were clearly positive, 8 were
doubtful, and 2 negative. Repeating the same serum with a synthetic
peptide (Organon Teknica) that used antigenic-structural and non-struc-
tural segments, we confirmed the positivity (positive values) in 12 of the
15, resulting in 3 negatives who were determined positive with ELISA 3.
All the questionable ones determined with ELISA 3, as well as the 2
negatives, were confirmed negative with the synthetic peptide method.
Using the protein band confirmation test (Matrix, Abbot), we detected:
Core, NS3, NS4 (yeast) and NS4 (E. coli), 100% of them correlated with
the results we got with synthetic peptide. Reviewing the results that we got
before with ELISA 2, we can see that 6 positives are now negative with
synthetic peptide and the confirmation test. The other 14 (9 + and 5 —)
do not change. Conclusions: (1) It seems that serology to HCV antibodies
using synthetic peptide is more specific than third generation ELISA. (2)
As the results with synthetic peptide have the highest correlation with the
confirmation test, it seems that synthetic peptide is a good method of
screening for HCV.
Platelet antiaggregant could prevent the progression of diabetic ne-
phropathy. MT Gonzalez, A.M Castelao, J.M. Cruzado, C. Vinzia, J.
Cembrano, and J. Alsina, Nephrology and Endocrinology Departments,
Hospital de Bellvitge, Barcelona, Spain. The incidence of chronic renal
failure due to diabetic nephropathy is continuously increasing. Other
organs are also affected by microangiopathy. Disturbances in clothing
pathways play a role in the progression of microangiopathy (an increase in
levels of thromboxane A2 has been implied in ischemic phenomena in
extremities and many vital organs, such as brain and heart). Consequently,
platelet antiaggregants, by inhibiting these clotting factors, could amelio-
rate the perfusion in the microcirculation preventing the progression of
diabetic nephropathy. The aim of our study is to compare the evolution of
two groups of patients with mild renal insufficiency due to diabetic
nephropathy (plasma creatinine under 170 smol/liter), both treated by
ACEL. Group I (G I, 15 patients) acts as a control group, and in group II
(G II, 13 patients) dypiridamole (225 mg) and aspirin (150 mg) were
added in a randomized trial. The period of follow-up was 1 year.
Parameters of renal function at the beginning and at the end of the study
were compared by statistical methods. We obtained the following results:
Pre 12 months P
GI
Plasma urea 10.5 3.2 (5.3—15.5) 11.5 4.8 (5.1—22.2) NS
mmol/liter
Plasma 117 25 (74—168) 137 38 (82—210) 0.003
creatinine
pmol/liter
GFR ml/min 76.6 26 (45—1 35) 60.8 31.6 (29—96) NS
Proteinuria 3.3 2.7 (0.3—9.6) 3.3 3.7 (0.26—14.3) NS
mg/dayGil
Plasma urea 9.7 2.5 (6.2—15) 10.1 3.4 (6—18.8) NS
mmol/liter
Plasma urea 120 29 (68—166) 127 38 (68—177) NS
wnol/liter
GFR mI/mm 85 32 (47—153) 91.8 24(51—117) NS
Proteinuria 2.3 2.8 (0.3—10) 2.7 3 (0.23—7.8) NS
mg/day
The increase in plasma creatinine levels only in the group of patients
treated with ACEI alone could suggest that platelet antiaggregants could
prevent the progression of diabetic nephropathy when this treatment is
administered early in the development of renal insufficiency or in the
microalbuminuric period. More studies are necessary to confirm these
data.
Effects of low protein diet and enalapril on kidney function in mi-
croalbuminuric IDDM patients. f.M Mallafré J.A. Oliva, MA. Ortiz, J.
Carrió, andJ.M Pou, Dept. of Nephrology, Hospital Creu Roja, and Dept. of
Endocrinology Hospital Sant Pau, Barcelona, Spain. Diabetic nephropathy
is one of the most severe complications of IDDM, and many of these
patients can progress to end-stage renal failure. Some therapies were used
to prevent nephropathy or evolution to substitutive techniques at end-
stage renal failure. We studied the effects of two therapies in 14
normotensive IDDM patients with microalbuminuria. Low protein diet
and enalapril were the two therapies used in a crossover study for three
months (0.7/g/protein/kg/24 hr and enalapril 5—7.5 mg/day). Microalbu-
minuria, GFR and RPF, plasma renin and aldosterone (basal and
post-stimulated), and urinary aldosterone were measured at starting time
and after every period of therapy. Microalbuminuria was decreased after
enalapril and diet (P < 0.053 toP < 0.0056). The average or decrease was
higher with diet than with enalapril (P < 0.05). GFR and RPF did not
change with any therapy. Basal and post-stimulated renin did not modify
with diet. Basal and post-stimulated renin did not modify with diet. A
positive increment of basal and post-stimulated renin was observed after
enalapril therapy (P < 0.000022; P < 0.0000171). Plasma aldosterone was
at the same levels in the three periods, but after enalapril we observed an
insignificant decrease. Urinary aldosterone was down after enalapril (P <
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0.043). Blood pressure was always normal but after enalapril decreased
significantly. Conclusion: Low protein diet and enalapril decrease mi-
croalbuminuria of IDDM patients. These two therapies did not modi1,
dynamic parameters and only enalapril could promote a decrease in blood
pressure and renin-angiotensin-aldosterone levels.
Diabetic nephropathy. A thirteen year experience in joint endocrinol-
ogy/nephrology follow-up. A.M Castelao, M. T Gonzalez, C. Vinzia, N.
Virgili, J.M Cruzado, R. GarcIa, J. Soler, and J. Alsina, Nephrology and
Endocrinology Departments, Hospital Bellvitge, University of Barcelona,
Barcelona, Spain. Diabetic nephropathy (DN) can involve more than 40%
of insulin-dependent diabetes mellitus (IDDM) patients and more than
30% of non-insulin-dependent (NIDDM) patients. From our initial
experience in 1978 until December 1992, we have studied 315 diabetic
patients. Their characteristics are as follows:

















38.2 10 (25—64)(N = 30, 35%)
40.7 11(24—66)
41.8 11(27—68)
All the patients developed proteinuria, while 96.3% of IDDM and 100%
of NIDDM patients were hypertensive, and 50.6% of IDDM patients
developed ESRF (the other ones died or are still in follow-up), versus
25.7% of NIDDM patients (29 still in follow-up, 60 died before ESRF). In
conclusion, in our clinic DN in NIDDM is 2.7 times more frequent than
IDDM, leading to an elevated rate of ESRF. Many patients died due to
intercurrent causes before achieving renal replacement therapy.
Lack of glomerular function reserve in patients with incipient diabetic
nephropathy in relationship to glomeruloscierosis and young controls
with normal renal function. A. Felip, A. Galan, M Granada, J. Bonet, A.
Caraips, and R. Romero, Hospital Germans Trias y Pujol Badalona, Spain.
Study objective: To study the glomerular filtration rate (GFR), renal
functional reserve (RFR) and hormone response after oral acute protein
load (APL) in men. Patients: Seven healthy volunteers, 13 with glomer-
ulosclerosis and 8 with incipient diabetic nephropathy. Interventions:
After APL with lactoprotein, we determined: inulin clearance (C1),
p-aminohippurato clearance (Cph) and RFR. We also measured: renin,
aldosterone, glucagon, HGH, cortisol, atrial natriuretic peptide, vasopres-
sin and urine POE2. Results: After APL we observed a significant increase
of GFR in healthy controls (115 vs. 144 ml/min) and glomerulosclerosis
(85 vs. 113 mI/mm), but not in incipient diabetic nephropathy (107 vs. 120
mI/rn). Basal filtration fraction was significantly higher in incipient diabetic
nephropathy than in the control group (18.27% vs. 34.38%) and not
increased after APL. RFR increased in the volunteers and the patients
with glomerulosclerosis, but not in the diabetic patients. Basal glucagon
was significantly higher in diabetic patients but not increased after APL as
in normal healthy controls and glomerulosclerosis patients (151 vs. 173;
102 vs. 170; 142 vs. 200). Conclusions: The APL produce a significant
increase of OFR in controls and glomerulosclerosis patients but not in
diabetic nephropathy. Incipient diabetic nephropathy patients have higher
filtration fraction that controls or glomeruloscierosis patients, demonstra-
tive of glomerular hyperfiltration. Glucagon is significantly higher in
diabetic patients and not increased after APL, contrary to observations in
the others two groups, suggesting that it may play an important role in
glomerular hyperfiltration.
Long-term treatment of anemia in predialysis chronic renal failure
patients. J.L. Miguel Alonso, J. Martinez Ara, G. del Peso, and A. Zamo-
rano, Nephrology and Laboratory Services, La Paz Hospital Madrid, Spain.
We studied 11 patients with ESRD before they started on dialysis, with a
creatinine clearance < 20 mI/mm and severe anemia treated subcutane-
ously with rHuEPO, for more than 12 months. Four patients completed at
least 24 months of treatment. There were 9 females and 2 males, aged 54
12.5 years. The primary causes of nephropathy were diabetes in 4,
chronic tubulointerstitial nephropathy in 4, Alport syndrome in 1, PKD in
1, and chronic glomerulonephritis in 2. Four patients required transfusions
before treatment with rHuEPO. Six patients had a vascular access for
future hemodialysis at entry into the study. RHuEPO doses were raised in
NIDDM 1/3 of the patients when the blood Hb did not increase in 1 g/dl. The Hb
target was 12 g/dl. At the entry of the study: Hb 9.03 0.48 g/dI; Crs 5.1
230 1.9 mg/dl; Cr 13.2 5.7 mI/mm; endogenous EPO 17.2 6.0; U
112 females, ferritin >80 ng/ml. The initial rHuEPO doses were 75—150 U/kg/week,
118 males once weekly or thrice weekly. All patients received oral iron supplemen-
63 9 (39—87) tation and 4 patients received iron by intramuscular route. All the patients
50.5 10 (30—80) were checked every three months, and the results compared with the year
59 10 (34—87) prior to the study for the 1/Crs against time and the blood pressure. At the
60.7 9 (44—87) end of the study six patients were on dialysis. All patients experienced an
(N 43, 18.6%) increase in Hb after the first month of therapy. The ratio of Hb/rHuEPO
60.8 9(36—87) doses at 3 months were: 11.8 1.2 g/dl/83 25 U at 12 months: 11.1
61.7 83 (38—87) 1.4 g/dl/82 47 U at 24 months 12 0.8 g/dl/75 27 U. There appeared
to be a trend towards increasing albumin, P, and K. Systolic, diastolic and
mean blood pressure did not vary during the follow-up. No patients
86 '37w experienced a clotted access; however, 50% of the patients experienced a39 17 constant decline in 1/Crs, while the others experienced a decrease in the
30 '13' tendency of the 1/Crs against time. We conclude that therapy with
4 rFIuEPO effectively increased hematocrit levels in patients with predialysis
15 '66' chronic renal failure. Transfusion requirement dropped dramatically and14 '61 we observed in this cohort a clear increase in vitality and a greater38 6 improvement in quality of life. On the other hand this treatment did not
4 7%) accelerate the progression of the renal failure.
The extrahospitalary renal clinic: Necessity, results and perspectives. J.
Pascual, C. Quereda, L. Orte, F. Liano, .1. Ortuno, Dept. of Nephrology,
Hospital Rambn y Cajal, Madrid, Spain. The Nephrology Departments
have traditionally been confined as marble towers within the limits of the
hospital. The evolution of the health care and that of the specialty itself
make it necessary to change this conception. Nephrology has a potential
relevance in the integration between primary and tertiary cares that has
remained forgotten. In February 1992 we set up a pilot experience of a
renal out-of-hospital clinic in the Center for Secondary Specialized Care
of the 4th Health Area in Madrid, which covers 400,000 people. This was
communicated to all primary physicians and other specialists, focusing the
aims to attending patients with nephropathies or severe arterial hyperten-
sion (AH), The present study summarizes the experience of one year. We
have attended 360 new patients, 55% referred by general practitioners and
the rest by specialists. The diagnoses at referral were: AH (66%), AH +
chronic renal failure (CRF) (22%, CRF (4.5%), urinary sediment alter-
ations (6.4%), other (3.3%). Age was 58 15 years (37% >65 yr) and
42% were males. At first visit, only 14% had well-controlled blood
pressure, 27% had severe AH, and 35% WHO grades Il—Ill. Metabolic
alterations were frequently associated: obesity (53%), hyperuricemia
(47%), hypercholesterolemia (46%); 35% had CRF and 48 were diabetics,
half of them with nephropathy, while 92% of cases of AH were essential
and the rest were secondary. Principal diagnoses were AH (N = 239), AH
+ CRF (N = 77), CRF (N = 14), isolated microhematuria (N = 17), othei(N = 13). Ninety-three percent continue further revisions at the clinic.
while 2 were admitted to hospital and 7% were definitively discharged.
The extrahospitalary renal clinic approaches and integrates the primar)
and tertiary care, facilitates the communication between general practi.
tioners and specialists, thus allowing the access of patients with potentiall)
serious disorders in early stages to nephrology care, and lightens th
assistance within the hospital. The early detection and treatment of rena
disorders and the consolidation as a reference unit for the rationa
treatment of All constitute the basic objectives. The implementation 0



















Prevention of HgCI2-induced nephritis in the Brown Norway (BN) rat
by treatment with antibodies (Abs) against VLA-4 integrin.A. Molina, T.
Bricio, A. Martin, and F. Mampaso, Dept. of Immunopathology, Hospital
Ramón y Caja4 Madrid, Spain. HgC12 induces an autoimmune disease in
the BN rat involving synthesis of anti-glomerular basement membrane
(GBM) Abs with development of nephritis and proteinuria. An accompa-
nying tubulointerstitial nephritis (TIN) constantly forms part of the renal
injury. This disease is the consequence of the appearance of autoreactive
T cell inducing polyclonal activation of B cells. The administration to
HgCI2-treated rats (1 mg/kg, three times a week) of anti-a4 integrin (0.5
mg on days 0, 8, and 13), but not of OX-i mAb (anti-CD45), completely
abrogated the development of TIN. Furthermore, anti-a4 also prevented












Group I HgCI2 134 46 1.16 0.07 +++ +++
(N =8)
Group II HgCI2 + anti-a4 36 F' 0.34 0.03a
(N =6)
Group III HgCI2 + OX-i 147 28 1.07 0.06 +++ +++
(N =6)
Group IV H20 15 2 0.10 0.01 — —
(N =6)
Means su (between days 13—15); °P < 0.001; bp < 0.01.
Our results confirm that in vivo VLA-4 functions in adhesive interaction of
circulating leukocytes and vascular endothelium, being centrally important
in the extravasation and migration of T lymphocytes to sites of tissue
injury. Finally, these in vivo findings strongly support in vitro preliminary
evidence of the contribution of VLA-4 in mediating intercellular adher-
ence of leukocytes through the existence of additional, yet unknown,
ligand/s.
Anti-neutrophil cytoplasm antibodies (ANCA) and extracapillary gb-
merulonephritis: Treatment results and activity follow-up. JR. Gomez-
Martino, A. Covarsi, R. Novillo, N. Marigliano, 0. Sanchez, and J.M
Sanchez, Hospital "San Pedro de Alcantara," Caceres, Spain. We have
reviewed the cases of extracapillaiy glomerulonephritis seen in our service
between October 1987 and March 1993 (5 years and 5 months). We have
studied treatment results and their correlation with ANCA titers in order
to evaluate this immunologic marker with regard to disease activity. We
performed a total of 122 renal biopsies of which 11(9.1%) turned out to
represent extracapillary glomerulonephritis; 6 of them being idiopathic (3
with a granular immunofluorescence pattern; 1 with linear IgG pattern; 2
with negative immunofluorescence) and one being postinfectious endoex-
tracapillary glomerulonephritis. The remaining four (36.4%) were glomer-
ulonephritis secondary to systemic vascubitis (3 were microscopic PAN and
1 was a case of Wegener's granulomatosis). In 8 patients ANCA were
determined, using indirect immunofluorescence. We found 6 of them
positive (75%), identiiing the two described patterns: pANCA (1 type III
idiopathic extracapillary glomerubonephritis and 1 microscopic PAN) and
cANCA (2 microscopic PAN and 1 Wegener's granulomatosis). All
patients were treated with boluses of 6-methyl-prednisolone that were
followed by prednisone and oral cyclosphosphamide. Eight patients
received additional treatment with plasmapheresis. In the six ANCA
positive patients we observed a decrease in antibody titer after treatment
initiation that coincided with clinical improvement and negative autoan-
tibody titers in all of them, in a period of time varying between 4 weeks and
7 months. We did not find prognostic differences between plasmapheresis
treated and untreated patients. Conclusion: (1) We regard ANCA as
being a reliable immunologic marker to confirm the diagnosis of extra-
capillary glomerulonephritis, because of its high specificity. (2) Its speci-
ficity and sensitivity permit early immunosuppressant treatment in those
severely ill patients who cannot tolerate aggressive diagnostic tests. (3) We
regard ANCA as being a very useful immunologic marker to follow-up
disease activity. (4) We could not find differences in kidney survival and
patient mortality whether or not plasmapheresis was used.
Magnetic resonance angiography (MRA) in polycystic kidney disease
(PKD): A preliminary study. M Rivera, A. Gonzalo, J. Fernández-Ur-
danibia, J. Navarro AntolIn, and J. Ortuño, Nephrology and Radiology
Services, Hospital Ramón y Cajal, Madrid, Spain. PKD is associated with
intracranial aneurysms (ICA). Furthermore, the rupture of an ICA may be
the first clinical symptom of PKD. It is therefore essential to detect an ICA
prior to its rupture. Conventional arteriography remains an invasive
technique and it is considered impractical as a screening test. Recently
MRA has been proposed as the best currently noninvasive technique to
screen for ICA since it detects ICA of 3 mm or larger. Since May 1992, we
have performed 7 MRAs in PKD patients according to the following
criteria: (1) first degree relative with an ICA; (2) headache or migraine;
(3) acute cerebrovascular attack (ischemic or hemorrhagic). The mean age
was 47 years (range 27—66); 4 were male and 3 female. Mean serum
creatinine was 1.7 mg/dl (range 1—3.1). Six were hypertensive and 1
normotensive. A giant intracavernous ICA was found in an asymptomatic
patient. Thus, MRA avoided the realization of conventional arteriogra-
phy, mainly in 3 patients with chronic renal failure (Cr > 2 mg/dl).
Conclusion: So far, we have made restricted indications of MRA, but it
will probably be more extensively used in the future.
Urinary elimination of albumin in children treated with recombinant
human growth hormone (rHGH). V. Garcia Nieto, J.M. Rial Rodriguez, C.
Leon, J. Chahin Haddad, M Quintero Quintero, M Muros de Fuentes, and
I. Rodriguez Rodriguez, Nephrology and Pediatric Endocrinology Units,
Nuestra Señora de Ia Candelaria Hospita4 Santa Cruz de Tenenfe, Spain.
Increased rates of glomerular filtration have been reported in adult
volunteers and in cases of hypophyseal deficit receiving rHGH treatment.
Similarly, in pathological conditions such as diabetes mellitus which
develop with glomerular hyperfiltration, they are reported to favor the
appearance of microalbuminuria which is the first biochemical datum
suggesting the onset of diabetic nephropathy. We wanted to establish
whether increased urinary albumin excretion (UAE) occurred in children
treated with rHGH. Methods and materials: We studied 52 patients (31
males, 21 females) aged 14.1 2.7 years, treated with rHGH for an
average period of 35 months (group P). Results were compared with those
of a control group of ii healthy children treated for normal variants of low
stature (group C). Initially, creatinine clearance (Cr) and UAE were
calculated from urine taken over 24 hours. In those cases of elevated
UAE, we collected 3 consecutive samples of 12 hours nocturnal urine to
confirm that increase. Results: In group P, C. and UAE were significantly
higher than group C (153 45 vs. 131 24 ml/min/1.73 m2 and 10.13
11.87 vs. 5.22 3.41 g/min/1.73 m2, respectively; P < 0.05 for both
parameters). In 12 patients, hyperfiltration was observed (Ccr > 178.4
ml/min/i.73 m2). In addition, ii patients had UAE values higher than 12
.tg/minhi.73 m2 (+ 2 SD of the controls). We observed different patterns of
nocturnal excretion of UAE in 9 of these patients. Four showed persis-
tently elevated UAE, 3 had elevated UAE in 2 of the 3 samples, while the
remaining patients were not confirmed at rest (exercise UAE). Conclu-
sions: Hyperfiltration was observed in 23% of patients treated with rHGH;
21.1% presented periodic increase of UAE, which was confirmed in 7 of
them (13.4%) under resting conditions. The increased elimination of UAE
in some children treated with rHGH is striking, and the question arises as
to whether some sort of therapeutic action should be taken or not.
Which is the specific AIDS-associated glomerular alteration? E. Cas-
tellote, J. Bonet, J. Teixidó J. C. Martinez-Ocaña, and A. Caralps, Hospital
"Germans Trias i Pujo4 " Badalona, Spain. The human immunodeficiency
virus (HIV)-associated nephropathy was first described by RAO in 1984.
It is histologically characterized by a focal and segmental glomeruloscie-
rosis and tubulointerstitial lesion with varying degrees of severity. It has a
course as a nephrotic syndrome with a rapid evolution to end-stage renal
disease. This nephropathy has a geographical distribution with different
prevalences depending on the studied population. Seven hundred twenty
patients with AIDS have been studied in our hospital. Only 4 patients
(0.6%) have developed proteinuria >3.5 g/day. They were white men,
aged between 31 and 57 years. Kidney biopsies were performed because of
a clinical-biological syndrome in all cases. Three were intravenous drug
addicts and the last one was an active heterosexual. The renal function was
normal in all cases. The immunological studies (rheumatoid factor,
complement and circulating immunocomplexes) were normal. The kidney
biopsies showed: 2 cases of membranous nephropathy, a case of diabetic
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nephropathy, and the latter was a mesangial 1gM proliferative glomeru-
lonephritis. Conclusion: Specific HIV-associated nephropathy was not
found in any of the biopsies. The glomerulopathy incidence in AIDS is
low. The renal course is not different from the expected for each
glomerulopathy found.
Cellular mechanisms involved in the proliferative effect of endothelin
on cultured mesangial cells. A. Montero, A.M RodrIguez-Lopez, and J.M.
López-Novoa, University of Salamanca, Salamanca, Spain. It has been
shown that endothelin-1 (ET-1) has a mitogenic and proliferative effect on
cultured mesangial cells. With the aim of elucidating the mechanisms
involved in this effect, we have measured the FT-i induced DNA synthesis
(3H-thymidine uptake) and the ET-1 induced protein synthesis in mesang-
ial cells made quiescent by incubating them during two days in medium
supplemented with 0.5% fetal calf serum. ET-i increased the DNA
synthesis in a concentration-related way (FT-i 10 nM: 502 45%; ET-1 1
nM: 436 32%). Similar results, although quantitatively less important,
were obtained in protein synthesis. Verapamil treatment (10 .rM) com-
pletely blocked the increases in DNA and protein synthesis induced by all
doses of FT-i. An intracellular calcium chelant, TMB-8 (0.1 LM), reduced
the effect of FT-i on the DNA synthesis (48 5%) and on the protein
synthesis (46 5%). An inhibitor of protein kinase C, staurosporin (0.1
ILM), reduced the effect of ET-1 on DNA synthesis (42 6%) but
completely blocked the effect on protein synthesis. ET-i induced the
expression of the protooncogene c-fos (PCR). Verapamil did not block the
expression of c-fos. These data suggest that extracellular calcium influx
and the release of calcium from the calciosomes, together with the
activation of protein kinase C, play a role on the proliferative effect of
ET-1, although the control of hypertrophy is different from that of
hyperplasy.
Gentamicin activates cultured rat mesangial cells: Inhibition with
antagonist of platelet activating factor. A. RodrIguez-Barbero, L. Rivas-
Cabanero, and J.M López-Novoa, Departamento de FisiologIa y Farmaco-
logIa, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain.
Gentamicin (0)-induced renal failure (RF) is associated with a massive
tubular necrosis and reduced glomerular filtration rate (GFR). Gentami-
cm-induced decreases in GFR have been associated with a marked decline
in the glomerular capillary ultrafiltration coefficient which could be
mediated by mesangial cell contraction or release of vasoactive hormones.
To assess a possible role of mesangial cell activation in response to
gentamicin, we have studied the effect of gentamicin on mesangial cell
contraction and proliferation. Moreover, we attempted to assess a possible
role of platelet activating factor (PAF) as a mediator of the observed
effects of gentamicin on mesangial cells. Gentamicin induced contraction,
measured by changes in planar surface area (PSCA), that were dose- and
time-dependent. The maximum effect (27 5%) was reached at 60
minutes and gentamicin iO M. Preincubation of mesangial cells with the
PAF antagonist BN-52021 (5.10—s) significantly blunted (12 2%) the
contractile response to gentamicin. The mesangial proliferation was
determinated by DNA synthesis (H3-Thymidine uptake) on quiescent
mesangial cells. Gentamicin induced a dose-dependent 3H-Thymidine
uptake into DNA (G iO M: 445 18%; G 10-6: 123 12%; G iO M:
179 42% over basal. BN-52021 (5.10—s M) significantly reduced (i0 M)
the gentamicin-stimulated thymidine incorporation to DNA from 445
18% to 119 15%. The present studies demonstrate that gentamicin
activates mesangial cell function. These actions seem to be mediated, at
least in part, by PAF synthesis and release. The effect of gentamicin on
mesangial cells could play a role in gentamicin-induced decrease in GFR.
Determination of serum-free gamma-carboxy glutamic acid by use of
high performance liquid chromatography (HPLC). A preliminary study in
children with chronic renal failure. J. Baeza, M Vazquez Martul, J.L. Ecija,
J.M. Carbonell, and P. Arnaiz, Biochemical and Nephrology Sections,
Hospital Niño JesOs, Madrid, Spain. Plasma gamma-carboxy glutamic
(GLA) is an amino acid which comes from a post-translational carboxy-
lation of glutamic acid which requires the presence of vitamin K. GLA
binds Ca and hydroxyapatita, and it has been found in several proteins.
GLA is present in coagulation factors II, VII, IX, X and in plasma proteins
C, 5, Z, in bone, and in small amounts in kidney and in urine. The
catabolism of all these proteins makes GLA plasma levels. In 1989, for the
first time, Fournier studied plasma levels of GLA and he documented
higher levels in primary hyperparathyroidism. Yoshimori described GLA
increased in hemodialysis patients, suggesting GLA as a renal osteodys-
trophy marker. We studied the plasma GLA in 21 children having a
moderate degree of chronic renal failure (CFR) (GFR <75 to 40); 13 had
a more severe degree (GFR <40 to 18) than the other 8 patients. A
control group (CG) of 22 healthy children were age-matched. The results
of GLA are given in pmol/ml, indicating range, mean and 1 standard
deviation.
Range Mean so Minimum Maximum Significance
CG 22 1.29 1.37 0.92 5.11 (Mann-Whitney)
CRF 21 12.84 1.48 1.79 52.97 p < 0.001
Plasma GLA correlated significantly (r—0.698, P < 0.01) to GFR, but it
did not correlate to parathormone, 1,25 dihydroxyvitamin D, ionized
calcium, phosphorus, alkaline phosphatase, bicarbonate and plasma levels.
Conclusion: Because we have found increased plasma GLA relatively
higher to other aminoacids values, we point out that GLA may be an early
biochemical marker in renal osteodystrophy in patients with chronic renal
failure. Nevertheless, more studies are needed.
High morbidity and mortality rates in elderly systemic lupus erythem.
atosus (>50 years) related to steroid therapy. D. Hernández V. Lorenzo,
M. Losada, M. Rufino, J.M. González-Posada, E. de Bonis, B. Maceira, A.
RodrIguez, and A. Torres, Nephrology Unit, Hospital Universitario, Tenenfe,
Spain. In 6—20% of patients with systemic lupus erythematosus (SLE),
onset occurs after the age of 50 years. In these patients treatment with
large doses of corticosteroids (CT) and immunosuppressive agents is
associated with major morbidity and mortality. To determine whether any
relationship exists between treatment with high doses of CT and the
appearance of major complications (MC), we retrospectively analyzed 12
patients (2 M and 10 F; 61.7 6.4 years) with SLE diagnosed for the first
time in the fifth decade of life. Patients received conventional dose of CT
or bolus of 6-methylprednisolone when renal failure was present. We
compared the frequency of major clinical complications and survival for
patients with cumulative CT doses: higher (Group I, N = 7, 14.5 7.7 g,
immunosuppressive agents associated in two cases), and lower than 3 g of
prednisone (Group II, N = 5, 0.8 1.1 g, no immunosuppressive agents
associated). All patients in Group I presented severe complications (4
bacterial pneumonia, 2 urosepsis caused by gram-negative bacteria, 1
primary lung cancer, i breast cancer, 1 myocardial infarction, 1 ischemic
stroke, 1 hip fracture, 1 diabetes, and 15 bacterial peritonitis in one patient
on maintenance peritoneal dialysis) and 5 patients died. In contrast, no
patients suffered complications or death in Group II (P < 0.001). Time-lag
between onset and diagnosis and follow-up after diagnosis were similar in
both groups (33.2 12.4 vs. 45.8 44.5 and 48.5 8.4 vs. 39.4 30
months, respectively). Eight patients (66%) showed lupus nephritis and 3
evolved to end-stage chronic renal failure. These patients received higher
doses of prednisone (14.8 3.4 vs. 1.7 1.1 g; P < 0.05) and showed a
tendency toward higher incidence of MC (6/8 vs. 1/4). In conclusion,
treatment with high doses of corticosteroids in elderly SLE patients (>50
years) is related to life-threatening complications. As a result of the high
morbidity and mortality rates in older SLE patients related to steroids, and
because these patients have a relative benign course, this drug should be
used at the minimum dose to control clinical manifestations, even if renal
failure is present.
Automatic study of renal pathology by digital image analysis. M.
Masseroli, F. O'Valle Ravassa, A. Montes Puerta, M. Gómez Morales, M
Aguilar Peña, J.L. Lopez Hidalgo, MA. Lucena Robles, M. T. Medina Cano,
and R. Garcia del Mora4 Dept. of Pathology, University Hospital, and
Nephrology Service, Vi,en de las Nieves Hospita4 Granada, Spain. Back-
ground: Presently, the interpretative character of morphological damage
in renal pathology should be substituted by a dynamic and scheduled
evaluation of lesions based on quantification of parameters and follow-up
of their evolution. In this respect, glomerular proliferative cell phenomena
and interstitial fibrosis are the two most useful lesions in histopathological
studies. Design: The direct projection in real time of an image analysis
package in a Visilog 3.6 (Noesis) environment is presented. This was
carried out as follows: (a) automatically quanti!'ing the glomerular
cellularity and excluding the interstitial, and (b) establishing the amount of
fibrosis per mm2 of renal interstitium. Material and methods: In both
cases, the study was carried out in paraffin embedded renal tissue and
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stained with Mayer's progressive hematoxylin and Syrian red, respectively.
The images were captured using a BCD-700 CCD vidamax video camera
connected to a BH-2 Olympus microscope (X200 magnification), and a
256 grey level scale (black and white) was processed by macro using
Visilog image analysis program packages set up in MS-DOS.
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Results: The flow diagram shows the main modules of the program for
automatic quantification lesions. This consists of two parts: (1) Data
capture and image processing; and (2) Processed image analysis with
minimum operator interference. This latter stipulation was to restrict the
image threshold and its intermediate correction. Conclusions: This pro-
gram allows the accurate quantification in a minimum time of glomerular
cellularity and interstitial fibrosis intensity (real time of image set up and
interpretation is 2.50 and 3.10 minutes, respectively).
Value of bone turnover (HPT) markers in the evaluation of secondary
hyperparathyroidism in chronic renal failure (CRF). C. Bemis, A. Diez, E.
Gruss, P. Sanz, J. Mote/ion, B. Rincon, J.A. Sanchez-Tomero, and J.A.
Traver, Services of Nefrologla and Bioqulmica, Hospital Princesa, Univer-
sidad Autónorna, Madrid, Spain. The value of new bone turnover markers
of secondary HPT in CRF must be assessed. We studied 10 CRF patients
with severe HPT (iPTH = 837 + 296 g/liter) and 9 patients with mild HPT
(iPTH 113 + 67). We determined: bone alkaline phosphatase isoen-
zyme (BAPi) by IRMA, tartrate resistant acid phosphatase (TRAP), total
alkaline phosphatase (TPA), osteocalcin (OS), carboxy-terminal propep-
tide of type I procollagen (PICP), and carboxy-terminal phelopeptide of
type I collagen (ICTP). Results: The comparison of the mean values
between the severe and mild HPT was: BAPi 60.4 + 37.3 g/liter versus 19.6
+ 8.1 (P < 0.05), ICFP 52.8 + 8.6 g/liter versus 40.3 + 14.7 (P < 0.05),
osteocalcin 283 + 120 g/liter versus 60.8 + 47 (P < 0.05),TPA 445.3 + 262
lU/liter versus 251.5 + 95.7 (P = NS), TRAP 9.2 + 1.7 U/liter versus 8.4
+ 2 (P = NS), PICP 261 + 125 g/liter versus 179.1 + 47.7 (P = NS), Ca
9.1 + 0.6 mg/dl versus 9.1 + 0.4 (P = NS), P 6.2 + 1.3 mg/dl versus 5.2 +
1.3 (P NS). There was a positive correlation of jPTH with BAPi (r =
0.71),TPA (r = 0.64), osteocalcin (r = 0.75), and ICTP (r = 0.49). Neither
TRAJ' nor PICP showed a correlation with iPTH. We conclude that
determining BAPi, osteocalcin and ICTP can be useful in the diagnosis
and follow-up of secondary hyperparathyroidism in CRF.
Treatment of anemia associated with advanced renal insufficiency
(ARI) with subcutaneous erythropoietin (rHuEPO). A. Navas-Parejo, J.
Garcia-Vaidecasas, M. Manjon, J.G. Hervas, J. Sanchez, and S. Cerezo,
Service of Nephrologv, University Hospital, Granada, Spain. Introduction:
The use of rHuEPO has proven effective in treating anemia in chronic
dialysis (CD) patients. Since this pathology is defined in patients with AR!,
we have started a treatment protocol with subcutaneous rHuEPO in this
patients. Material and methods: We included 12 patients (4 males, 8
females), average age was 60.7 15.6 years (range 24—78). All the
patients had Ccr <20 mI/mm and hemoglobin (Hb) <9 g/dl. Other causes
for anemia were excluded. The treatment began with rHuEPO doses of 75
U/kg/week, divided 3 times, with the aim of achieving Hb = 11 1 g/dl
and hematocrit of 31 1%. They were followed-up 7.6 7.7 months on
average (range 1—30). Results: All the patients responded to the treatment
with an almost significant increase of Hb in the first month (P < 0.01),and
it was definitely significant from the second month on (P < 0.05). By the
third month the therapeutic aim was achieved in the case of the majority
of the patients and the rHuEPO dose was reduced to 50%. From the 6
patients with Cr <10 mI/mm, 2 died after 6 months and 4 started CD in
a period of 1 to 3 months. In the 6 patients with Cr >10 mI/mm, their
AR! was not essentially modified, with an average Cr = 14.2 mI/mm at
the beginning and C. = 11.86 mI/mm at the end of the follow-up. From
the 8 hypertensive patients, it was necessary to increase the hypotensive
treatment in 5, but they kept their arterial pressure under control.
Conclusions: (1) rHuEPO is effective in the treatment of anemia in
predialysis. (2) rHuEPO doesn't seem to modify the evolution of renal
insufficiency. (3) Our patients had no significant complications.
Low-protein diets in chronic renal failure patients. Multicenter study.
R. Montes Deigado, A. Guerrero, C. MartIn, E. Fernández Ruiz, C. Remón,
J. Lopez, C. Minguez, J. Garcia, F. Garcia-Sierra, MJ. Marco, V Cabello,
and J. Mateos, Nephrology Services of Hospital Viigen del RocIo, Sevilla;
Hospital de Puerto Rea4 Hospital Municipal de La LInea, Hospital Puerta
del Mar, Cádiz, Spain. Low-protein diets are prescribed to reduce the rate
of progression of chronic renal failure (CRF) and to control uremic
symptoms without altering the nutritional status. We studied 78 patients
with CRF treated daily, during 15.7 8.9 months, with either 0.3 g protein
supplemented with essential amino acid and ketoanalogues ("0.3" group,
60 patients) or with 0.6 g protein ("0.6" group, 18 patients). Phosphorus
intake was 6 mg/kg for group "0.3" and 10 mg/kg for group "0.6." Both
groups received 35 Kcal/kg/day. Retrospectively, the patients were classi-
fied as "compliant" (C, 55%) or "non-compliant" (NC, 45%), according to
urinary urea excretion (Maroni). The percentage of patients that reached
end-stage CFR was not significantly different in group "0.3" versus group
"0.6" (43 and 44%, respectively); moreover, these end-stage CRF patients
were not significantly different when we considered the compliance,
number of months to reach final stage (means range from 7.9 to 10.4
months), or linear regression slopes of creatinine clearances over time in
groups C and NC. We did not find correlation in creatinine or creatinine
clearance and glomerular filtration rate as determined by 99mTc..DTpA
using Gates's method, measured at zero and three months. Urea and
proteinuria decreased significantly in group C. Also, group C patients had
a significantly better control of phosphorus, calcium-phosphorus product
and intact parathyroid hormone, and a decrease of phosphorus and uric
acid in urine. There were no significant variations in weight and other
anthropometric measurements. Serum albumin concentration decreased
significantly in both groups after 6 and 12 months. In conclusion, these
results suggest that our low-protein diets had a beneficial effect on urea
and calcium-phosphorus metabolism, but did not have a positive influence
on the progression to renal insufficiency as measured by our methods. In
order to detect early malnutrition, we recommend periodic surveillance of
serum albumin and anthropometric measures.
Tubular adaptation to acute metabolic alkalosis. A. Martinez, A.
Tejedor, C. AlbarracIn, J.A. Lázaro, P. Conthe, A. Biu,rdn, E. Junco, and F.
Valde,rábano, Hospital General Universitario "Gregorio Maranón, "Madrid,
Spain. Metabolic alkalosis is a potentially dangerous process, able to
induce respiration depression, hypercapnia and hypoxia. We show the
renal tubular response to metabolic alkalosis in minipigs. Methods: Six
animals were studied under basal conditions (0.2 mEq/kg hr NaCI i.v.
infusion) for 60 minutes and under acute metabolic alkalosis (2.5 mEq/g
hr HCO3Na iv. infusion) for 60 minutes. During both periods acid base
balance, renal hemodynamics and tubular function were studied. Results:
Acute HCO3 infusion raised plasma pH from 7.39 to 7.51, and HCO3]
from 19.3 to 32.5 mEq/liter (P < 0.05). P02 was unchanged but PCO2
significantly rose from 32 to 40 mm Hg, even under mechanical ventilatory
control, suggesting extracellular HCO3 buffering. 1K], decreased signifi-
cantly. GFR increased by 40% (P < 0.05), with no changes in RPF or
RBF. Filtration fraction increased by 15%, but we did not observe
increases in proximal reabsorption, suggesting a glomerulo-tubular bal-
ance break-down during acute metabolic alkalosis. Fractional excretions
of H20, Na, K, Cl and HCO3 increased significantly during alkalosis.
Proximal reabsorption decreased, raising Cl distal offer more than 5 times.
Free water clearance was also reduced, suggesting an inhibition of Na
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transport at the thick ascending limb level. However, distal reabsorption of
HCO3 was increased during the time of observation, with significantly
higher rates of H secretion, This effect was due to direct stimulus of HCO3
on distal H pumping. K secretion was also higher during alkalosis, but
neither K nor H increments in secretion were due to modifications in the
electronegative distal luininal potential as showed by the absence of
modifications in the transtubular K gradient. Acid net excretion varied
from a net 75 .sEq acid/mm to a net 43 rEq base/mm in alkalosis: 7% of
the change was due to a reduction in titrable acidity, 2% to a reduction in
ammoniagenesis, and 91% to an increase in HCO3 excretion. Conclusions:
Tubular adaptation to acute HCO3 infusion determines an increase in
glomerular filtration, and a decrease in proximal and thick ascending limb
reabsorption. Distal HCO3 reabsorption seems to, temporarily, oppose
alkalosis correction.
Treatment of proteinuria-related hyperlipidemia with pravastatin. C.
Alamo, J.L. Aranda, R. Sanchez, A. Araque, C. Guijar,v, A. Mazuecos, F.
Pulido, and M. Praga, Hospital "12 de Octubre," Madrid, Spain. Hyperlip-
idemia associated with renal diseases can play a role in the progression of
renal failure, in addition to its atherogenic influence. Experimental studies
have shown a beneficial effect of hyperlipidemia treatment on the course
of renal damage. We have prospectively studied 16 patients with protein-
uria >2 g/24 hr, creatinine clearance >30 mI/mm and hypercholesterol-
emia (LDL-cholesterol >190 mg/dl), in order to assess the effect of
pravastatin, a hydrophilic inhibitor of HMGCo A reductase, on lipid
values and renal function parameters. Diagnoses were membranous
glomerulonephritis (10 cases), refiux nephropathy (2), IgA (1), inactive
extracapillary GN (1), and diabetic nephropathy (1). Patients were
randomized into two groups: Group A, treated with hypolipemic diet plus
pravastatin (20—40 mg/day); and Group B, treated only with hypolipemic
diet. Duration of the study was 6 months. Group A showed a significantly
higher decrease of total cholesterol (—27% vs. —6.7%, P < 0.01) and
LDL-cholesterol (—44% vs. —9%, P < 0.01). HDL-cholesterol and
triglycerides did not show significant changes. Renal function worsened in
both groups, without statistical significance (—0.28 0.06 mI/sec vs. —0.14
0.10 mI/sec). Proteinuria increased in both groups, without statistical
significance. No clinical or analytical side-effects were identified, and there
were no changes in liver and muscle enzymes. In conclusion, pravastatin
treatment exerts a marked favorable effect on cholesterol levels of
proteinuric patients, with an excellent tolerance. However, no beneficial
influence on proteinuria or renal function was observed. It is possible that
longer follow-up could be necessary to evaluate this influence.
Pravastatin therapy in hypercholesterolemia of patients with chronic
renal failure. J. Motellón, J.A. Sanchez Tomero, C. Bemis, E. Gruss, B.
RincOn, E. Muñoz, P. Sanz, G. Banil, andf.A. Traver, Service of Nephrology,
Hospital de Ia Princesa, Universidad Autónoma, Madrid, Spain. 1-lypercho-
lesterolemia is a major risk factor in the development of atheroesclerosis
and coronaiy heart disease. This fact, plus the frequent co-existence in
renal patients of some other vascular risk factors (diabetes, hypertension,
age) makes necessary an optimum treatment of this dyslipemia. Several
studies report the efficacy of some HMG-CoA reductase-inhibitors (by-
astatin, simvastatin) in the treatment of hyperlipidemia in renal patients,
but few references exist about pravastatin. We present the results obtained
from a group of 17 patients with mean age 54 + 16 years. Criteria for
inclusion were: proteinuria (prt) >400 mg/dl, total cholesterol (CT) >230
mg/dl, CT/cHDL >4.5. All subjects had remained hyperlipidemic after
lipid-lowering diet therapy for 3 months and none of them was on any
other lipid-lowering drugs. Patients with poor adherence to treatment
were excluded. Pravastatin 20 mg once a day was initiated. Plasma urea,
creatinine, glucose, uric acid (AU), CT, triglycerides (TG) c-HDL, c-LDL,
C-VLDL, Apo A, Apo B were measured, and 24 hours urine samples were
analyzed for protein at the start of study and after 3 months therapy.
Results:
CT!
CT LDL VLDL HDL TG HDL ApoA ApoB AU Cr Prt
Basal 313 237 25 42 182 7.9 148 168 8.8 3.2 2666
3 months 255 195b 24 42 155 6.6" 154 147 7.8" 3.3 2720
"p <0
.001; bp < 0.01.
Conclusions: (1) Pravastatin seems to be an effective lipid-lowering drug
in patients with chronic renal failure. (2) Long-term studies are necessary
to assess the influence of plasma cholesterol levels on CRF evolution.
Early and spontaneous complete remission of minimal change ne-
phrotic syndrome in adults. A. Araque, M Praga, A. Mazuecos, T Ortuño,
J.M Alcdzar, R. Sanchez, A. Andrés, and J.L. Rodicio, Hospital "12 de
Octubre," Madrid, Spain. The incidence of spontaneous remission in
minimal change nephrotic syndrome (MCNS) is unknown, since the
general attitude is to rapidly treat it with steroids once the diagnosis is
established. We have observed 6 patients (5 females, 1 male) with MCNS
who presented an early and spontaneous remission of the nephrotic
syndrome. Age was 34—87 years (59 15). All of them had started with
edema in the 1—2 weeks before admission. Every case had complete
nephrotic syndrome: total proteins 4.3—5.9 g/dl (4.9 0.5), serum albumin
1.4—2.4 g/dl (1.9 0.3), and serum cholesterol 309 —578 mg/dl (428 78).
Proteinuria was 5—21 g/24 hr (9.5 4). Renal function was normal in every
case. None of them had received new drugs coinciding with the onset of
edema. Renal biopsy was performed in 3 cases: glomeruli were normal,
with negative immunofluorescence and podocyte fusion in electron mi-
croscopy. The other 3 cases were not biopsied given the rapid evolution to
spontaneous remission. Every patient was treated with diuretics and none
of them received steroids or immunosuppressive drugs. Proteinuria spon-
taneously started to decrease, reaching its complete disappearance 15—24
days (19 3) after the onset of edema. No patient showed relapses of the
nephrotic syndrome in the follow-up. In conclusion, some patients with
MCNS can exhibit early spontaneous remissions. Since steroid treatment
is not without dangerous side-effects, we think that steroids could be
delayed until 2—4 weeks after the onset of edema, in order to identify these
cases of spontaneous remissions.
Obesity-related proteinuria. Effects of body weight loss and captopril.
E. Hemández, M Praga, M. Leon, L.M Ruilope, C. Montoyo, J.M Morales,
and J.L. Rodicio, Hospital 12 de Octubre, Madrid, Spain. Several cases of
obesity-related proteinuria have been reported. We have identified 20
obese [body mass index (BMI) 37.6 3.9] patients (13 F, 7 M; 49 11
years) with proteinuria >1 g/day (1.3—6.4 g/day, >( 2.9 1.6). Eight cases
had only one functioning kidney and 5 had sleep apnea syndrome. Renal
biopsies, performed in 6 cases, showed: focal glomerubosclerosis (3),
minimal change nephrotic syndrome (2), and mesangial proliferation (1).
Nine patients (Group I) were treated with hypocaloric diets: BMI had
decreased from 37.1 3 to 32.6 3.6 (P < 0.05) and proteinuria from 2.9
1.7 to 0.4 0.6 g/day (P < 0.05) after 12 months of follow-up. Body
weight loss correlated with proteinuria decrease (r = 0.69, P < 0.05). Eight
patients (Group II) were treated with captopril without dietary changes.
BMI did not change (38.8 5 to 38.2 6) but proteinuria decreased from
3.4 1.7 to 0.7 24 hr (P < 0.05) after 12 months. At the end of
follow-up (38.7 16 months proteinuria was 1.1 1.6 g/day in Group I
and 1.1 0.8 g/day in Group II. Renal function remained stable in both
groups. Three patients (Group III) did not follow hypocaloric diets or
tolerate captopril. Proteinuria increased and renal function worsened in
these patients, one of them needing chronic dialysis after 36 months of
follow-up. In conclusion, body weight loss or captopril treatment induce a
similar sharp decrease in proteinuria associated with obesity; in the
absence of these treatments a progressive decline of renal function can be
observed.
Immunosuppressive treatment (IT) in membranous glomerulonephri-
tis (MGN) with deteriorating renal function. A. Araque, M. Praga, A.
Mazuecos, C. Alamo, E. Hernández, J.M. Morales, and J.L. Rodicio,
Hospital 12 de Octubre, Madrid, Spain. Although many cases of MGN
attain spontaneous remissions, those with established renal insufficiency
(RI) show a progressive course. We have treated 10 cases of MGN with
progressive RI (Cr > 1.5 mg/dl) and nephrotic syndrome with the
following IT: oral prednisone 1 mg/kg/day/lst month; 0.5 mg/kg/day/2nd
month; 0.5 mg/kg/48 hr/3rd to 6th month, and oral chlorambucil 0.15
mg/kg/day from 1st to 6th month. Renal function improved in every case.
Cr decreased from 2 0.4 mg/dI at the onset of IT to 1.3 0.3 mg/dl at
the end of IT (P < 0.001), and creatinine clearance increased from 38.8
13.8 to 66.6 27.1 mI/mm (P < 0.05). Proteinuria decreased from 13.2
3.8 to 5.8 2.7 g/day (P < 0.001) with improvement of total proteins (4.8
0.4 to 5.4 0.6 g/dl; P < 0.001) and serum albumin (2.3 0.4 to 3
0.6; P < 0.01). The beneficial effects on renal function and proteinuria
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were apparent from the 2—4 month after the onset of IT. Follow-up after
the end of IT has been 16.8 13.7 months. Renal function and proteinuria
have remained stable (1.3 0.3 mg/dl and 3.4 1.6 g/day, respectively).
In five patients IT was withdrawn earlier (3.1 2.3 months) because of
pneumocystis pneumonia (1), bacterial pneumonia (1), herpes infection(1), and leukopenia (2). These 5 patients also showed improvement of
renal function and decrease of proteinuria. In conclusion, IT improved the
clinical course of MGN with deteriorating renal function; however, the
side-effects of IT were serious.
Independent effect of PTH and phosphorus (P) on calcitriol (CTR)
levels in renal failure (RE). I. Berdud, M. Concepción, A. MartIn-Malo, S.
Tallón, J. Borrego, A. Torres, M. Rodriguez, and P. Aijama, Hospital "Reina
Sofia ", Córdoba, and Hospital de Tenenfe, Tenerife, Spain. High PTH level,
P retention, and decreased CTR production occur in RF. Phosphorus and
PTH have opposite effects on CTR production. This study evaluates the
effect of a normal PTH levels on CTR production in uremic rats fed a
normal (0.6%) and high (1.2%) P diet. A 5/6 nephrectomy was performed
in all rats. Half of the rats underwent parathyroidectomy and a normal
PTH level (NPTH) was achieved by a continuous PTH infusion (0.044
jsg/hr) via a subcutaneously implanted miniosmotic pump. The rest of the
rats remained PTH intact and developed secondary hyperparathyroidism
(HPTH). After two weeks, mean SE levels of calcium (Ca) (mg/dl), P



























P < 0.01, vs. HPTH 1.2%; NPTH 0.6%.
In the uremic rat a normal PTH level is associated with a decrease in
serum CFR in both normal and high P diets. In rats with severe HPTH
induced by a high P diet, the CTR was not significantly decreased despite
high P levels. In conclusion, in RF high PTH can stimulate CTR
production despite P accumulation.
Incidence and long-term evolution of idiopathic hypercalciuric renal
lithiasis (IHC). Thiazides versus diet treatment. C. AlbarracIn, A. Tejedor,
JM Lopez Gómez, R. Jofre, M Goicoechea, A. MertInez, and F. Valderrá-
bano, Servicio de NefrologIa, Hospital General "Gregorio Marañón", Ma-
drid, Spain. IHC is the most frequent alteration found in patients with
relapsing renal lithiasis (RRL). There is no general agreement about the
most efficient treatment of IHC, although thiazides are generally used in
renal HC (RHC) and in absorptive HC (AHC) not controlled with Ca
restriction. We studied the incidence of IHC in our RRL population and
their short- and long-term evolution under treatment. One hundred three
patients with RRL were studied at times 0, 0.5, 1, 2, 3 and 4 years from
diagnosis. Plasma and 24 hour urinary excretion of creatinine, uric acid,
P043, Na, K, Cl , HCO3 and urine Mg and oxalic acid
were studied, as well as plasma PTH, urinary Cail and creatinine after a
12 hour fast. IHC was detected in 40% of patients (Ca excretion >250
mg/24 hr, without other findings): in 35% IHC was the only lithogenic risk
factor; in 5% other factors were associated. IHCs were classified upon the
fasting Ca/creatinine index and PTH plasma levels in AHC (36%),
RHC (17.5%), and indeterminate HC (46.5%). Thiazides were used in
50% of IHC patients, and a Ca and Na restrictive diet was used in the
remaining 50%. In the diet treated group, calciuria decreased from 281
45 mg124 hr at the time of diagnosis to 209 55 mg/24 h the first year of
treatment (P < 0.05), to 183 56 mg/24 hr the fourth year (P < 0.01).
Patients with AHC treated with thiazides reduced calciuria from 337 43
mg/24 hr to 239 50 mg/24 hr the first year, but an important rebound
(368 105 mg/24 hr) was observed after 4 years of treatment. Thiazides
consistently reduced calciuria in nonabsorptive HC from 352 79 mg124
hr and 198 92 mg/24 hr after 1 and 4 years, respectively. Conclusions:
IHC is the most prevalent metabolic condition in our RRL population.
Dietary Na and Ca restriction in ICH effectively reduces calciuria at its
short- and long-term evolution. Thiazide treatment shows a rebound after
4 years of treatment.
Acute renal failure (ARE) in the intensive care unit (ICU): treatment
and prognostic factors. J. Lavilla, M. Martin, L. Mesa, C. Vazquez, J.
Buades, P. Errasti, and A. Purroy, University of Navarre, Navarre, Spain.
Introduction: ARF in ICU is a very common complication and the use of
dialysis is usually required [hemodialysis (HD), hemofiltration (HF), or
hemodiafiltration (HDF)]. We present the incidence and outcome of ARF
in our ICU during a one year follow-up. Material and methods: Between
February 1992 and February 1993, 950 patients were admitted to the ICU,
and 55 (5.8%) had ARF. We have evaluated the type of treatment
[conservative, (C), HD, HF, HDF], renal function recovery (RFR), days in
ICU (T), mortality (M), and number of the non-renal organ failures
[respiratory (R), cardiovascular (CV), hematological (H), and liver (L)].
The results are in the following table
Renal function recovery, mortality, and days in ICU
Treatment
RFR





C 37 23 62 2 5.4 6
HD 9 5 55.5 4 45.5 19
HF/HDF 9 5 55.5 8 89 21
Non-renal organ failure
Number None One >One
Treatment N % N % N %
C 19 51 10 27 8 21
HD 1 11 3 33 5 56
HF/HDF 0 0 0 0 9 100
Type R CV L H
Treatment N % N % N % N %
C 12 32 8 22 7 19 6 16
HD 6 67 4 44 9 44 1 11
HF/HDF 9 100 7 78 4 44 6 67
Conclusions: (1) In our experience most of the patients were treated with
conservative measures; of those needing substitutive treatment we used
mainly HD (alone or combined with HF/HDF). (2) The recovery of renal
function was similar with both treatments, but the need of HFIHDF is a
predictor of higher mortality and it is related to previous multiple organ
system failure.
Scleroderma renal crisis. Clinical-histological correlation. X Borrellas,
J. Fort, A. Segarra, V. Fonollosa, C. Pilar SimeOn, J. Camps, R. Roca, J.L.
Tovar, A. Olmos, and L. Piera, Nephrology Department, Hospital General
Universitari, Vall d'Hebron, Barcelona. Aim: To analyze the clinical,
biochemical and histological features of scleroderma renal crisis (SRC).
Patients and methods: We studied 7 patients between 1989 and 1992
diagnosed with systemic sclerosis with SRC (defined as the presence of
acute renal failure and renal pathologic features or biochemical evidence
of renal infarction), evaluating the mode of presentation, visceral involve-
ment, serological characteristics, response to treatment, and pathological
features (renal biopsy and/or necropsy when it was possible). Results:
Seven patients (5 female and 2 male) with a mean age 58 9.6 years and
SRC treated early with ACEI (serum creatinine < 2.5 mg/dl) inS cases. In
6, skin involvement had less than four years of evolution with rapid
progression before the renal crisis, while 100% had severe gastrointestinal,
pulmonary and cardiac involvement with pericardial effusion in 6 cases.
We detected hypertriglyceridemia in 6 cases. Survival at 12 months was
0%. The findings at necropsy revealed intestinal, pancreatic, hepatic and
pulmonary involvement. Conclusions: SRC is a life-threatening complica-
tion with a severe vascular and systemic involvement that progresses
rapidly. The prognosis is malignant in spite of the early treatment with
ACEI and good control of blood pressure. Pericardial involvement is
frequent and etiologically related with the disease. Simultaneously with
the crisis we detected an acute alteration of the lipid profile.
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Evolution of glomerulonephritis (GN) incidence in Spain during the
years 1991 and 1992. Spanish Regist,y of Giomerulonephritis (REGN),
Spain. The REGN has presented during 1993 the epidemiology of GN in
Spain for the years 1991 and 1992. Data reported to REGN included:
cases of GN diagnosed by biopsy, clinical features that conditioned renal
biopsy and GN diagnosed only on a clinical basis. Patients were considered
as "adults" when they were 15 years old and over, and "children" if they
were younger. Patients with a functioning kidney allograft were excluded
from the study. Patients were classified according to their kidney histo-
logical features into 8 categories of primary GN (PGN) and 4 of secondary
GN (SGN). Sixty-five referring hospitals reported adult cases and 20
hospitals reported GN in children, with about a 70% rate of response.
Adults' results: The number of biopsy patients registered during 1991 was
1169 and 992 during 1992. Clinical data were reported from 2152 patients
biopsied between 1989 and 1992. The percentage PGN/all GN was 70% in
1991 and 68% in 1992. The annual ratios of membranoproliferative MP
GN/PGN during 1991 and 1992 were 7.5% and 8.2%, respectively, similar
to the 1987—1988 ratio (8.9, 8.2%), suggesting that the descending curve
observed over the past decade is reaching a plateau. IgA GN frequency
remained without significant variation, with about 22—24% of PGN being
the most frequent GN in Spain. Clinical syndrome of IgA GN at time of
renal biopsy has changed, macroscopic hematuria is decreasing and
persisting urinary abnormalities (proteinuria and microscopic hematuria)
are increasing. Extracapillaiy GN (EGN) and MP GN are more frequent
in northern Spain than in the rest of the country. Patients with nephrotic
syndrome (NS) (39.4%) presented: 19.7% membranous GN (MGN);
15.3% focal glomerulosclerosis (FGS); 14.5% minimal change GN (MC);
11.9% LES. LES represents 37% of SGN. Systemic VAS, with 24%, is the
second most frequent cause of SGN. GN associated with neoplasia was
found only in 4.1% of SGN. Incidence of glomerular diseases in adults,
biopsied in Spain between 1987 and 1992, has not changed significantly,
maintaining about 43—46 new patients/year/million of inhabitants. Chil-
dren's results: The report included 954 children diagnosed with GN on a
clinical basis, and 403 of them were biopsied between 1989 and 1992.
Fifty-five percent of NS were biopsied while there were only 22% acute
nephritic syndrome and 21% vasculo-glomerular acute renal failure.
Minimal glomerular abnormalities, with 26.8%, were the PGN most
frequently biopsied in children, and IgA GN 25% was the second one.
VAS was the first cause of SGN, 43.8%, (SchOnlein-Henoch purpura) and
LES, 20.8%, the second one.
Predictive factors of mortality in acute renal failure patients. .J. Fort, J.
Camps, M. Martin, J. Bartolome, J.A. Rodriguez, A. Segarra, R. Roca, X.
Bo,relias, P. Ruiz, A. Olmos, and L. Piera, Service of Nephroiogy and
Preventive Medicine, General Hospital Vail D 'Hebron, Barcelona, Spain.
Aim: The assessment of predictive factors of mortality in patients devel-
oping acute renal failure (ARF). Patients and methods: From 1986 to
1991, 344 patients who developed ARF during their stay in our hospital
were included in the study. Information about etiology of ARF, compli-
cations, underlying diagnoses, treatment and laboratory determinations
was collected. Univariate analysis of these factors was carried out between
the groups of survivors and nonsurvivors. Stepwise logistic regression was
undertaken afterwards in order to obtain a predictive model of mortality
in these patients. The final logistic equation was validated in a second
group of 83 patients with ARF admitted to the same hospital in 1992.
Results: There were 225 men and 119 women, from 14 to 91 years (mean
age of 57.3 17.0 years) included in the study. The initial serum
creatinine level was 7.5 3.5 mg/dl. The outcomes for these patients were:
194 (56.4%) developed oliguria; 48.5% needed dialysis, requiring an
average of 6.8 8.4 episodes; 182 died, the overall mortality being 52.9%.
The factors found to be significantly associated with mortality in the final
logistic model were: age, oliguria at admission, acute respiratory distress
syndrome, presence of arrhythmias as a complication as well as vasomotor
nephropathy as an etiology of ARF and abdominal sepsis, gram-negative
sepsis and myocardiopathy as a main illness. Prediction of mortality could
be made with a sensitivity and specificity of 83.5% and 81.5%, respectively,
when selecting a cut-off point that maximized both. Conclusions: In the
group of patients studied, (with the above-mentioned variables) who were
finally selected by the logistic model, strong independent predictive factors
of mortality having a high sensitivity and specificity should be considered.
Acute renal failure in intensive care unit patients. Predictive factors of
mortality. J. Fort, J. Camps, L. Liopart, X Pens, M Martin, X Borrelias, P.
Ruiz, A. Olmos, and L. Piera, Services of Nephrology, Intensive Care Unit,
Preventive Medicine, Hospital General Universitario Vail D'Hebron, Barce-
lona, Spain. Aim: To study predictive factors of mortality in intensive care
unit (ICU) patients suffering from acute renal failure (ARF). Patients and
methods: During a period of 6 years, we studied 120 patients (84 M and 36
F) who presented ARF during their stay in the ICU. We analyzed the
following clinical and analytical variables: etiology of ARF, main illness,
complications, parameters of renal function and calcium-phosphorus
levels, as well as the presence of oliguria or not at admission and the type
of treatment they received. In order to compare the group of patients who
died with the survivors, we carried out a univariate analysis: chi-square and
Student's t-test for each one of the studied variables. Later on, the
significant factors were included in a logistic regression analysis. Results:
The mean age of the patients was 53.5 SD 16.4 years; 60.8% of patients
needed dialysis, requiring an average of 5.3 SD 4.8 dialysis sessions. The
overall mortality was 96/120 80%. The variables which were finally
included in a logistic regression model were: age of the patients, acute
respiratory distress syndrome (ARDS), liver transplantation, sepsis as a
main illness, the number of dialysis required as well as the need of
continuous arteriovenous hemofiltration (CAVHF), and the phosphorus
serum level. The variables which were statistically significant in the
prediction of risk of death were: the age, the presence of ARDS (OR =
3.5 confidence limits 95%: 1.03—12) and the need for CAVHF (or = 8.6
C.L. 95%: 1.44—51.1). Conclusions: In the studied ICU patients, the age,
the presence of ARDS as a complication and the need for CAVHF as a
depurative therapy should be considered as major predictors of mortality.
Nitric oxide synthesis is increased in rats with gentamicin-induced
renal failure. L. Rivas-Cabañero, A. Montero, A. Rodniguez-Barbero, and
J.M López-Novoa, Departamento de FisiologIa y Farmacologla, Facultad de
Medicina, Universidad de Salamanca, Spain. Gentamicin (G)-induced
renal failure (RF) is associated with a massive tubular necrosis and
reduced glomerular filtration rate (GFR). As NO seems to play a role in
regulating glomerular function, we have looked for a possible impairment
of NO synthesis in G-treated animals. Rats received G, 100 mg/kg/day
subcutaneously for six days. Control rats received isotonic saline. Glomer-
uli were isolated by mechanical sieving and incubated for 15 minutes in the
presence of IBMX (1 mM) and substances which modify NO synthesis and
NO production. cGMP was extracted and measured by RIA. G-treated
animals increased plasma creatinine levels (31 4 vs. 7.5 0.3 mg/liter in
control ones, P < 0.01) reflecting RF. Basal glomerular cGMP generation
was 0.17 0.04 pmol/mg protein in control (N = 11) versus 2.02 0.63(N = 22; P < 0.01) in G-treated ones. Acetylcholine (Ach) (10—v M)
increased cGMP production by 59% in G-treated rats versus 68 18% in
control rats. Bradykinin (BK) (10 M) had a similar effect. In controls,
L-NAME (10—a M) reverted the Ach- and BK-stimulated cGMP produc-
tion to values similar to the basal ones. However, in G-treated rats,
L-NAME decreased cGMP production by 37 10% below basal values.
L-Arginine stimulated cGMP production by 85 6% in control, but
stimulation was not significant in G-treated ones. Atrial natriuretic
peptide (ANP) (10 M) stimulated cGMP production by 193 7% in
controls and by 167 23% in G-treated rats. These results suggest that
glomerular NO synthesis is stimulated in G-treated rats, while they show
a maintained response to ANP.
Incidence and characteristics of acute renal failure (ARF) in children
in the Madrid area: A Prospective and multicentric study. Madrid ARE
Study Group, Madrid, Spain. From October 1991 to June 1992 we
prospectively studied all cases of children with ARF treated by pediatric
nephrologists. All patients were admitted to 4 hospitals in Madrid, taking
care of 342,000 habitants with ages lower than 15 years. The number of
patients was 57 (33 males and 24 females). Mean age was = 4.5 5.4 years
and median age = 2.24years. Thirty-two of them were living in Madrid (90
cases/million pediatric population/year) and 25 in other areas. The
underlying disease was: heart disease (16), perinatal pathology (11),
nephropathy (9), shock not due to heart disease (6), tumor (4), and
miscellaneous (11). Initial allocation of patients was in different units:
intensive care (24), neonatal (12), nephrology (7), surgery (6), general
pediatrics (6), and other (2). Twenty-two children needed surgery while
hospitalized; in 19 of them surgery preceded ARF. Etiology of ARF was:
acute tubular necrosis (ATN; 22), pre-renal (9), glomerulonephritis (9),
newborn kidney (10), and urologic obstruction (7). Mortality was 26.3%
(15 cases): 12 with ATN, 3 newborns and 1 pre-renal. The underlying
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diseases were: heart disease (9), shock (4), and prematurity (2). Thirteen
patients needed dialysis and 6 of them died. Conclusions: In this study we
established for the first time in our country the incidence of ARF in
children treated by pediatric nephrologists. The causes and the mortality
rate of this syndrome were also defined. It is of interest that mortality was
associated with heart diseases in most cases. On the contrary, all patients
with nephropathy survived.
Incidence of acute renal failure secondary to salmonella enteritidis. B.
Rincón, C. Bernis, ML. Jimenez, E. Grnss, J. MotellOn, P. Sanz, E. Muñoz,
G. Barn!, J. Sanchez- Tomero, M. Naya, and .1.A. Traver, Service of Nefro-
logIa, Hospital de la Princesa, Universidad Autonoma, Madrid, Spain. We
studied in a sanitary area with 500,000 inhabitants the number of cases of
acute gastroenteritis caused by salmonella enteritidis that required med-
ical care in our hospital and how many developed acute renal failure
(ARF), during 1992. We got data from patients admitted to the hospital
during 1992 with gastroenteritis caused by salmonella. Stool cultures were
taken in all cases. On admission blood pressure and hydration state were
registered. Urea, creatine, sodium, potassium, and creatininase were
determined in serum. Sodium, potassium, urea and sediment were ob-
tained from urine specimens. Renal function and urine specimens were
also taken on discharge. We define ARF as creatinine levels higher than
2 mg/dl. Results: Forty-two patients (age 48.5 23) were admitted with
stool culture positive for salmonella enteritidis; 31 cases (age 39 18)
were discharged from hospital within 12 hours and all had normal renal
function. Eleven cases required hospitalization (age 61.7 19) and 7
developed ARF (age 67 17). On admission creatinine values were 5.7
3 mg/dl, urea 146.4 48, and sodium 130 2. In 3/42 (4.7%) creatininase
was high. Urine specimens were negative for proteinuria and there was
microhematuria in 5. Potassium was normal. Average duration of ARF
was 7.8 3.5 days with normal urine values and renal function at
discharge. Conclusions: ARF secondary to salmonella enteritidis was
found in 1.4 patients/100,000 inhabitants/year (10% of the total number of
ARF in our hospital's area and 16.6% of the cases that required medical
treatment for salmonella gastroenteritis). All the patients recovered renal
function but they needed a period of hospitalization of 12 days. Although
3% had rhabdomyolysis, the determining factor of ARF was inadequate
hydroelectrolytic replacement, which could be easily prevented by early
treatment.
Acute renal failure and rhabdomyolysis. Statistical analysis of prog-
nostic factors and outCome. X. Borrellas, J. Fort, J. Camps, M Martin, and
J. Bartolome, J.A. Rodriguez, A. Olmos, L. Piera, Departments of Nephrology
and Preventive Medicine, Hospital Vail d'Hebron, Barcelona, Spain. Aim:
Evaluation of prognostic factors of acute renal failure (ARF) associated
with development of rhabdomyolysis (RBM). Patients and methods: We
studied 35 patients with ARF [serum creatinine above 4 mg/dl: and RBM
creatinephosphoinase (CK) greater than 1000 U/liter] between January
1986 and June 1992. Laboratory measures and the following categorical
variables were tested: causes, clinical factors, associated complications and
response to initial hydration. We used the BMDP statistical package. The
association of the distinct qualitative variables with mortality, need for
dialysis (D) and time of recuperation was evaluated with Fischer's Exact
Test. We compared the mean of the continuing variables between
different groups with the Mann-Whitney test. The correlation between
laboratory measures was determined with the Spearman's test. Results:
The only quantitative variable significantly associated to mortality was the
peak LDH (P = 0.007). The need of D was related with the presence of
hypotension (P = 0.01), low level of consciousness (P = 0.01), higher peak
CK levels (P = 0.005), serum potassium (P = 0.004), peak serum
phosphorous (P = 0.002), peak LDH levels (P < 0.001), lower minimum
serum calcium (P = 0.01) and serum bicarbonate (P = 0.002). Initial
hydration reduced the need for D (P < 0.04). Conclusions: The presence
of elevated peak LDH levels in patients with ARF associated with RBM
is related with a higher mortality rate. The elevated peak CK levels
indicate high risk for receiving D and longer time of recuperation of renal
function but are not related to mortality. The associated clinical factors
significantly contribute to the probability of receiving D.
Comparative analysis of urea distribution volume (V). H. Garcia, C.
Caivo, G. Fernández, E. Bosch, and C. Ruiz, Nephroiogy and Laboratory
Units, General Hospital, Casteilón, Spain. Introduction: The body urea
distribution volume (V) is a required parameter for the calculation of urea
generation (G), for the dose of dialysis (KT/V), and the nutritional status
(per) of dialysis patients. It can be assumed as a constant value of body
mass and can be calculated for each patient on hemodialysis (HD).
Material and methods: The V of 40 hemodialysis patients (26 male and 14
female) was studied, with ages between 30 and 81 years (mean 58) and
mean lean body weight of 65.39 kg (40.3—98). The following calculations
were made: I. Vi assuming it as 58% of lean body weight in each patient.
II. VHM using Watson's anthropometric method. III. V2 using Mal-
chesky's mass balance method. IV. With Gotch's urea kinetic model
(variable volume and monocompartmental) V3 is calculated. The used
values were urea before and 15 minutes after HD, residual urea clearance
(KRU) and dialyzer clearance (K), corrected from plasmatic volume and
recirculation, as well as eliminated urea, measured in the partially
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Conclusions: I. Maichesky's mass balance model allows more precise
calculation of V, eliminating errors that interfere with the calculation of K,
which is needed for the urea kinetic model. In our patients, V2 is 58.2%
of mean lean body weight, while V3 is 61.93%, with a bigger standard
deviation than V2, which suggests an overestimation of V3 and a more
reliable V2, showing itself as the more recommendable method. II. The
distribution of individual values does not correlate well with Vi and V2, as
would be expected from their mean values.
Predictive value of the proteins C and S in the study of the coagulation
in patients on hemodialysis (HD). J.A. Oliva, R. Lafuente, J. Carrió, A.
Mongay, and f.M Mallafre, Dept. of Nephrology. Hematology Lab. Hospital
Creu Roja Barcelona, Spain. The appearance of postdialysis bleeding or
thrombotic accidents during dialysis, constituted some of the more
frequent complications in these patients. We studied 42 patients with
ESRD on hemodialysis, 22 M and 20 F, aged 36—86 years (X = 64.9 13.31),
on HD 7—144 months (X = 55.47 43.2). In 10 patients we detected
hemostatic problems postHD (HPP), and in 2 hypercoaguality (HC). In all
these patients the values of platelets, thrombin T, and APTF were normal.
We determined the pre- and postHD values of fibrinogen (F) antithrombin
III activity (ATIII), protein C activity (Prot C) protein C activity plasminogen(P), and D-dimer (DD). The predialysis values were: (F): 261—774 (X =
431.17 131.69), ATIII 73—106 (X = 93.3 7.4), Prot C 55—120 (X = 89.3
18.9), Prot 5 36—200 (X = 89.47 31.3), P 54—127 (X = 92.1 15.9), DD
500—1000 (X = 532.25 124.86). The postHD values were: (F) 242—853 (X
= 466.55 149.52), ATIII 70—124 (X = 98.36 11.8), Prot C 61—200 (X =
121.21 32.54), Prot S 70 —200 (X = 149.60 43.9), P 43—140 (X = 98.3
21.2), and DD 500—4000 (X = 642.85 664.67). We observed significant
differences (P < 0.0001) between the protein S and C values (pre- and
postHD) and between the ATIII and plasminogen (P < 0.01). In the basal
study we detected low levels of prot C in 6/42 patients, prot S in 5/42 patients,
and both proteins in 7/42 patients. In the postHD study we observed high
levels of prot C in 3/42 patients, prot S in 13/42 patients and both prots in
13/42 patients. In 9/10 patients with HPP, we detected high levels postHD of
plot C and/or plot S. In the 2 patients with HC we detected low levels prel-ID
of plot C and/or S. In conclusion: The study of the S and C proteins is
essential in the control of the hemorrhagic and/or thrombotic success in these
groups of patients.
Quantification of dialyzer clearance (K) with partial dialysate collec-
tion and other methods. H. Garcia, C. Calvo, G. Fernánadez, E. Bosch, and
C. Ruiz, Nephrology and Laboratory Units, General Hospital, Castelión,
Spain. Introduction: Any error in the calculation of effective dialyzer K
influences the estimate of KT/V. Here we compare the manufacturer's
calculated K (K3J,,,l/mj,,) and that obtained from blood and dialysate
samples. Material and methods: Forty patients were studied, 26 males and
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14 females with a mean age of 58 (30—81), on hemodialysis with
cuprophan (36) and polyamide (4) membranes, during 239.5 minutes
(195—300), with a mean blood flux of 288 mI/mm (210—350) and dialysate
flux of 529 mI/mm (475—570), measured hourly. A continuous and partial
volume of dialysate was collected using a Y collector system and blood
samples were obtained for hematocrit, recirculation and K determinations
with different methods and correction of various factors, using the
following equation for calculation of dialysate K: KD3 = total eliminated
urea/(peripheral blood urealo.93). Mean hematocrit was 33.12% (22.5—
43.8), recirculation 8.75% 4.89, and residual urea clearance 0.68 ml/min
(0—2.88). Different KT/V estimates were obtained with diverse calculated
K values, respective dialysis times and a V of 58% of lean body weight.











K300 (manufacturer's) 235 12 NS NS 1.52
K (diffusion) 225 28 r = 0.49 r = 0.95 1.45
K (+convection) 227 28 r = 0.49 r = 0.95 1.46
K (+plasma vol.) 195 25 r = 0.49 r = 0.95 1.26
K (+recirculation) 183 25 r 0.49 — 1.18
KD3 (dialysate) 162 28 — r = 0.95 0.97
Conclusions: I. Mean calculated values of K were progressively lower as
corrections of different factors were made. II. Mean KT/V values were
overestimated with lowering errors as different calculations (from manu-
facturer to those obtained from blood samples) were compared with KD3
(dialysate) values. III. The correlations between lCD3 and K values
obtained from blood samples were weak. IV. KD3 and K(+recirculation)
had no significant correlation with manufacturer's supplied K. V. KTIV
(In) underestimates the value of KT/V with KD3. VI. Obtaining partial
dialysate samples is a more simple, exact and reproducible method than
calculations from blood samples for K calculation, making it recommend-
able for KTIV calculation in clinical practice.
Effect of uremic plasma and dialysis membranes on the activity of the
enzyme ALA-dehydrase (ALA-D) in erythrocytes. J.L. Miguel Alonso, C.
Solis, F. Bon'ego, MJ. Fernández, A. Buflo, and f.M Ara, Nephrology and
Biochemistry, Services, Hospital La Paz, Madrid, Spain. In our previous
work we described a low activity of the enzyme ALA-D in eiythrocytes
from dialyzed patients, The factors that contribute to this fact are unclear.
We studied the activity of ALA-D in 27 patients on chronic hemodialysis
(HD), 15 dialyzed with cuprophan membranes (HDCU) and 12 with PAN
membranes (HDPAN), as well as 17 patients in CAPD. We also deter-
mined the activity in healthy controls: 55.3 6.1 U/mI erythrocyte.
According to the type of dialysis we found the followin activities: CAPD:
34 9,7*; HDPAN: 28.2 11*; HDCU: 20.2 6.5" (° = P < 0.001 vs.
controls, ** = P < 0.05 vs. HDPAN). During the session of HD the
activity of the enzyme was modified: 22 9.1 preHD vs. 24.3 10.1
postHD (P < 0.001), and this modification was greater in the HDPAN
group. There was no relation with the age, time of dialysis and plasma zinc
levels. To study the effect of uremic factors, we determined the activity of
ALA-D in erythrocytes from controls suspended in uremic plasma, and we
found no variation. After 24 hours incubation at 37°C with uremic plasma
we found a decrease in the activity of 65%, and incubated with their own
plasma the decrease was 46% (P < 0.05). There were no significant
differences when we incubated uremic eiythrocytes with their own plasma
(72%) and control plasma (67%). Zinc is one of the main cofactors for
ALA-D. When we added zinc to the sample, there was a significant
increase in the activity in uremic and control erythrocytes which means
that there is a loss in the activity but not a degradation of the protein.
Conclusions: (1) In uremic plasma there are inhibitor molecules of
ALA-D activity which need time to effect their action. Normal plasma is
not able to normalize this activity. (2) The better preserved activity in
patients in CAPD and with HDPAN point out the relevance of the type of
dialysis membrane in the loss of ALA-D activity.
Cytokine introduction in hemodialysis with high flow membranes. A.
Otero Glz., E. Armada Rodriguez, J. Esteban Morcillo, P. Gayoso, Nephrol-
ogy Hospital, Investigation Unit, Hospital Cristal-Piñor, Crense, Spain.
Chronic hemodialysis (HDCr) promotes different secondary effects and
among them, a bigger susceptibility to infections, neutropenia and amy-
loidosis. The pathogenesis of these phenomena seems to be bound to the
production of cytokines such as interleukin 1 (IL-i) and tumora necrosis
factor (TNF). Their activation is independent of the complement system
and it is probably due to the fact that the secondary phenomenon of the
retrofiltration can stimulate them. The objective is to evaluate the genesis
of IL-i and TNF in HDCr with high flow membranes and different dialytic
techniques: HDCr free of acetate (BFA) and conventional HD (VHD)
with a bicart model dialysis bath. We selected 12 patients on HDCr, 6 (5
males and i female of 59 years of age and 20.5 months on HDCr) in AFB
with a capillary dialyzer of acrylonitrile of 1.15 m and UF coefficient: 31
mI/hr (Filtral 12) and 6 (4 males and 2 females of 63 years of age and 40
months) on HDV with polyacrylonitrile flat dialyzer of 1.25 m and UF
coefficient: 31 mi/hr (Crystal 3400). IL-i and TNF were determined by
enzymoimmunoanalysis and monocyte recount (M). In all patients, ac-
cording to their dialysis time (0, 20, 60, and 240 minutes). The statistical
methology used was the calculation of the media, Ds and comparison of
media by Student's t-test.
0 20 60 240
AFB
IL-i 30.4 21* 15.6 17° 15.5 16° 20.4 16°
TNF 11.2 9 6.9 4.6 7.3 6.5 9.7 10
M 359 157 319.4 239 517 520 351 154
HDV
IL-i 34 23 21.1 15 24.5 i3 24.9 16
TNF 10.9 8.5 8.7 5.85 7.1 6 13.9 10
M 402 338 349 477 293 169 262 116
ap < 0.05
In AFB, stimulation for cytokine does not exist, and the descent for IL-i
is due to its captivation by the membrane. Although TNF goes down, it is
not significant. The use of sterile ID in dialysis with high flow membranes
is justified.
Influence of the residual renal function (RRF) on the nutritional state
(N.E.) of patients on hemodialysis (HD). F. Armada, A. Otero, J. Esteban,
B. Uriel, Service of nephrology, Investigation Unit, Hospital Cristal Piñor,
Orense, Spain. NE determines the morbidity/mortality of the patients on
HD, depending on the quantity of HD received (Kt/V), according to the
kinetic model of urea (KMV). The objective was to analyze the possible
influence of the RRF on the NE in a group of patients in the HD program,
who were stable (without any associated catabolic factors), dialyzed with
the same membrane (AN69) and the same buffer (CO3H), and evaluated
periodly following the KMV. A total of 58 determinations in 36 patients
were made KT/V, Kt/V, PCRN, TAC, RRF, Hct, CO3H, PTHi, protein-
uria, nutritional parameters (Crp, Alb, Cholesterol, lymphocytes) and
anthropometric measurements (triceps skinfold, midarm circumference,
relative corporal weight). Two groups were established in accordance with
RRF: (-1-)> 1 mI/mm; (—) 0—0.6 mI/mm. The statistical methodology was
comparison of media by Student's t-test and multiple correlation analyses.
The plasma levels of Hct (30.8 4.6 vs. 29.9 4.09), predialysis CO3H
(22.9 2.7 vs. 22.4 3.7) and PTHi (122.8 vs. 104.8) were similar in both
groups. The PCRN was significantly correlated with the KT/V and Kt/V (P
< O.Oi); there was also a significant correlation between RRF and the
PCRN and TAC (P < 0.01).
N pa-
tients KT/V Kt/V PCR TAC FRR
RRF (+) 20 1.21 0.2° 0.84 o.ia 1.3 0.2° 77 13* 2.2 1.2°
RRF (—) 16 0.98 0.1 0.95 0.1 1.1 0.2 60 15 0.2 0.3
°P < 0.01
Due to the RRF (+) group receiving fewer doses of dialysis (Kt/V), and
the PCRN and TAC being significantly greater than the RRF (—) group,
and excluding catabolic factors, we conclude that the RRF is a decisive
factor in the NE of patients on HD.
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Comparative study of the nutritional state in chronic hemodialysis
(HD) and in continuous ambulatory peritoneal dialysis (CAPD). A.
Molina, E. Sanchez, I. Nebreda, C. Terroba, A. de Paula, A. Rodrigo, M.E.
Plagaro, andJ. Benito, "Rio Hortega "Hospital, Valladolid, Spain. Objective:
To compare the nutritional status of HD and CAPD patients. Patients:
There were 25 patients on HD, 17 men (M) and 8 women (W), aged from
25—76 years (median age: M 57, W 67). Their time on HD varied from 3
to 214 months. There were 5 cases with diabetes mellitus (DM). The HD
scheme tended to achieve a Kt/V of at least 1, along with a protein
catabolic rate (PCR) of at least 1 glkg/day. There were 16 patients in
CAPD, 8 M and 8 W, aged between 41—73 years (median age: M 55, W
69). The time spent on CAPD varied from 11 to 58 months (X SD: 33.4
13.3 months). There were 5 cases with DM. The study groups were
homogeneous according to age (Kruskall-Wallis test) and sex (chi-squared
test). Methods: Caloric nutrition (CN) and protein nutrition (PN) were
based on the following parameters: % of ideal weight, body mass index,
triceps skinfold thickness, midarm circumference, midarm muscle circum-
ference, and muscle area of the arm. CN was divided into these categories:
normal (NCN), mild to moderate caloric malnutrition (MCN), serious
caloric malnutrition (SCN), and obesity (0). PN was divided into: normal
(NPN), mild to moderate proteic malnutrition (MPN), and serious proteic
malnutrition (SPN). The residual renal function (RRF), PCR and Kt/V
were established in HD and in CAPD, and TAC of urea in HD. The
results are in the table.
CAPD(N= 16) HD(N=25)
Men Women Total Men Women Total
NCN 2 0 2 7 2 9
MCN 3 0 3 2 0 2
SCN 0 1 1 7 3 100 3 7 10 1 3 4
NPN 1 6 7 2 5 7
MPN 4 2 6 5 1 &'
SPN 3 0 3 10 2 12
ap = o.oo4l;'p= 0.1655
Conclusions: Those patients undergoing CAPD were significantly more
obese than those on HD (Fisher exact test = 0.003176). The patients on
HD tended toward more serious proteic malnutrition (Fisher exact test =
0.0569).
PFD with active charcoal: An easy and efficient hemodiafiltration
technique. C. Sanz Moreno, J. Hemandez Perez, E. Besada, J. Fernandez
Fernandez, D. Sanz Guajardo, and J. Botella, Puerta de Hierro, Madrid,
Spain. Hemodiafiltration techniques have shown their efficacy in improv-
ing the uremia treatment, but they need the infusion of a high volume of
reposition liquid and therefore a precise control of the infusion and the
ultrafiltration. It has been proven in the PFD technique that the interpo-
sition of an active charcoal filter between the ultrafiltration and the dialysis
chambers enables us to use the patient's ultrafiltrated liquid as reinfusion
liquid; charcoal will have eliminated a great number of uremic toxins, no
matter their molecular weight. We have used this technique during 8
months in 4 patients, previously on PFD for at least 6 months. During that
time, urea, creatinine and uric acid amounts remained stable. Kt/V
decreased (1.02 0.19 vs. 0.98 0.12) but with no statistical significance.
Beta-2-microglobulin values remained stable; they were measured at the
beginning of the PFD session (30.7 8.5 vs. 32.8 8.2 g/ml) and at the
end of it (25.5 7.3 vs. 21.3 3.8 g/ml); this proves that its elimination
doesn't decrease when replacing the ultrafiltrate. Values of HCO3, pH,
pCO2, albumin, total proteins, etc., remained stable. This technique is
easier as the same ultrafiltration pump is the infusion one, with no risk of
unbalance between them; moreover, there is no need to use perfusion
liquid. Clinical tolerance is excellent. In conclusion, we believe that PFD
with active charcoal simplifies hemodiafiltration without losing efficacy.
Nutritional assessment of patients with end-stage renal failure (ESRF)
in chronic maintenance hemodialysis (HD). A. Molina, E. Sanchez, I.
Nebreda, C. Te,roba, A. de Paula, A. Rodrigo, ME. Plagaro, and J. Benito,
"Rio Hortega" Hospital, Valladolid, Spain. Objective: Nutritional assess-
ment of ESRF patients on chronic maintenance HD. Patients: There were
25 patients: 17 men and 8 women, aged between 25 and 76 years (median
age of the men 57, of the women 67). The time they have been undergoing
HD varies from 3 to 214 months. There were 5 cases with diabetes mellitus
(DM). The HD scheme tended to achieve a Kt/V of at least 1, along with
a protein catabolic rate (PCR) of at least 1 g/kg/day. Methods: Caloric
nutrition (CN) and protein nutrition (PN) were based on the following
parameters: % of ideal weight, body mass index, triceps skinfold thickness,
midarm circumference, midarm muscle circumference, and muscle area of
the arm. CN was divided into: normal (NCN), mild to moderate caloric
malnutrition (MCN), serious caloric malnutrition (SCN), and obesity (0).
PN was divided into: normal (NPN), mild to moderate protein malnutri-
tion (MPN), and serious protein malnutrition (SPN). The residual renal
function (RRF) was determined, as well as PCR, TAC of urea, and Kt/V.
CN NP
0 NCN MCN SCN NPN MPN SPN
Men 1 7 2 7 2 5 10
Women 3 2 0 3 5 1 2
The results were: 36% of the patients had NCN; 16% were obese; 48%
presented some degree of caloric malnutrition. There were no significant
differences in CN according to age or sex, while 28% had NPN, and 72%
had some degree of protein malnutrition, there were no significant
differences in PN relating to age, however, men had a stronger tendency
than women toward serious protein malnutrition. (P = 0.031).
CN NP
0 NCN MCN SCN NPN MPN SPN
DM 3 1 0 1 4 0 1
NoDM 1 8 2 9 3 6 11
The results were: The diabetics had obesity more frequently than the
non-diabetics (P = 0.0204) as well as a better protein nutrition (P
0.0139). The time undergoing HD, RRF, PCR, TAC of urea, and Kt/V did
not correlate with the anthropometric parameters which we use to
measure the nutritional status. Conclusions: We presented the results of a
nutritional study of patients on HD, differentiating according to age, sex
and the presence or absence of diabetes mellitus. This study will help us to
adopt correct dietary measures.
Effect of different membranes on amino acid losses during hemodialy-
sis. J.F. Navairo, R. Marcén, R. MartIn, J. Teniel, C. Gámez, and J. Ortuno,
Departments of Nephrology and Investigation, Hospital Ramón y Cajal,
Madrid, Spain. This study evaluates the losses of free amino acids during
hemodialysis using 3 different membranes: cuprophan (CUP), polysul-
phone (POL) and polyacrilonitrile (PAN). Five patients on maintenance
hemodialysis were studied during 3—10 sessions. Every patient was dia-
lyzed at least one with each membrane. The dialysis schedule was similar
in all procedures: mid-week hemodialysis, 3 hours, hollow fiber dialyzer, I
m2 of surface, blood flow of 300 mI/mm and dialysate flow of 500 mI/mm.
Losses of essential amino acids (EAA), non-essential aminoacids
(NEAA), and total aminoacids (TAA) (mg/session), and the number of
hemodialysis sessions with each membrane are expressed in the table:
CUP POL PAN
EAA 819 383 1124 376 1992 1018"
NEAA 3028 1146 3152 1023 4553 1927
TAA 3848 1436 4276 2389 6526 273T
NHD 11 9 8
"p < 0.01 vs. CUP; bp < 0.05 vs. POL; cp < 0.05 vs. CUP
Dialysis with high permeability membranes increases amino acid losses in
hemodialysis patients. The long-term effect on protein metabolism and
nutritional status of these patients deserves prospective study.
Ambulatory blood pressure monitoring (ABPM) in patients treated
with hemodialysis (HD). E. Gonzalez Pan-a, M Rodeles, and A. Mendez,
Servicio de Nefrologla, Hospital Del Aire, Madrid, Spain. The use of the
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ABPM in patients with arterial hypertension is a common method to
control the circadian variations of blood pressure. These variations in
patients on HD depend on different factors, such as the day of the week
and the HD session. Objectives: We tried to determine the advantage of
the ABPM in the study of patients on HD, observing the variations of BP
in relationship with the way to perform the HD and the day of the week,
inctuding a rest period of 48 hours. Patients and methods: We studied five
patients with the ABPM in different clinical situations, who were hemo-
dialyzed for more than two years. In all patients the ABPM was done
during 24 hours. In the first protocol, ABPM was done on an interdialysis
day during 24 hours; in the second, ABPM was done on the first day with
HD of the week; in the third, HD occurred on an intermediate day of the
week, and the last, during the weekend. Results: The BP measurements
during HD are very similar to the ones recorded during the rest of that
day. The mean diastolic BP is significately lower the rest day than on the
day after the weekend. In this period of time, important peaks of BP exist,
which are higher and more frequent, than in the rest day. When the BP
was recorded the same day of the HD, the mean BP was similar to that of
the rest day, but brief lowerings of diastolic BP occurred, which coincided
with rises of BP. Conclusions: (1) A higher vascular risk existed in the
weekend, due to casual elevations of BP, the same as the day of HD,
because hypotension, particularly diastolic, was associated with rises of the
heart rate. (2) The interdialysis day is the most hemodynamically stable in
all studies.
Bacterial eudotoxin levels in hemodialysis baths with different filters.
F.J. Merida, E. Gonzalez Parra, G. Ramos, and A. Mendez, Nephrology and
Phamiacy Services, Hospital del Aire, Madrid, Spain. With high permeabil-
ity membranes and the bicarbonate bath, a higher and better hemodialysis
process has been achieved. The method of bicarbonate addition to the
dialysis bath is not totally perfected, and therefore endotoxins can be
found in the bath. High permeability filters could enable the transfer of
these endotoxins to the blood flow. Some investigators recommend
avoiding these baths before exposing the patient to chronic antigenic
stimulus, or the incorporation of a filter to the bath to avoid this transfer.
Objectives: (1) Evaluation of the levels of endotoxins in bath using
different filters and baths, before and after the filtering process. (2)
Evaluation of the level of endotoxins in blood at the beginning and end of
the dialysis process (3) Analysis of correlation between endotoxin levels
and total colony counts. Patients and methods: For 5 patients on
hemodialysis, the total colony count, the nature of the microorganisms,
and the endotoxin concentration were determined using Cuprophan filters
(CUP) with bicarbonate, polyacrilonitrile filters (PAN) with bicarbonate
and polyacrilonitrile filters with acetate (ACT). The measurements were
taken in the bath before and after the filter, fifteen minutes after
hemodialysis began. Additionally, the concentration of endotoxins in the
blood was determined at the beginning and end of the hemodialysis
process. The endotoxin detection was verified through a cromogenic test
of final points (Coatest, Kabi Diagnóstica), using apirogenic material, and
the total cotony count was performed in tryptic soy agar after incubation
at 37°C during a lapse of 72 hours. The foltowing vatues were considered
as reference values: up to 200 forming colony units/mI in water, up to 2000
FCU/mt in dialysate, up to 0.125 EU/mI in the baths. Results: (a) Dialysis
baths: (1) The prevailing fiorae in the baths of hemodialysis were
non-fermented gram-negative bacilli. (2) The average endotoxin bath
concentration levels, in the entrance and exit of the hemodialyzers were
0.141 EU/mI and 0.145 EU/mI, the standard deviation being 0.362 and
0.303, respectively. Through the test of the matched mean values both
groups of results did not present significant differences. Considering the
type of filter and bath, we observed the following: PAN plus ATC: no
hemodialysis liquids had endotoxins, although two of them had colony
counts in excess of 2000.
CUP plus bicarbonate: entrance ii = 0.185 EU/mt a = 0.295, exit i
= 0.197 EU/isO a = 0.243
PAN plus Bicarbonate: entrance i = 0.360 EU/mI a = 0.655, exit
= 0.345 EU/mI a = 0.455
(b) Blood: The average endotoxin blood concentration levels, before and
after the sessions, were 0.138 EU/ml and 0.175 EU/ml, the standard
deviations being 0.092 and 0.132, respectively. Through the test of the
matched mean values both groups of results did not present significant
differences. Considering the type of the bath, we observed that the mean
values with bicarbonates were: 0.125 0.085 EU/mI and 0.210 0.166
EU/mI, white with acetate the measurements were 0.15 1 0.106 EU/mI
and 0.140 0.093 EU/mt. Conclusions: (1) The dominant fiorae in
hemodialysis baths were composed predominantty of non-fermentative
gram-negative bacteria. (2) No correlation has been noted between cotony
counts and bath endotoxin concentrations, nor between the water used to
prepare the solutions. (3) No significant differences have been observed
between the concentration of endotoxins in the entrance and the exit of
the hemodialyzers, independent of the filters and baths used. (4) The
current bicarbonate baths contain higher levels of endotoxin than acetate
baths. This difference is not observed in relation to the colony counts. (5)
No significant differences have been observed in the endotoxin levels in
blood after and before the hemodialysis sessions.
Bienergetic radiographic absorptiometry in patients on hemodialysis.
A. Martinez Alvarez, I Ocharan, A. Maza, JA. Lopez Ruiz, C. Cabrejas, A.
Marco, I. Saralegui, J. Echevania, and J. Rodriguez Arzadun, Hospital de
Galdakao, Osakidetza, Bizkala, Spain. In order to assess bone loss in
uremic renal osteodystrophy (URO), we have measured total and regionat
mineral bone density (TMBD and RMBD, respectively) by using bioen-
ergetic radiographic absorptiometry (BRA) in a population of patients on
hemodialysis (HD). Thirty-one patients have been evaluated, with a mean
age of 55 and a mean time on hemodialysis of 31 months (range 2—120).
Bone absorptiometry consisted of measurement of total body (TMBD)
and regional analysis of the head, upper limb, lower limb, abdomen, ribs,
pelvis and spine (RMBD). TMBD inversely correlated with alkaline
phosphatase and parathyroid hormone levels; it also correlated inversely
with age, but only in females. TMBD showed significantly lower values in
HD patients than in chronic renal failure patients and controls. All the
regional parameters correlated inversely with alkaline phosphatase levels.
Conclusion: BRA is a non-invasive method which quantifies TMBD and
RMBD with a very low radiologic exposure and correlates adequately with
levels of alkaline phosphatase and parathyroid hormone in URO. TMBD
measures total cortical bone of the skeleton with good accuracy, and
RMBD allows a selective analysis of regional bone changes and a evolutive
control in these patients, given the nonuniform decrease of mineral
density in the skeleton.
1311-fi2microglobulin radionuclide imaging versus ssmTcMDPscans in
patients with dialysis-related amyloidosis. .J. Fort, M. Fraile, J.M. Gonzalez,
M. Martin, I. Camps, A. Olmos, C. Piera, and L. Piera, Nephrology, Nuclear
Medicine and Preventive Medicine Departments, Hospital General Universi-
tario Vall D'hebron and Hospital Clinic, Barcelona, Spain. AIM: The
evaluation of two non-invasive radionuclide procedures 131-I-fl2micro-
globulin scintigraphy (I-132m) and ssmTc..MDP scans (MDP) to screen for
dialysis-related amyloidosis (DA). Patients and methods: We studied 24
patients (14 males) who were classified into two groups: Group A, 14
patients with probable DA, diagnosed by clinical features and electromio-
graphic studies, 9 of whom had proven DA at biosy; Group B, 10 patients
without signs of DA. 1311-f32m was labeled by the Chloramine T method
and scans were performed 48 hours after injection. An (MDP) i.v.
injection was given and multiple views of joints were obtained 3 hours
later. Patients also underwent joints x-ray examinations as well as calcium
bone disease analysis (CBDA) in order to assess renal osteodystrophy.
Statistical analysis was performed by means of BMDP statistical package.
Differences of mean age and years on dialysis (YD) were analyzed with the
Mann-Whitney test, while the relation between diagnostic techniques,
considering each joint separately, was done with the Mac Nemar test.
Results: Mean age of the patients was 58.1 5D 8.9 years and the average
(YD) was 11.4 SD 2.4 years. The I-)32m gave positive uptake of carpaljoints in 7 of 9 patients with proven DA. No significant differences either
in the age or in the number of years on dialysis were seen between both
groups. Taking into account the whole population, no significant differ-
ences in the uptake obtained between both techniques were found. When
we considered the group of patients with normal x-ray of the joints, the
I-j32m gave more positive results in the diagnosis of DA than with the
MDP, P = 0.02. Nevertheless, when we took into account the CBDA
instead of radiology, no differences were seen in patients with lack of
osteodystrophy. Although in the asymptomatic patients the MDP gave less
positive uptake (P < 0.001) when we considered patients who showed
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normal radiology, the I-132m, gave more positive results in diagnosing DA
(P < 0.001). Conclusions: The I-2m scintigraphy had a superior sensi-
tivity in diagnosing DA than MDP. In those patients without overt renal
osteodystrophy, both techniques were quite similar for the diagnosis of
DA. In asymptomatic patients with normal x-ray of the joints, the I-f32m
detected DA deposits earlier and more frequently than with DMP.
Antibodies (Ab) Directed against hepatitis C virus (HCV) in hemodi-
alysis (HD) patients: A 3-year follow-up study. J. Garcia-Valdecasas, M.C.
Bernal, F. Garcia, A. Navas-Parejo, JG Hervas, and £ Cerezo, Hospital
Universitario de Granada, Granada, Spain. The aim of this study was a 3
year follow-up study of Ab against HCV and its relationship with
transaminase (TR) levels in HD patients. We measured in 186 HD
patients the Ab directed against HCV by 2nd generation ELISA and
RIBA tests for 3 years every 2 months. Alanineaminotransferasa (ALT)
was measured monthly. Elevation of ALT over 150% of the upper limit of
normal was considered a marker of hepatitis. We found 60/186 (32.2%)
HCV positive patients; 17 of them (28.3%) showed variation of the
presence of Ab; 2/17 (3.3%) became negative (both had normal ALT 2
years prior to conversion); 8/17 (13.3%) lost Ab against viral peptides, but
they continued positive: 3 of them lost the Ab against 5-1-1 peptide (2/3
had no elevation of ALT during the entire study period); 3 lost the Ab
against C100-3 peptide (1/3 had no elevation of ALT during entire study
period); 2 lost the Ab against 5-1-1 and C100-3 viral peptides, and both
had no elevation of ALT during the study; 7/17 (11.6%) showed variation
in positive or negative Ab against C22, C33, 5-1-1 and C100-3 peptides,
(they always had an elevation of ALT). No patient had an isolated loss of
C22 or C33 peptides. Conclusions: (1) Our HD patients demonstrated a
high prevalence (32.2%) of Ab against HCV. (2) 28.3% of patients had
modification of Ab against HCV: 2 became negative, 8 lost Ab against
viral peptides, and 7 showed variation in positive or negative Ab against
viral peptides. (3) Patients who become negative had normal ALT 2 years
before. (4) Ab against 5-1-1 and C100-3 viral peptides had more modifi-
cations. (5) Patients who showed variation in positive or negative Ab
always had elevations of ALT.
Usefulness of bone radiology and parathyroid ultrasonography in the
pursuit of patients with hyperparathyroidism treated with vitamin D i.v.
C. Sanz Moreno, J. Hemandez, J.M. Garrancho, C. Glez. Heniando, J.L.
Gallego, and J. Botella, Puerta de Hierro, Madrid, Spain. We have studied
12 patients with severe hyperparathyroidism (PTH 562.9 293.8 pg/mI)
treated with vitamin D3 i.v. Before the treatment we evaluated volume,
morphology and echography of parathyroid glands through ultrasono-
graphic study and we found a good anatomical-functional correlation in 11
of the 12 cases. All patients had radiologic data of osteitis fibrosa with
subprioteal resorption and vascular and/or soft tissue calcifications. After
the analytical control of hyperparathyroidism with vitamin D iv. (PTH
96.3 77.4 pg/mI) studies were repeated (3 and 6 months after the
beginning of the treatment). Parathyroid ultrasonography showed changes
in the glandular volume in only 2 patients and increase of echogenicity of
parathyroid nodes in 4 patients; the remaining patients showed no
changes. Bone radiology showed improvement in only 5 of 12 patients. We
believe that parathyroid echography and bone radiology are useful
methods in the diagnosis of hyperparathyroidisin, but they are not
sensitive enough to evaluate the response to treatment with vitamin D iv.
Evaluation of transaminase (TR) as a hepatitis C virus (HCV) repli-
cation marker in hemodialysis (HD) patients. J. Garcia-Valdecasas, MC.
Bernal, F. Garcia, M Manjon, J. Sanchez, and S. Cerezo, Hospital Univer-
sitario de Granada, Granada, Spain. The presence of antibodies (Ab)
directed against HCV associated with high TR is considered to be an HCV
replication marker. In contrast, the presence of Ab against HCV with
normal TR for more than 2 years is suggestive of no actual infection. The
aim of this study was to explore the relationship between the presence of
Ab and TR levels as a viral replication marker in HCV infection in HD
patients. We measured in 107 HD patients the Ab directed against HCV
by 2nd generation ELISA and RIBA tests. In a selected group we
evaluated further the relationship between TR levels and viral genome of
HCV. Selection criteria were: Ab positive against C22, C33-c, 5-1-1 and
C100 peptides; no infection by HAV, HBV, HCMV, EBV, HSV; no
hepatotoxic drugs nor cholelithiasis. Elevation of alanineaminotransferase
(ALT) over 150% of the upper limit of normal was considered as a marker
of hepatitis. Total RNA of HCV was extracted and reversely transcribed
to complementary DNA; after nested PCR, amplificates were hybridized
with a digoxigenin labeled probe. Results: 27/107 had positive Ab directed
against HCV; 8 of them were selected to study viral genome; 3/8 showed
persistent elevation of ALT; 2 of them had viral genome positive by PCR;
2/8 showed alternating elevation of ALT, and 1 of them had viral genome
positive by PCR; 3/8 showed normal levels of ALT, and 2 of them had viral
genome positive by PCR. Conclusions: (1) In HD patients, the presence of
all Ab directed against HCV does not necessarily indicate viral replication
or infectivity. (2) Serum TR levels do not correlate with viral replication.
(3) There are patients with TR elevation without a relationship with
known viral infection or hepatotoxic therapy.
Antibodies (Ab) directed against helicobacter pilori (Hp) in hemodial-
ysis (HD) patients: Relationship with histological lesions of gastric
mucosa. J. Garcia-Valdecasas, A. Quiros, E. Quiros, M Manjon, A. AJkir,
and S. Cerezo, Hospital Universitario de Granada, Granada, Spain. Patients
with gastritis and peptic ulcers have a high prevalence of Ab directed
against Hp. The aim of this study was to explore the prevalence of this Ab
in HD patients and its relationship with gastroduodenal pathological
changes. We measured IgA and IgG Ab directed against Hp in 61 HD
patients (mean age 54 14 years). Gastroscopy and gastric histopatho-
logical studies were also carried out in these patients. We found 67.2%
patients with Ab directed against Hp (mean age 51 15 years in positive







IgG 9 (34.6%) 14 (4Ø%)
IgA + IgG 4 (15.4%) 7 (20%)'
Negative 10 (38.5%) 10 (28.6%)a
a Not significant
Conclusions: (1) A high prevalence of Ab directed against Hp was found
in patients on hemodialysis. (2) In these patients no relationship was
found between Ab against Hp and histopathological lesions of gastric
mucosae.
Transmission of hepatitis C virus (HCV) in hemodialysis (HD) units.
Efficacy of preventive measures and patient isolation. J. Garcia-Valdeca-
sas, MC. Bernal F. Garcia, .1. G. Hervas, A. Navas-Parejo, A. Saleh, and S.
Cerezo, Hospital Universitario de Granada, Granada, Spain. The prevalence
of antibodies directed against HCV in HD units, presumably reflecting the
evidence of infection, increases each year. We studied seroconversions
(SC) occurring in our HD units over the past 3 years, before and after the
institution of infection control protocols. One hundred seven HD patients
at 3 units (A, B and C) had serial measurements of antibodies directed
against HCV evaluated by a 2nd generation ELISA, confirmed by 2nd
generation RIBA. Testing was performed every 2 months from March
1990 to March 1993. Alanine aminotransferase (ALT) was measured
monthly. Elevation of ALT over 150% of the upper limit of normal was
considered a marker of hepatitis. Unit A: Six of 27 patients (22.2%) were
HCV positive at the initial testing, and 3 patients seroconverted the first
year for a total prevalence of 33.3% and incidence of 14.3% of infection.
After the institution of infection control measures and isolation, there was
a 2.8% incidence of SC/year (P < 0.05 compared to first year). Unit B: 7
of 28 patients (25.0%) were HCV positive at the initial testing, and 5
patients seroconverted the first year for a total prevalence of 42.8% and
incidence of 23.8% of infection. After the institution of infection control
measures and isolation, there was a 3.1% incidence of SC/year (P < 0.001
compared to first year). Unit C: 14 of 52 patients (26.9%) were HCV
positive at the initial testing, and 5 patients seroconverted the first year for
a total prevalence of 36.5% and incidence of 13.2% of infection. After the
institution of infection control measures without isolation, there was a
7.1% incidence of SC/year (NS). Conclusions: (1) HCV infection is
prevalent in HD patients. (2) Horizontal (among patients) and vertical
(through machine) transmission may be important routes of infection. (3)
Infection control measures and isolation may significantly reduce the
incidence of HCV infection in HD patients. Isolation is necessary to
reduce HCV infection to a minimum in HD patients.
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Erythropoietin (rHuEpo), interleukin 2 soluble receptors (IL-2R) and
lymphocyte subpopulations in hemodialysis (liD). R. Bustamante, M
Arranz, J. Bustarnante, C. Rubio, NS. Jabaiy, A. Mendiluce, J. Nuñez, and
E. Hemandez, Servicio de Nefrologla, Hospital Universitario, Va//ado/id,
Spain. Recombinant human eiythropoietin (rHuEpo) seems to affect the
immunity of uremic patients. To partially evaluate this we studied
interleukin 2 soluble receptors (IL-2R), lymphocyte and lymphocyte
subpopulations in 20 subjects: 10 patients on hemodialysis treated with
rHuEpo, and 10 patients on hemodialysis without this treatment were
analyzed and compared. The mean ages were 53 14.7, 9 males and 11
females, dialyzed with non-cellulose membranes with 1 m2 surface area, 4
hours 3 times per week. The two groups were similar in age, sex, and
hemodialysis techniques. Samples were drawn at 9 am, in all patients.
Lymphocytes were determined by standard laboratory methods, lympho-
cyte subpopulations by immunofluorescent staining with monoclonal
antibodies and IL-2R and erythropoietin levels by ELISA. The mean
doses were 45 U/kg after HD. The plasmatic levels of EPO and hematocrit
(Hct) were similar for the two groups (with Hct 28,7 3.2% and 28.9
5.4% and hemoglobin 9.6 1.3 mg% and 9.4 1.8 mg%). We did not see
a significant decrease of IL-2R in the group with rHuEpo treatment.
There was a significant decrease of T4 lymphocyte and T4 cells/T8 cells
ratio (P < 0.05) in the group with rHuEpo treatment. In this group EPO
levels had a significant correlation with T lymphocyte levels. In conclusion,
there was a decrease of T4 cells and the T4/T8 cell ratio and a
non-significant decrease of IL-2R.
The angiotensin converting enzyme (ACE) and recombinant human
erythropoietin in hemodialysis (HD). M Arranz, R. Bustamante, NS.
Jaba,y, V. Perez Diaz, J. Bustamante, C. Rubio, and J.M. Briso-Montiano,
Servicio de NefrologIa, Hospital Universitario, Valladolid, Spain. ACE levels
can rise with hemodialysis, being related not only to stimulation of
pulmonary vascular endothelium but also to plasma volume lost during
HD. Treatment with recombinant human erythropoietin (rHuEpo) pro-
duces changes in these levels. The objective of this study is to determine
the relation between ACE levels in patients undergoing hemodialysis with
rHuEpo treatment. We have determined ACE and erythropoietin (EPO)
levels as well as standard laboratory parameters in 14 patients undergoing
hemodialysis of whom 7 were treated with rHuEpo. Samples were taken at
9 a.m. in all patients, which ECA levels determined by a colorimetric
enzymatic method and EPO by ELISA. The mean ages were 54.5 for the
rHuEpo treatment group, 55 without rHuEpo, and 38 in the control
group. The ACE levels rose in the two groups compared to the control
group, and we saw a greater increase in those without rHuEpo treatment
(52.6 24.8 vs. 37.4 17 U/liter), an almost significant statistical increase
(P < 0.1). We saw a non-significant decrease of ACE levels in the group
with rHuEpo treatment (37.4 17 U/liter). The EPO levels were similar
for the two groups (11.8 vs. 10.8 U/mI). We did not see significant
differences among those subjects or with the control group (9.9 U/mI). In
conclusion, there was a decrease of ACE levels with patients undergoing
rHuEpo treatment in hemodialysis.
The biocompatibility of hemodialysis membranes. R. Bustamante, M.
Arranz, J. Bustamante, C. Rubio, N.S. Jabay, .1. Nuñez, and A. Mendiluce,
Servicio de Nefrologia, Hospital Universitario, Valladolid, Spain. The bioin-
compatibility of hemodialysis membranes is a stimulus for the production
of proteins in the acute phase of inflammation. We have studied the
behavior of factors, such as leukocyte elastase (EL), fibronectin (FB), 132
microglobulin (/32m), the C3a complement fraction (C3a), interleukin 2
soluble receptors (IL-2R), and at antitripsin (alA), and the relation with
the utilization of hemodialysis membranes such as cuprophan, EVAL,
polysulfone and polyacrilonitrile in 65 patients undergoing hemodialysis,
and 10 healthy subjects. EL and j32m were determined by ELISA, FB and
alA by nephelometry, C3a by radial immunodiffusion, IL-2R by immu-
noenzyme assay, and leukocytes by standard laboratory methods. In the
patients with cuprophan membrane there was a very significant decrease
of leukocytes at 5 minutes related to the J32m, C3a and IL-2R. After 30
minutes we saw a significant increase of /32m, EL, C3a and IL-2R. The f32m
increase had a significant correlation with elastase and C3a. alA de-
creased at the initiation of hemodialysis and increased after 30 minutes.
When we used the EVAL membrane the /32m, C3a, FB and IL-2R were
not modified during hemodialysis. The leukocyte elastase rose after 30
minutes and alA increased progressively. A significant correlation was
found between fibronectin and C3a and alA and IL-2R. With the
polyacrilonitrile membranes the 132m decreased, EL increased after 120
minutes, and C3a at 240 minutes. The FB, alA and the IL-2R did not
change. A significant correlation was found between EL and C3a, EL and
alA and alA and IL-2R. With the utilization of polysulfone membranes
132m decreased, the leukocyte elastase, FB and alA increased significantly
with the hemodialysis, and IL-2R and C3a were not modified. A significant
correlation was found between /32m EL and between FB and alA.
Left ventricular diastolic function and hypotension during hemodialy-
sis. M Asensio, D. Muñoz, V. del Villar, M. Gofli, M. U/la, and MC. de Ia
Higuera, Department of Medicine, Soria Hospital, Sona, Spain. Introduc-
tion: During hemodialysis (HD), symptomatic hypotension (SH) defined
according to criteria of Rozich et al (whose prevalence is placed between
20—50%) has multifactorial etiology: variations in serum osmolarity,
lowering in extracellular volume, autonomous dysfunction, alterations in
acid-base balance, hypoxemia and biocompatibility of membrane; though
the contribution of decreased ejection fraction and cardiac index to the
genesis of SH is known, the potential alteration of diastolic ventricular
function has been less studied. Aims: To analyze the differences in left
ventricular diastolic function during HD between the patients who present
SH and those who do not. Patients and methods: Twenty-seven patients
on periodic HD have been studied. In 10 patients (group A) a mean (X)
of 2.1 SH in five subsequent dialyses was detected. In 17 patients (group
B) SH episodes were not detected. No differences in ages were present
between both groups. By means of echocardiography 2D and doppler
(ATL Ultramark 7) before and after the third HD, the following were
measured: left auricular (AD) and ventricular systolic (SVD) and diastolic
(DVD) diameter in mm, peak E and A wave in cm/s (PE, PA), wave E and
A velocity time integral in cm2/s (EVTI, AVTI). Blood pressure (sBP,
dBP) and heart rate (HR) were also determined. In every studied variable,
X and so were determined, and results pre- and post-HD were compared
between both groups by means of the Student's t-test.
Pre-HD (X SD) Post-HD
Group A
(X so)
Group BGroup A Group B
sBP 145.3 16.4 149.6 15.4 115.5 20.8 130 19.3
dBP 82.5 8 85 7.2 70.2 13.4 79.6 97
HR 72.3 7.5 68.1 7.8 87.7 14.6 80.4 13
SVD 32.5 0.4 34.4 4.5 29,7 2.8 31.1 4.4
DVD 47.9 0.5 47.7 4.2 40 3.8 43.7 44a
PE 71.7 14.5 79.8 19.5 56.3 11 63.8 15.8
PA 71.8 10.7 67.8 26.8 78.8 17 76.9 16.5
EVTI 7.7 0.3 9.9 3.2a 7 0.4 8.6 2.3a
AVTI 7.6 1.2 8.7 3.2 7.9 0.9 9.7 4
AD 33.1 3.1 34.3 4.1 30.4 3.5 32.4 3.5
a p < 0.05; Student's t-test
Conclusion: In the present study diastolic function is worse pre-HD and it
deteriorates mroe during HD in the group of patients who develop SH.
Mass transfer of bicarbonate and acetate in paired-filtration dialysis
(PFD) and high-flux dialysis. J. Hernandez-Jaras, A. Ga/an, and J. Martin,
Hospital de Gandla, Valencia, Spain. PFD is a hemodiafiltration technique
that attempts to maximize diffusive and convective clearances through the
separation of two functions in a single device with two segments. Large
amounts of bicarbonate and other buffers are lost by convection in the
ultrafiltrate. The present study was designed to evaluate the bicarbonate
mass transfer across the PFD two chamber filter and to compare this data
with that obtained during high-flux hemodialysis. Two different groups of
patients on chronic hemodialysis (3 hr 3 times/week) were studied. Group
1 consisted of 8 patients using a SG3 filter (polysulphone 0.55 m2
hemophan 1.36 m2). Group II also consisted of 8 patients using a 1.4 m2
surface polysuiphone membrane hollow-fiber dialyzer. Bicarbonate (33
mEq/l) and acetate (4 mEq/liter) were used as buffer in the dialysate. The
bicarbonate's (Lbic) and acetate's (Lacet) losses across the first chamber
were evaluated. Likewise mass transfer of bicarbonate (Jbic) and acetate
(Jacet) for each hour and total were evaluated in both groups. Lbic in the
first chamber was 186.05 10.5 mEq. Lacet was 4.3 1 mEq.
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Total
1st hr 2nd hr 3rd hr mEq
Jbic were
Group I 104.5 17 65.6 6.7 56.8 14.9 227.1 31.7












ap < 0.001; bp = NS
In Group I, ultrafiltrate rates (UF/min) significantly correlated with Lbic
in the first chamber. Jbic in the second chamber also significantly
correlated with UF/min (r = 0.75, P (0.05) and Pbic (r = 0.76, P (0.05) in
the first chamber. Conclusions: Large amounts of bicarbonate are lost by
convective transport in the first chamber. This loss correlates with the
amount of ultrafiltrate produced during the treatment. Small amounts of
acetate contained in bicarbonate dialysate produce an important base
gain. Separation of two transports, convective and diffusive, allows substi-
tution by diffusion of the bicarbonate lost via ultrafiltration across the first
chamber. In PFD a lower quantity of base in reinfusion liquid can be
utilized than in other hemodiafiltration techniques.
Intravenous (i.v.) vs. subcutaneous (s.c.) administration of erythropoi-
etin (EPO) in hemodialysis (HD) patients. P. Vidau, J. Peral, R. Tomé C.
Rodriguez, and J. Herrera, Servicio de Nefrologia, Hospital General de
Asturias, Oviedo, Spain. The efficacy of replacement therapy with (EPO)
on the anemia of chronic renal failure is now well established. However,
the most effective route of administration is still a matter of discussion. It
has been suggested that s.c. administration permits the dosage to be
reduced by 30—40%. The aim of this study was to investigate prospectively
and compare the clinical effect of i.v. and s.c. administration of EPO,
respectively. Eleven patients on chronic HD were studied, age range 21—70
years, mean HD time 7.54 3.8 years. They all had been treated
previously by EPO i.v. 3 times per week for more than a year, mean 20.18
6.38 months. The dose was reduced when hemoglobin exceeded 12 g/dl.
Hemoglobin, hematocrit, EPO dose and iron status, as indicated by iron
ferritin, were evaluated. The period of observation included a year prior to
the conversion and a year after conversion of iv. to s.c. The results are
summarized in the next table:
Parameters i.v. EPO s.c. EPO P
Hemoglobin 8.27 1.44 9.74 1.44 <0.001
Hematocrit 25.55 4.37 29.70 4.06 <0.001
Ferritin 124.50 55.9 233.29 162.2 <0.05
EPO JU/ 7070.45 2195 6277.27 1693.3 NS
week
Abbreviation NS is not significant
Conclusion: The results indicate that s.c. administration of EPO is more
effective that i.v. route. In these patients the conversion of i.v. to s.c. route
permitted a mean dose reduction by 11.12%. In spite of this reduction
hemoglobin and hematocrit levels increased significantly with s.c. admin-
istration.
Interdialytic ambulatory blood pressure monitoring (ABMP). Compar-
ison with pre- and post-dialytic blood pressure (BP). V Peral, P. Vidau, R.
Tome, C. Rodriguez, and J. Herrera, Servicio de Nefrologia, Hospital General
de Asturias, Oviedo, Spain. BP changes in hemodialysis (HD) patients are
influenced by several factors. The most important one is the increase in
blood volume during the interdialytic period. The interpretation of BP in
these patients is difficult. It is not known whether pre- or post-dialytic BP
is predictive for the average interdialytic BP. Both pre- and post-dialytic
BP are usually evaluated with an aneroid manometer. The aim of this
study was to evaluate whether pre- or post-dialytic BP correlated best with
the average BP during the interdialytic period. We studied 14 chronic HD
patients, mean age 40.14 18.35 years, mean duration on dialysis 3.78
35 years. Six of them had an acetate bath and 8 had bicarbonate. BP was
recorded non-invasively using a Spacelabs 90207 oscillometric BP moni-
tor. Measurements were started at the beginning of the HD session,
continued during 48 hours and terminated at the start of the subsequent
HD session. Four patients with acetate and 4 with bicarbonate were
hypertensive, and they were treated with antihypertensive agents. We
considered post-dialytic BP the average of BP measurements during 4
hours post-first HD session and predialytic BP the average of BP
measurements during 4 hours pre- the subsequent HD session. Pre- and
post-dialytic BP were compared with the average pre- and post-dialytic BP
measured during a month previously and also with interdialytic and
intradialytic BP. BP during the first and second day was also evaluated.
The relationship between weight gain and rise of BP during the interdia-
lytic period and the relationship between variations of Na concentration in
dialysis solution and BP were studied. Conclusion: The difference between
pre- and post-dialytic BP was not significant. Neither pre- nor post-dialytic
BP was significantly related to pre- and post-dialytic BP measured during
the month previously. Neither pre- nor post-dialytic BP was compared
with interdialytic BP. This suggests that both pre- and post-dialytic BP are
representative for interdialytic BP. No differences were observed between
the first and second day BP. Correlation between weight gain interdialysis
and predialysis BP was significant (P < 0.001). The only difference
between acetate and bicarbonate bath was a rise in pre-dialytic BP with
acetate (P < 0.05).
Determination of anticardiolipin antibodies (aCL) in hemodialyzed
patients. E. Castellote, J. Bonal, E. Abella, M. Casals, and A. Caralps,
Hospital Universitario "Gennans Trias i Pujol' Badalona, Spain. The
presence of aCL in hemodialyzed patients is increased, although its
clinical significance is under discussion. aCL were determined using an
ELISA (Menarini) method in 31 stable patients under a conventional
hemodialysis program. One year later, a second determination was
performed in the 12 (35%) baseline positive patients (35% IgG+, 19%
IgM+) by means of 2 methods (ELISA Menarini and ELISA Knicker-
bocker), to study the evolution of the antibody levels, the possible
influence of the method used, and the relationship between aCL and
clinical events. Seventy percent of the positive patients had no antibodies
in the second determination. The results were compared using a Wilcoxon
test and the possible linear correlation was analyzed.
IgG GPL/ml 1gM MPLImI
Mean Mean
N = 12 SD r Wilcox. SD r Wilcox.
Baseline 28 21 0.65
(P<0.05)
P < 0.01 13 16 0.53
(NS)
NS
Final 10 11 NS P < 0.05 14 21 0.9 NS
(Menarini) (P < 0.01)
Final 3±2 16±22
(Knicker.)
Age (56 vs. 61 years), sex (7F:4M vs. 11F:9M), duration of dialysis (34.2 vs.
34 months) and dialysis membrane used were similar in patients with and
without aCL. The statistical analysis did not show any differences in the
incidence of clinical events, considering as outcome measures: arterial and
venous thromboses, fistula repairs, and death. Conclusions: (1) The
clinical importance of aCL in dialysis patients is uncertain. (2) The aCL
levels change with time. (3) The analytical method used can influence the
aCL value (essentially IgG).
The increase of dialitic efficiency favors ingestion. V. Va/verde, C.E.
Bosque, and M. Herrero, Dept. of Nephrology, General Hospital Elda,
Alicante, Spain. Efficient HD usually favors appropriate ingestion which
conditions a good nutritional result (PCR > 1). We selected 19 patients
among our population of stable chronic hemodialysis individuals without
apparent clinical problems. Those patients had PCR lower than 0.75 with
KT/V > 1 in three consecutive bimonthly determinations. We increased
dialytic efficiency in these patients by raising blood flow, then we increased
the membrane surface (to a maximum of 1.9) and in some of them, we
extended the time (maximum 270 minutes). KT/V-PCR determinations
were made bimonthly during one year (in the middle of week). We used
post-HD samples obtained 20 minutes after HD was finished.
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6 months before 1 year later
Membrane Age
KT/
V PCR T QB Sup.
KT/
V PCR T QB Sup.
Cup (10) 58 1.3 0.73 3 250 1.6 1.6 1.03 3.30 280 1.8
HPM (9) 52 1.21 0.71 3 250 1.4 1.36 1.17 3.30 275 1.6
After 12 months PCR normalization was obtained (PCR> 1) in 16 of the
19 patients. In the three remaining patients, different pathologies were
identified: TB, chronic pyelonephritis, and severe HPT. In patients with
Cup (Cuprophan) KT/V was necessaiy up to 1.6 in order to normalize
PCR, whereas HD patients with HPM (high-performance membrane)
needed lower increases (1.36). Conclusion: With low PCR and excluding
adjacent pathology, dialytic efficiency must be increased, independently of
KT/V. This increase in "dialysis doses" favors ingestion and a better
nutritional state, resulting in PCR normalization.
Consequences of treatment of hyperparathyroidism on erythropoietin
needs. V. Valverde, E. Bosque, and M Herrero, NefrologIa, Hospital General
del SVS, ELDA, Alicante, Spain. Hyperparathyroidism (HPT) is one of the
causes of a poor response to recombinant human erythropoietin (EPO) in
patients with chronic renal failure on hemodialysis (HD). We have
reviewed, retrospectively, the evolutive response to EPO in 11 patients
with renal failure on HD. Those patients required EPO doses higher than
360 U/kg/week in order to obtain a medullaty response. An adequate
treatment of hyperparathyroidism in these patients led to a drastic
reduction in EPO requirements.
Hb Hct EPO Ca P A.F. PTH Al/pDFO
Initial 7.3 21.8 450 9.9 6.8 110 650 31/76
Correc HPT 8.1 24.3 300 10.3 7.1 960 310 47/105
HPT supres. 11.5 34.1 75 10.1 5.4 86 64 48/57
In three patients, suppression of HPT with oral bolus of 1,25(OH)2D3 (1.5
to 2 .rg postHD) was obtained. In six of them a good response was
measured to i.v. doses of calcitriol post-HD; two other patients needed
subtotal parathyroidectomy during the course of treatment with i.v. by
calciphylaxis. Conclusions: (1) Reduction in PTH secretion caused by oral
or parenteral treatment with 1,25(OH)2D3 or subtotal parathyroidectomy
improved the response to EPO, dramatically reducing EPO requirements.(2) High EPO requirements in patients with severe HPT may be condi-
tioned by extensive bone marrow fibrosis. It might even be tentatively
concluded that PTH has a blocking effect on medullary response to EPO.
Also, a 1,25(OH)2D3 requirement for medullary response may be needed.
More research is necessary to make these mechanisms clear.
Modifications of echocardiographic parameters in hemodialysis pa-
tients: Erythropoietin (rHuEPO) ell'ects. N. Marigliano, H Torrealday, 0.
Vaccari, A. Covarsi, 0. Sanchez, R. Novillo, JR. Gómez-Martino, and J.D.
Pedrera, Sección de Nefrologia, Unidad de Cardiologia, Hospital San Pedro
de Alcántara, and Farmacologia, Unive,idad de Extremadura, Cáceres,
Spain. The heart function in patients with renal chronic failure (CRF) on
hemodialysis (HD) is modified by different agents (anemia, hypervolemia,
hypertension, fistula, etc). The treatment with rHqPO modifies the
echocardiographic values of the myocardium. The aim of the present study
has been to analyze the echocardiogram changes after the improvement of
clinical and hematological parameters of these patients. We've studied the
hemodynamic effects of treatment with rHuEPO (25 lU/kg/s.c.) for 6
months in 9 patients (4 women and 5 men) with a time on HD of 30.5
5.7 months. In this study at the beginning and after 3 and 6 months
treatment with rHuEPO, the following parameters were investigated:
hematological values, blood pressure, and echocardiographic modifica-
tions. The results show a significant improvement of anemia (Hct 28 1.5;
Hb 9.5 0.4), and there were no significant changes in blood pressure. At
the same time the echocardiographic changes have shown an important
decrease in the diastolic diameters of the left ventricle after treatment
(57.88 1.42 / 52.32 2.29). A minor presence of pericardial effusion was
noticed and the ventricular relaxing index, having not been modified, was
high. The aortic speed, the left ventricular posterior wall and the cardiac
mass also showed significant decrease. We conclude that the echocardio-
graphic parameters, cardiac function, systolic function changes, and
cardiac mass improve in HD patients after improvement of the renal
anemia, with the patients being in grade I of the NYHA.
Parathyroidectomy in hemodialysis (lID) today: When and how much?
M. V. Moreno, MA. Fnaos, C. Calvar, B. Ramos, J. Femandez-Gallego, and
E. Lopez de Novales, Nephrology Unit, Hospital Regional de Mdlaga, Spain.
In the last ten years parathyroidectomy (PTX) has been almost the only
therapeutic approach in the treatment of secondary hyperparathyroidism
(HPS) in patients with chronic renal failure treated with dialysis. High
doses of oral or parenteral calcitriol decrease the rate of PTX due to direct
suppression of PTH synthesis. Nevertheless, in cases of severe HPS with
large hyperplasia, high doses of iv. calcitriol may not reverse the HPS. We
evaluated the indications and results of 10 PTX (8 subtotal and 2 total with
autograft) performed in the last three years. All patients were on HD for
7.6 3 years, mean age 41 16 years. Bone biopsy (8 cases) showed
severe osteitis fibrosa without aluminum in 7 patients and mixed disease in
1. Six patients received high doses of i.v. calcitriol (1—3 g after HD)
during 9.8 5.7 months (3—18), and in spite of significant decreases of
iPTH it was necessary to stop the treatment due to frequent episodes of
hypercalcemia and hyperphosphoremia.
Pre-PTX 6 months 12 months













EPO U/kg/week 58 16 49 12 39 15
ap <0.001; bp < 0.05
Complications after PTX were scarce and minor. In conclusion, PTX is
still necessary today in those cases of severe HPS refractory to iv. calcitriol
treatment. Nevertheless, the removal of 3½ glands could be excessive,
since it leads to a low PTH situation and predisposes to parathyroid
hypofunction.
Chronic hepatitis C virus (CH-HCV) in hemodialysis (HD) and kidney
transplantation (KT): Histopathology and evolution. E. Andrés, T
Casanovas, C. Baliellas, C. Benasco, S. Gil-Vernet, J.M Griñó, A.M
Castelao, MT Gonzalez, L.A. Casais, and J. Alsina, Departments of
Nephrology, Gastroenterology and Pathology, Hospital de Bellvitge, Barce-
lona, Spain. HCV infection is the main cause of CH among renal patients
undergoing on HD or KT. From 1987 to 1992 we studied 32 patients with
CH-HVC (14 on HD and 18 with KT). All of them had positive anti-HVC
antibodies (EIA 2, RIBA 2), and ALT levels were almost twice normal
values during more than 6 months. Patients with HBV infection were
excluded. Liver biopsy (LB) was obtained after informed consent. Clinical
follow-up was done as usual. We found the following histological and
biochemical results:
HD ALT KT ALT
Minimal lesions (ML) 1 1.6 2 1.4
Chronic lobular hepatitis (CLH) 3 4.3 3 3.4
Chronic persistent hepatitis (CPH) 5 1.8 6 2.9
Chronic active hepatitis (CAH) 5 2.4 2 2.7
Chronic active hepatitis with bridging 0 5" 4.2
hepatic necrosis (CAHB)
Total 14 18
Normal values of a ALT < 0.7 kat/liter; "P < 0.05.
In the HD group (follow-up 27 18.2 months) the majority of patients
had stable ALT levels. Four patients received a renal graft, 3 of them
(CLH or CPH) with a good evolution. On the other hand, 1 (CAR)
showed increased ALT after KT. One patient died because of an
unrelated disease. In the TR group (follow-up 37.9 12.2 m), biochem-
istry was also stable in general. But 2 patients (CAHB) required a double
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liver-kidney transplant. Conclusions: (1) ALT does not correlate with the
severity of liver injury in CH-HCV. So LB is mandatory to establish a
diagnosis and prognosis. (2) The distribution of histological pattern is
similar in HD or KT, but we observed CAHB only in the KT group. (3)
Outcome is more severe in patients with previous kidney graft.
Renal replacement therapy (RRT) and mortality in diabetic nephrop-
athy. A.M Castelao, MT. Gonzalez, C. Vinzia, E. Andrés, J.M. Griñó, .1.
Soler, and J. Alsina, Nephrology and Endocrinology Departments, Hospital
de Bellvitge, University of Barcelona, Barcelona, Spain. Since we started our
joint endocrinology/nephrology follow-up of diabetic nephropathy (DN)
from January 1979 until December 1992, we have controlled 315 diabetic
patients, 85 of whom were insulin dependent (IDDM) and 230 non-insulin
dependent (NIDDM). Here are the patients' follow-ups:
IDDM NIDDM
Patients 85 230
Starting age of RF 40 11(24—66) 61 9 (36—87)
ESRF age 41.8 11(27—65) 61.7 8(38—87)
Chronic hemodialysis 30 41
Peritoneal dialysis (CAPD, IPD) 7 15
HD-PD (change of technique) 4 3
Renal transplant 15 (17 TR) 4
Renal + pancreas transplant 5 —
Total patients on RRT 43" (50,6%) 59 (25.7%)
Patients dead (total) 48 (56%) 94 (41%)
Patients dead (total) before Dial. 12 (14%) 60 (64%)








2 RT before dialysis
In conclusion, 102 patients have been placed on RRT. Some patients died
before reaching ESRF, many of them due to intercurrent causes. Higher
mortality rates in IDDM patients can be explained by the longer evolution
and the severity of complications in these patients. Cardiovascular mor-
tality is the most frequent and probably explains many of the deaths of
unknown origins.
Longitudinal study of HCV infection in one hemodialysis unit. Corre-
lation between seroprevalence, viremia and ALT levels. LA. Oliva, MG.
Ercilla, R. Maymó, K Celis, J. Carrió, J.M Barrera, J.M Mallafré, and M.
Bn1guera, Dept. of Nephrology, Blood Bank, Hospital Creu Roja Immunol-
ogy Dept. and Liver Unit, Hospital Clinico, Barcelona, Spain. Hemodialysis
patients are a population at risk for HCV infection because of the
requirements of blood transfusions, the use of common equipment, and
the close contact these patients have with each other. The seroprevalence
anti-HCV was prospectively evaluated in 69 patients in a single hemodi-
alysis unit between 1989—1992. Anti-HCV was detected by a second
generation ELISA test (ORTHO Diagnostic Systems) and the RIBA SIA
Prototype (CHIRON Co.) was used to characterize the specificity of
antibodies. Furthermore, the presence of HCV-RNA in serum was
determined by nested PCR using primers of the 5' non-coding region. The
HCV subtypes were analyzed by PCR using primers of the core variant
regions (Okamoto 1992). Twenty-nine patients out 69 (42%) were anti-
HCV positive, all confirmed reactive with four/five bands by RIBA.
HCV-RNA in serum was tested in all seropositive patients. The subtype
study of HCV showed that all patients were typed as class II, and 4 showed
a double pattern HCV I + II.Twenty-four patients were already seropos-
itive before the study was started, as demonstrated by frozen serum
samples. In the historical data, a rise of ALT levels was recorded in 11
(46%) ranging from 45 to 618 U/liter. In the remaining 13 the transami-
nases were always within normal levels. Five patients seroconverted
anti-HCV at three years follow-up, showing an ALT increase ranging from
45 to 492 U/liter in only 3/5 patients (60%). The seroconversion was also
demonstrated by PCR. In four of these patients, the HCV screened blood
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was negative. The mean of blood units transfused was 16.54 15.85
(range 2—60), 3.25 2.50 (range 2—7) in the chronic HCV infected and
acute HCV infected, respectively. However, 1 chronic patient and 1 acute
patient were never transfused. We confirm a high rate of seroconversion,
the active HCV replication in some patients with normal ALT levels and
the predominant class II virus infection.
Optimizing erythropoietin treatment in hemodialysis patients: Use of
intravenous FE-gluconate. IL. Gómz, M. Suria, M. Hermenegildo, E.
Albert, L. Lozano, J.L. G" Ramos, E. Alcoy, and N. V Jiménéz, Departments
of Nephrology and Pharmacy, Hospital Dr. Peset, and Department of
Pharmacy, and Pharmaceutics, University of Valencia, Valencia, Spain. Iron
deficiency is the most frequent reason for the lack of response to
erythropoietin (rHuEPO) treatment in hemodialysis (HD) patients. Oral
iron therapy is not well-tolerated and compliance is not always guaran-
teed. To evaluate the effect of intravenous (i.v.) iron therapy on the
treatment response to rHuEPO, a prospective study has been carried out
during 14 months, including 41 HD patients treated with rHuEPO during
at least 4 months, maintaining regular doses of rHuEPO i.v. and with iron
deficiency (serum ferritin levels <150 ng/ml and/or transferrin saturations
< 20%). During the study 11 patients were excluded. All patients were
prescribed oral Fe therapy (p.o. Fe) during the first 3 months; later they
received iv. Fe-gluconate (iv. Fe) (Ferrlecitr) at the end of each dialytic
session: dose = reserves-needs; reserves (mg) = 400 x (log ferritin-log
50), needs bases in Cook's formula, distributed along 6 weeks, and after
that 62.5 mg/week as maintenance dose. rHuEPO administration was i.v.









Basal p.o. Fe 3 months 6 months EPO
26.6 3.4 26.6 3.7 30.2 3.6 30.7 3.31 29.4 2.7
9.0 1.2 9.6 0.9 10.0 1.1 10.3 1.17 10.0 1.0
57.2 44.2 44.7 42.5 90.0 74.2 215.3 90.2 209.1 85.1
53.7 24.4 48.7 16.6 56.2 25.5 59.1 26.1 58.1 24.1
iron
Trans. 18.7 10.8 22.0 8.4 24.0 12.7 28.6 8.6 27.5 8.2
sat.
TIBC 265.6 58.2 224.5 41 239.9 34.9 197.4 42.8 185.5 39.1
The increase in hematocrit (Hct) and hemoglobin (Hb) was statistically
significant from the first month of i.v. Fe treatment (P < 0.001) and
ferritin from the second week of i.v. treatment (P < 0.001), maintaining
both stable until the end of the study. Using s.c. rHuEPO, a 37% dose
reduction (P < 0.001) was obtained, without any modification in Hct and
Hb values (P = NS). Conclusions: (1) iv. Fe treatment has improved
rHuEPO efficacy in HD patients, which has not been achieved using p.o.
Fe. (2) Variability in serum Fe concentrations and elapsed time for
rHuEPO response are lower in i.v. Fe-treated patients than p.o. Fe-
treated patients. (3) Utilization of rHuEPO s.c. allows reduction in dose
without modifications in therapeutic response. (4) Using Fe i.v. and
administering rHuEPO s.c., optimization of the treatment with rHuEPO
has been achieved without considerable adverse effects.
Ca acetate (CaAC) versus Ca carbonate (CaCO3) for the control of
serum phosphate (P) in hemodialysis (HD) patients. J. Almirall, L.L.
Veciana, and J. Llibre, Consorci Hospitalari Parc Tauli Sabadell, Cetirsa,
and Hospital Mutua de Terrassa, Barcelona, Spain. Recent studies have
shown that CaAC is a more effective phosphate (P) binder than other Ca
salts; however, in clinical practice few reports have compared them, and
results disagree. We evaluated in a 24 week prospective cross-over study
the clinical efficiency of CaAC and CaCO3 in 10 selected chronic HD
patients. Serum analytical tests included weekly control of Ca, P and AP.
PTHi was obtained initially and at the end of every period of the study.
The same good control of P level (4.7 0.6 vs. 4.9 0.8 mg/dl) was
obtained with CaAC (mean doses 4.1 0.3 g/day) as with CaCO3 (mean
doses 4.01 0.8 g/day). Mean serum Ca levels were similar (10.3 0.5 vs.
10.2 0.5 mg/dl). The doses of elemental Ca administered were signifi-






mg/day). However, the incidence of hypercalcemia (Ca > 11 mg/dl) was
similar in the two treatment periods (13% vs. 14%). Also, the incidence of
CaxP products over 65 was comparable (9.5% vs. 11.9%). In conclusion,
40% less Ca is needed to be supplied when CaAC is used; however, the
control of P and the frequency of hypercalcemia was the same as with
CaCO3. There is no clear advantage of CaAC over CaCO3 in a medium
length study.
Treatment of secondary hyperparathyroidism (HPT) with intravenous
calcitriol bolus (i.v.C). J. Almirall, V. Torregrosa, A. Cases, P. Arrizabalaga,
and J. Oliva, Consorci Hospitalari Parc Tauli, Sabadel4 and Hospital Clinic,
Hospital Creu Roja, Barcelona, Spain. We evaluated, in a prospective 6
month study, the response of PTHi levels to i.v.C in 21 patients with HPT
resistant to conventional treatment. Oral calcitriol was stopped and P
levels were controlled with OHA1. Then i.v.C was started at 1 sg doses
after HD, adjusting doses according to calcium levels (maximum 3 tg/HD
session). Serum Ca, P and AP levels were controlled weekly, and PTHi
levels every month. A clear drop in PTHi values were observed: basal 698
277 pg/mI, being 403 263 at 3 months, and 272 200 at 6 months.
Serum Ca levels slightly rose, basal 10.4 0.6 mg/dl, 10.6 0.6 at 3
months, and 10.8 0.5 at the end of the study. Ten patients presented a
serum Ca level over 11.5 during the study. All but one patient were
symptomless, 4 were treated reducing the i.v.C dose, 4 also required a
decrease of Ca in the HD solution, while 2 did not respond and were
excluded. The regression equation showed a 50% decrease in PTHi values
independent of serum Ca levels (direct inhibition). In the severe cases (10
patients), the response obtained was considered correct in 5 cases, partial
in 2, and void in 3. In conclusion, i.v.C is an effective method for HPT
control. This can avoid surgical PTX in some patients; however, the
response in severe forms is less satisfactory. Although Ca tends to rise, the
risk is clearly lower than with standard regimens.
Evolution of the osseous mass (OM) in patients on a program of
periodic hemodialysis (HD). A. Navas-Parejo, M Muñoz, M. Manjon, J.
Garcia-Valdecasas, F. Martinez, E. Raya, and S. Cerezo, Services of Nephrol-
ogy, Endocrinology, and Rheumatology, University Hospital, Granada, Spain.
Introduction: The determination of OM by means of densitometry is a
non-invasive accurate technique, useful in evaluating the way in which the
skeleton is affected in uremic patients. The evolution of the osseous
mineral density (OMD) in patients on HD is variable and not well defined.
Our aim has been to analyze the modifications of OMD in different
osseous areas in HD patients and to evaluate the influence of the stretch
of time in HD. Material and methods: We studied 110 patients on HD (59
male, 51 female), 52.5 14.3 years old on average (range 20—75). The
time they spent on HD was 42.8 28.6 months (range 1—156). The OMD
was quantified by means of dual-densitometry of x-rays (Hologic QDR
1000) at lumbar column (LC), femoral neck (FN) and Ward triangle
(WT). The results were expressed as Z-score SD in relation with the
standard population. Results: There was a significant reduction of OMD
in LC (—1.02 1.38; P <0.001), FN (—1.26 1.09; P <0.001), and WT
(—1.39 1.10; P < 0.001). Depending on the time they spent on HD the
lowest scores were observed in those with less than 1 year on HD (LC
—1.33, FN =
—1.32, WT =
—1.46) and the highest scores were in the
group with more than 5 years on HD (LC =
—0.98, NF = —1.26, WT
—1.34, NS); there was an increase of the Z-score after the first years on
HD (LC =
—0.90, NF = 1.14, Wi' = —1.34, NS). Conclusions: (1) Our
results confirm that those patients with renal insufficiency present a
decrease of the OM. (2) HD restrains this loss, basically at the beginning
of HD. (3) The restraint of the loss of OM is more evident in trabecular
bone.
State of adrenergic receptors in hypotensive hemodialyzed patients. N.
Esfotzado, A. Cases, M Bono, J. López-Pedret, J. Gaya, F. Rivera, and L.
Revert, Nephrology and Hormonology Units, Hospital Clinic i Provincial,
Barcelona, Spain. The pathophysiology of chronic hypotension (CH) in
chronic renal failure patients (CRF) is unknown, although an autonomic
nervous system (ANS) dysfunction seems to play a role in this disorder.
Recently, abnormalities in adrenoceptor (the effector of the ANS in target
tissues) number and function have been suggested. The aim of this study
was to evaluate the density of adrenoceptors: a2 (a2-A) assessed by
3H-yohimbine binding in platelets, and /32 (/32-A) assessed by 3H-
CGP12177 binding in lymphocytes, in 17 normotensive hemodialysis (HD)
patients (NHP), 16 chronic hypotensive HD patients (HHP), and 17
normotensive control subjects (C). Plasma catecholamine levels (CAr)
were higher in all HD patients than in C (P < 0.01). Although CA were
higher in HHP than in NHP, differences did not reach significance. a2-A
density was lower in HHP (147 32 sites/cell) than in NHP (191 53
sites/cell, P < 0.01) and C (185 33 sites/cell, P < 0.005), but no
differences were found between NHP and C. /32-A density was lower in
HHP (1330 314 sites/cell) than in NHP (1543 224 sites/cell, P < 0.05)
but similar to C (1394 215 sites/cell). No differences were found
between NHP and C. a2-A and (32-A affinity (Kd) was similar in the 3
groups. Our results suggest that the peripheral resistance to cat-
echolamines in target tissues observed in HHP is due to abnormalities in
adrenoceptors. Thus, adrenergic receptor alteration in HHP could be an
important etiopathogenic mechanism in the related-uremia CH develop-
ment.
Autonomic nervous system dysfunction in hypotensive hemodialysis
patients. N. Esforzado, A. Cases, M. Bono, J. López-Pedret, and L. Revert,
Nephrology Unit, Hospital Clinic i Provincial, Barcelona, Spain. Chronic
hypotension (CH) is a not uncommon complication in hemodialysis (HD)
patients, which causes an important morbidity in these patients. The
autonomic nervous system (ANS) dysfunction, frequently observed in HD
patients, may contribute to the pathogenesis of the CH in uremia. In order
to evaluate the ANS state in CH we studied 17 healthy normotensive
controls (C), 17 normotensive HD patients (NHP) and 16 hypotensive HD
patients (HHP). The Valsalva ratio (index for overall integrity of the
baroreflex arc), deep breathing test (parasympathetic pathway) and hand
grip test (efferent sympathetic pathway) were used to study the ANS
functionalism. The Valsalva ratio and the deep breathing test were lower
in all HD patients than in C (P < 0.005), but there were no differences
between NHP and HHP. Hand grip test response was lower in HHP (P <
0.001) than in NHP and C, but no differences were observed between NHP
and C. Plasma catecholamine levels (CAr) were higher in all HD patients
than in C (P < 0.01). Although CA were higher in HHP than in NHP,
differences did not reach significance. Our results suggest an alteration in
parasympathetic pathway in all HD patients, and an impaired sympathetic
response in hypotensive HD patients. Furthermore, the impaired sympa-
thetic response in hypotensive HD patients is due to a peripheral
resistance to sympathetic stimulation in target tissues, and is not secondary
to an alteration in efferent sympathetic pathway (outflow sympathetic
preserved).
Poor control of hyperparathyroidism with lowering dialysate calcium
concentration. V. Paraiso, J. C. Chacon, A. Fidalgo, and J. Martin, Service of
Nefrology, Hospital Ntra. Sra. de Sonsoles, Spain. Calcium content in
dialysis fluid has been classically fixed at 1.75 m to achieve a positive
balance. However, this calcium concentration combined with using CaCO3
and i.v. Vitamin D3 may result in hypercalcemia. With the purpose to
increase the use of these we studied 27 stable patients, 19 on HD and 8
HDF. The patients were maintained on 1.25 mat dCa for six months. PTH,
Ca, P, AF, total doses and iv. Vit D, CaCO3, (OH)3A1 and several clinical
parameters were measured. The results were compared with the param-
eters six months before as well as in a control group of 9 patients
maintained with 1.75 dCa throughout the study. We observed a significant
rise in PTH levels with 1.25 dCa respect to control group: 143 188%
versus 5.1 79% (P < 0.05). i-PTH clearly increased: 262 363 versus
185 133 pg/mI (P < 0.1) with respect to control group and also six month
before starting: 362 363 vs. 240 222 pg/mI (P = NS). No differences
were observed in calcium serum concentration between the two periods:
9.5 0.6 versus 9.4 0.7 mg/dl (P = NS) in the control group: 9.5 0.6
versus 9.9 0.5 mg/dl (P = NS). P serum was different with respect to six
months before starting: 5.9 1.1 versus 5.5 0.9 mg/dl (P < 0.5) but no
differences were observed in serum P in control group: 5.9 1.1 versus 5.4
0.6 mg/dl. CaCO3 oral intake was significantly increased in the control
group: 534 436 versus 260 413 g (P = NS) and six months before: 534
436 versus 279 419 g. Post-dialysis iv. Vitamin D administration was
increased in the dCa 1.75 group: 26.2 43.9 versus 7.7 13.4 mg (P <
0.01) and the group control: 26.2 43.9 versus 9.3 21.8 mg (P = NS).
No differences were observed in oral vitamin D and (OH)3 Al adminis-
tration. Intradialytic decrease in diastolic blood pressure was observed
with 1.25 dCa: 76.6 8.4 versus 82.8 9.8 mm Hg (P < 0.001). A
decrease in i-PTH was observed in HD with respect to 1.75 dCa group 507
154 versus 160 94.5 pg/ml (P < 0.5), but no difference was observed
on HDF 495 284 versus 267 359 pg/mI (P = NS). We observed in
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HDF an increase larger in PTH than in HD: 155 322 versus 103 146%
(P = NS) using higher doses of a i.v. Vitamin D 62 57 versus 157 34.1
sg (P = NS). Conclusions: (1) The increase in oral CaCO3 was not
sufficient to prevent the stimulation of i-PTH secretion observed with dCa
1,25 both in HD and HDF. (2) The i.v. Vitamin D administration is limited
by an increase in the serum phosphate levels. (3) The beneficial effect of
i.v. Vitamin D was effective in lowering i-PTH only in HD but not in HDF.
(4) The i-PTH control is more difficult in patients on HDF, probably
because of higher calcium negative balance.
Valvular heart disease in chronic dialysis patients. M Ramirez de
Arellano, MD. Martinez, M Chine, M. Fuiquet, MA de Migue4 and X
Cuevas, Nephrology and Cardiology Departments, Hospital de Tetrassa,
Terrassa, Barcelona, Spain. Objective: The identification of the frequency
of functional and structural alterations of the heart valves in chronic
dialysis patients and its relation with clinical findings. Patients and
methods: A non-selected population of 67 patients (35 male) of ages 60.1
13.6 years (20—86) and hemodialysis time of 46.9 33.4 months has
been studied through Doppler echocardiography (M-mode and 2D).
Furthermore, the valvular-structural alterations are related with the
modifications of the phospho-calcium metabolism. Results: The physical
exploration noted systolic murmurs in 44 patients and diastolic in 2
patients who did not show clinical symptomatology.
Valvular dysfunction Mitral valve Aortic valve Tricuspid
Insufficiency 26 (38.8%) 7 (10.4%) 11(16.4%)
Stenosis 2 (2.9%) 2 (2.9%)
Insufficiency + stenosis 2 (2.9%)
The insufficiency was multivalvular in 12 (17.5%) patients, affecting 2
valves in 10 and 3 in 2 patients. Structural alterations appear in 27
(40.2%): aortic valve cusps thickened in 15, calcification of the mitral
annulus in 11 and aortic valve calcification in 9. Nine patients with
calcification of the mitral annulus showed dysfunction, 7 regurgitations
and 2 stenosis combined with regurgitation. Conclusions: (1) The preva-
lence of valvular structural alteration is of 40.2% and it is associated with
dysfunction in 40.7% of patients. (2) The prevalence of valvular dysfunc-
tion is 46.2%, regurgitation being the most frequent, in a moderate degree
and with a tendency to multivalvular affectation. (3) Doppler echocardi-
ography is the exploration that defines structural and hemodynamic
alterations of heart valves.
Does the intravenous treatment with ferric gluconate modit' the levels
of aluminemia and the phospho-calcium metabolism of ferropenic pa-
tients on hemodialysis? X Cuevas, M. Fuiquet, M. Ramirez-Arellano, M
Chine, and J. Armengol, Department of Nephrology, Hospital de Terrassa,
Terrassa, Barcelona, Spain. Aluminum and iron share in a competitive way
the same plasmatic "transporter" protein. Objective: To know if the
treatment with ferric gluconate administered as a large intravenous dose
means modifications of the seric and the phospho-calcium metabolism.
Methods and materials: A cumulative dose of 1 g of ferric gluconate was
administered to 21 ferropenic patients on hemodialysis over a period of 3
weeks (125 mg post-hemodialysis over 8 sessions). It was a group of 21
patients of an average age of 59.5 16.6 years (22—84), sex (10 M, 11 F)
and a time on hemodialysis of 46.8 24.6 months (13—96). Pre- and
post-treatment was practiced on all of them: ferritin, transferrin, hemat-
ocrit, aluminemia, PTH-i, calcemia and phosphoremia. Results: Results
are expressed pre- and post-treatment.
ferritin (ng/ml) 66.85 53.62 (11—224); 253.71 124.46 (46—480).
transferrin (g/liter) = 2.41 0.48 (1.68—3.31); 1.94 0.26 (1.3—2.3).
hematocrit (%) = 24 (19—31); 25 (19—35).
aluminemia (g/1iter) 24.9 20.78 (5—78); 25.4 19.97 (5—71).
PTH-i (pg/mi) = 241.4 168.16 (31—629); 236 192.23 (14—628).
Ca (mmol/Iiter) = 2.31 0.24 (1.8—2.8); 2.41 0.27 (1.9—3).
P (mmol/liter) = 1.75 0.59 (0.6—3.3); 1.74 0.42 (1—2.8).
Conclusion: The treatment with a large dose of ferric gluconate in
ferropenic patients on hemodialysis does not mean modifications in the
aluminemia or in the phospho-calcium metabolism.
Neoplastic disease and hemodialysis. M Fuiquet, M Chine, M Ramirez-
Arellano and X. Cuevas, Nephrology Dept., Hospital de Terrassa, Terrassa,
Barcelona, Spain. Objective: To know the incidence, prevalence, type,
treatment, and evolution of neoplastic disease (ND) in our hemodialysis
unit over a period of 7 years. Methods and materials: Included were 151
patients on HD (93 males, 59 females) average age 56.6 years (18—85),
and average time on HD 38.9 months (1—192). They were analyzed
quarterly and annually, and underwent radiology controls (thorax, abdom-
inal echography) and gynecologic exploration. We analyzed and com-
pared: toxic habits, previous immunosuppressor treatment, cystic renal
disease (ACRD and PK), hepatitis virus (HVC+) and renal disease of the
neoplastic population (NP) as opposed to the rest of the population. Type,
extension, diagnostic method, treatment and evolution of ND were
studied in the NP. Results: Thirteen neoplasias were diagnosed in 12
patients (8.6%; 7 males, 5 females; age 68.5 years, 48—84): 3 in pre-HD
(1—5 years), 2 at the beginning of HD, and 8 during HD (x = 2.3 years,
1—5). Type of ND: 3 of skin (2 basocellular and 1 c. squamous), 3
myeloproliferatives (1 MML and 2 monoclonal bands), 2 breasts (c. ductal
infiltrant), 3 urological (1 c. prostate, 1 c. trans. of bladder and 1 c. trans.
of renal pelvis), 1 hepatocarcinoma and 1 carcinoide. Diagnosis: 8 through
clinical, 4 through controls (2 x-ray, 2 lab.) and 1 through surgical finding.
The time of observation of the ND was 2.2 years (0.3—8), with 3 deaths (1
because of ND), 6 patients treated (3 relapses) and 4 therapeutic
abstentions. Factors analyzed were:
Toxics H. R.C.D. Immu. Tr. HVC +
NP (12) 30% 75% 15% 15%
HDP (139) 27% 43% 25% 25%
Conclusions: (1) The incidence of ND was 1.2% patient/year. (2) Mortal-
ity in ND has corresponded to 0.7%. (3) The patients affected by chronic
renal disease and neoplastic disease may be included in a substitute
treatment program after a rigorous evaluation has been made.
Effect of rHuEPO therapy in dialysis on endogenous EPO after
transplantation. M Fernandez-Lucas, R. Marcén, J. Villafruela, J. Navarro,
J. Tenwl, L. Orofino, P. Serrano, and J. Ortuño, Hospital Ramón y Cajal,
Madrid, Spain. To evaluate the administration during dialysis of recombi-
nant human eiythropoietin (rHuEPO) and the effects on endogenous
erythropoietin (eEPO) serum levels after renal transplantation, we have
prospectively studied 65 recipients during a six month period. Group 1
comprised 31 patients who were treated with rHuEPO, for at least six
months, when they were on dialysis. Group 2 comprised 34 patients who
were not treated with rHuEPO. Hemoglobin and eEPO serum concen-
trations were determined on the immediate pre-transpiant and on the days
2, 4, 8, 15, 30, 60 and 180 post-transplant. There were no differences in
serum ferritin and hemoglobin levels before transplant, but eEPO levels
were significantly higher in the treated group (29.4 6.6 mU/mI vs. 8.6
1.5 mU/mi, P < 0.01). The untreated group experienced an transient
increase in eEPO levels between the 2nd and 4th day after transplant, that
was not found in the treated group (25.7 3.3 mU/mi vs. 8.7 1.5 mU/mi,
P < 0.001). No significant differences were observed since day 15 to the
end of the study period. We also found higher serum hemoglobin
concentrations in the untreated group at two months (12.2 0.3 g/dl vs.
11.2 0.2 g/dl, P < 0.05). We conclude that the administration of
rHuEPO during dialysis blocks the transient postoperative increase of
eEPO and delays recovery of anemia.
Effects of different biocompatible membranes on granulocyte surface
receptors. A. Martin-Malo, M.C. Alonso, F. Bon-ego, D. Castillo, MA.
Alvarez-Lara, M Espinosa, J. Peba, and P. Aijama, Hospital Universitario
Reina Sofia, Cordoba, Spain. Hemodialysis (HD) with cellulosic mem-
branes induces up-regulation of the granulocyte integrin adhesion mole-
cule, which might be the mechanism responsible for the transient neutro-
penia. This study evaluates the effect of membrane biocompatibility on the
expression of granulocyte surface receptors. Ten patients on maintenance
HD were randomly dialyzed with both cuprophan (CU) and polyacrylo-
nitrile (AN69) membranes. Blood samples were collected pre-dialysis
(Pre-HD) and at 15, 60, and 180 minutes after the onset of HD. At each
time blood was separated into plasma and cells. Separated granulocytes
obtained before dialysis were then incubated with their own Pre-HD
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plasma and with the plasma drawn at the above mentioned times. At each
point C3a, C5a, CD11a, CD11b, CD16, CD1O, CD13, and CD45RA were
determined.
Cuprophan AN69
Pre-HD 15 mm 60 mm Pre-HD 15 mm 60 mm
CD11a 6±3 7±2 6±4 6±2 6±0.9 6±1
CD11b 29±9 46±8a 37±lOa 26±7 27±6 26±8
CD16 140±41 158±40a 142±39 127±28 132±31 123±26
CD1O 5 0.4 6 0.8 5 0.6 5 0.6 5 0.6 5 0.5
CD13 19±4 27±4a 25±5a 18±2 19±3 19±4
CD45RA 5 0.9 7 2 6 1 5 0.8 5 0.9 5 0.9
C5a 10±3 31±5a 15±8 14±7 17±9 14±3
a p < 0.05 vs Pre-HD
Our results demonstrate an increase in the granulocyte surface receptors
during the first minutes of CU dialysis. However, no significant changes
were observed with a more biocompatible membrane (AN69), with which
C5a plasma levels remained stable. This may explain the rapid and
transient neutropenia during CU dialysis.
Treatment of chronic hepatitis C with interferon in hemodialysis
patients. M Espinosa, R. Gonzalez, M. Mata, M. Alvarez, A. Martin -Malo,
J. Borrego, and P. Aljama, Hospital Reina Sofia, Córdoba, Spain. Interferon
(INF) therapy has been shown to be useful in normalizing serum alanine
aminotransferase (ALT) levels, improving liver inflammatory lesions and
suppressing hepatitis C virus (HCV) replication. The aim of the study was
to analyze the efficacy and tolerance of long-term alpha INF treatment in
hemodialysis patients (HP) with chronic HCV. Six HP with active (5) and
persistent (1) chronic hepatitis were studied. All had evidence of HCV
infection, with HCV-RNA (PCR) and antibody to HCV (ETA) detectable
in serum. Patients received three million units of INF three times weekly
after hemodialysis for 1 year. The serum ALT level normalized in all
patients since the first month.
Basal
Month
1 3 6 9 12
ALT 99.3 24.3a 15.6a 22.5' 14.3a 157b
a p < 0.05, 'P < 0.001
Serum HCV-RNA became undetectable in 4 patients, decreased in 1, and
did notchange in the other patient at the end of the treatment. Side effects
were mild but required a reduction of the dosage in 4 patients with flu-like
syndrome (4), leukopenia (2), thrombopenia (1) and anemia (4). Eryth-
ropoietin therapy was increased or initiated by anemia in four patients.
Interferon therapy appears to be beneficial in HP with chronic hepatitis C
since it normalizes the ALT levels and inhibits HCV replication without
significant side effects. Erythropoietin therapy can be necessary in these
patients with anemia.
Influence of intravenous calcitriol on the response to erythropoietin
(EPO) in hemodialysis (HD) patients with hyperparathyroidism (HPT).
R. Sanchez, E. Hernández, M. Praga, A. Araque, C. Alamo, J.M Morales,
and fL. Rodicio, Hospital "12 de Octubre", Madrid, Spain. It has been
reported that the response to EPO in HD patients is influenced by the
presence of bone marrow fibrosis secondary to HPT. On the other hand,
iv. calcitriol is a very effective treatment of patients with advanced HPT.
We designed a prospective study to assess if i.v. calcitriol therapy modifies
the response to EPO. Seven HD patients (44 15 years, 6 males, 1
female; time on HD treatment 3—19 years; x = 9.6 6) with severe HPT
started therapy with iv. calcitriol; their EPO doses (107 35 U/kg/week
s.c.) were maintained without changes since 3 months before the onset of
calcitriol. Calcitriol doses were 1—2 j.tg [1.8 0.4 after each HD session (3
sessions per week)]. Duration of the study was 6 months. Hemogram,
ferritin and parathormone (intact molecule) were obtained monthly. PTH
decreased from 980 253 (normal values <50) to 471 314mU/dl (P <
0.001). Nevertheless, there were no significant changes of hematocrit or
hemoglobin. According to study design, EPO doses were maintained fixed
throughout the study. There were no relationship between PTH levels and
hematocrit-hemoglobin. In conclusion, a reduction of PTH levels with i.v.
calcitriol is not accompanied by an improvement in the response to EPO
after 6 months of treatment.
Elevation of lipoprotein Lp(a) in patients on hemodialysis (HD). C.
Alamo, A. Araque, M Praga, P. Larumbe, R. Sanchez, T Gómez, E.
Hemández, and J.L. Aranda, Hospital "12 de Octubre", Madrid, Spain.
Lp(a) is an LDL-lipoprotein that possesses a strong and independent
atherogenic role. Association between elevated Lp(a) and cardiovascular
diseases has been reported in the normal population. Normal levels of
Lp(a) are <10 mg/dl. We have measured Lp(a) levels in 40 patients on
HD (22 females, 18 males), aged between 27—81 years (52 13). Onset of
HD had been 1—20 years before (8 6). We found a marked increase in
Lp(a) levels: 27 28 mg/dl ranging between 0—90 mg/dl. There were no
correlations between cholesterol (138—283 mg/dl; x = 194 42) or
triglyceride (59—588 mg/dl; x = 167 106) levels and Lp(a). No
correlation was observed between Lp(a) and age or time on chronic HD.
Patients with arterial hypertension had levels not different from normo-
tensive ones (27 29 vs. 26 26 mg/dl), and there were no differences
between patients with liver disease or patients with normal liver enzymes
(20 20 vs. 27 29 mg/dI). Patients with histories of ischemic cardiopathy
or atherosclerotic complications (cerebrovascular accidents, peripheric
ischemia) had more elevated values of Lp(a) but without statistical
significance: 31 39 vs. 26 26 mg/dl and 35 25 vs. 25 28 mg/dl,
respectively. We analyzed Lp(a) levels according to the dialysis membrane
used: patients with cuprophan had higher levels than those dialyzed with
more biocompatible membranes (34 29 vs. 23 27), but this difference
did not reach significance. In conclusion, patients on HD show Lp(a)
levels clearly elevated, although the range was highly variable. No
correlations between risk factors (HTA, time on HD) or cardiovascular
complications and Lp(a) levels were observed. Prospective studies are
necessary to establish the role of Lp(a) in HD patients.
Residual renal function (RRF) in patients undergoing chronic hemo-
dialysis (CHD): Prognostic factors. F. Siguenza, F. Maduell, A. Caridad,
and R. Lopez-Menchero, Service of NefrologIa, Hospital SI'S Xàtiva, Spain.
In patients who continue to benefit from some degree of RRF, the amount
of CHD prescribed can be reduced; the normal course of events is for
RRF to diminish progressively with time (T). Objective: To assess the
RRF with T, and its influence on CHD schedule, and the influence of
diverse factors. Materials and methods: In 20 patients undergoing CHD,
12 males and 8 females, aged 50.1 15.9 (mean so), requiring CHD 3
times a week for 2 years, the following parameters were investigated, every
2 months, from the start of CHD treatment: TA sist (TAS), TA diast
(TAD), residual urea clearance (RUC), creatinine (Cr), KTV-c (corrected
with RUC), and diuresis. The parameters of CHD (flow blood, time on
CHD, dialyzers) were adjusted to obtain an effective CHD. We divided
patients into 2 groups: (A) interstitial nephritis (N = 10), (B) GN
nephroangiosclerosis (N = 10). Results: There was a correlation between
RUC and T (y = a + b.x): for group A it was (r =
—0.47) and for group
B (r = —0.62). There was no correlation between TAS, TAD and group
diagnostic with the slope of RUC.
A<lmonth>B A<2years>B
RUC mI/mm 3.82 1.4 2.18 0.81 2.03 0.7 0.47 fl3a
Cr 7.8 1 8.2 1.2 9.1 1.6 11.4 1.5'
%FRRofKTV-c 43±10 32±10c 23±7 6.8±5.5a
KTV-c 1.4 0.28 1.08 0.18 1.3 0.21 1.07 0.11c
Diuresis mI/day 1275 378 722 315b 804 322 259 15&'
ap < 0.001; bp < 0.01;C < 0.05
Conclusions: (1) There is a constant decline rate of the progression of
CRF which similar in the two groups, but with an RRF higher in group A.
(2) The evaluation of the RRF is important for the amount of CHD
prescribed, and is very important in group A.
Urea rebound: Influence of the urea distribution volume, dialysis time
and dialyzer clearance. F. Maduell, F. Siguenza, A. Caridad, and R.
Lopez-Menchero, Service of Nefrologia, Hospital de Xàtiva, Spain. Rapid
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removal of urea from plasma during hemodialysis creates intercompart-
mental imbalances, followed immediately after dialysis by urea rebound as
an expression of intercompartmental re-equilibration. In the present study
we have calculated urea rebound and evaluated the influence of the urea
volume distribution, dialyzer clearance and hemodialysis time on the urea
rebound. Twenty-seven patients were included in this study, 14 males and
13 females. Hemodialysis was performed with blood flow 350 mI/mm,
ultrafiltration 1.5 l/hr, 1.5 m2 cuprophan dialyzer and bicarbonate buffer.
Every patient received 3 dialysis sessions, changing dialysis time (1, 2 or 3
hrs). A subgroup of 15 patients received 3 additional sessions with blood
flow 250 mI/mm and I m2 cuprophan dialyzer, at three different dialysis
times of 1, 2 and 3 hours duration. Plasma urea concentration at the
beginning, at the end, and 45 minutes postdialysis were measured. All
dialysate was collected and urea concentration monitored. Urea rebound,
urea volume distribution, dialyzer clearance, and KT/V were calculated.
Urea rebound varied between 9—27% and no differences were found when
dialysis time was changed, 15.8 3.4% at 1 hour, 17.9 4.1% at 2 hours,
and 17.2 3.9% at 3 hours. Linear regression showed that urea rebound
values were inversely correlated with urea volume distribution and directly
correlated with KT/V. Urea rebound in the high-efficiency dialysis group
was higher than that observed in low-efficiency dialysis subgroup (16.7
3.8% vs. 10.2 3.1). In conclusion, our results suggest that individual
variability in urea rebound are correlated with the individual differences in
the urea distribution volume. The dialysis efficiency, rather than dialysis
time, seems to be responsible for the magnitude of the urea rebound.
Polymerization of normal and intact 132-microglobulin as the amyloid
protein in dialysis amyloidosis (A2m). J.M. Campistol, D. Bernard, G.
Papastoitsis, M Sole, AS. Cohen, and M. Skinner, Boston University School
of Medicine, Boston, Massachusetts, USA; Hospital Clinic, University of
Barcelona, Barcelona, Spain. An important question in the pathogenesis of
A132m is whether 132m polymerizes in amyloid fibrils as an intact molecule
or requires a proteolytic cleavage from a precursor protein. We studied
the biochemical characteristics of f32m from 3 different tissues with A2m
deposits, a gelatinous brown mass (2 g) from an amyloidoma of the
femoral head, and two femoral bone marrows (12 and 9 g). Amyloid fibrils
were purified using the classical water extraction method. Dry proteins (60
mg) were suspended in 6 M guanidine, the supernatant applied to a
Sephadex G-75 column equilibrated with 4 M guanidine, and 17%
SDS-PAGE gel electrophoresis and Western blot (using anti-human f32m
antibody) were used to study pooled fractions of the gel-filtration column.
Two peaks were obtained on the gel-filtration column. The second peak
corresponded to a molecular weight of 12 kDa. This molecular weight was
confirmed by a 17% SDS-PAGE gel, which demonstrated one major band
at 12 kDa and a minor band at 25 kDa. Western blot analysis with
anti-human 132m confirmed the 132m nature of these two bands (monomer
and dimers). No other bands were observed from this peak. The 12 kDa
band was micro-sequenced and the amino acid sequence corresponded to
that of normal /32m. In summary, A132m amyloid deposits are formed in
osteoarticular structures of intact and normal j32m.
Is isolation of monitors of patients on hemodialysis (HD) who are
hepatitis C virus positive (HCV+) useful in preventing transmission of
HCV? To evaluate the usefulness of isolation of patients who are HCV+,
we've studied the evolution of HCV in patients in 2 HD units during 20
months after separating those patients HCV+ from the rest in different
monitors of some of the units. In the first unit of 48 patients, with a rate
of seroeonversion the year before of 9.67%, the six HCV+ patients were
concentrated on 2 monitors. During the 20 following months, we studied
56 patients, none with seroconversion. The evolution was as follows: 2
HCV— patients were transferred to other centers; 7 were transplanted (2
of them HCV+); 12 new patients (all negative) were admitted, who
remained negative. In the second unit of 96 patients, with a seroconversion
rate in the last 2 years of 16.3% (32 patients HCV+), 8 monitors were
assigned to HCV+ patients. To arrange that, 10 patients HCV— who
shared monitors with HCV+ patients were put together on negative
monitors. Eight HCV— patients were forced to share monitors with
HCV+ patients. We've determined serology of all the 8 patients in the
study in the following 10 months: 70 repeated the previous determination;
13 are new HCV—; 5 were transplanted; 2 died; 5 were transferred to
another unit. No HCV— patients became positive in this unit (not even
the HCV— patients who shared monitors with HCV+ patients). Conclu-
sions: (1) Isolation of HCV+ patients on different monitors in the same
unit seems to be useless in preventing the transmission of HCV. (2)
Further studies will be needed to evaluate the importance of monitors as
a way of transmitting the virus, as may be the time of exposure of the
monitor to the virus (10 months in our study). (3) We think isolation is a
necessary precaution since we got a seroconversion rate in both units of
0%. No patients became positive in this unit, not even the HCV— patients
who shared monitors with HCV+ patients.
Study of zinc transport during hemofiltration. B. De Leon, G.M.
Gonzalez, J. MartInez Lanao, A. Gascón, and J.M Tabernero, Service of
Nephrology, University Hospital, Biochemistry Service, Virgen de Ia Vega
Hospital, Chair of Pharmacokinetics, Universidad de Salamanca,
Salamanca, Spain. The aim of the present work was to study zinc (Zn)
kinetics during hemofiltration with three different membranes [Polysul-
phone (Spiroflow HFT-10), Polyacrylonitrile PAN (AN69HF), and Cu-
prophan (GFE 1.1)] to determine their capacity to eliminate zinc and to
evaluate to what extent they contribute to the decrease in Zn levels shown
by some patients with chronic renal failure (CRF). Twelve patients on 3
hour sessions of hemofiltration with each of the membranes were studied.
The studies were conducted under identical conditions. Blood samples
were collected in commercial tubes for trace elements. Determination of
Zn levels in plasma, erythrocytes, and in the ultrafiltrate were performed
by atomic absorption spectrophotometly. The following studies were
made: plasma (CIp) and aqueous (Clw) clearance of Zn referred to 1 m2
of membrane surface and total Zn hemofiltered (ZnHFtotal); hematocrit
and total protein values were determined before and after hemofiltration
to quantify blood concentrations. The statistical study was conducted by
ANOVA. Results: The basal plasma Zn level of the subjects studied was
10.7 2.4 jsmol/liter (normal range 9.9—15.3 imol); 25% of the patients
had levels lower than normal. After three hours of hemofiltration no
significant changes were observed in plasma Zn concentrations with any of
the membranes used, after correcting the values for blood concentrations.
Intraerythrocyte Zn levels were elevated in the population studied (256
23.5 mol/Iiter) with respect to the controls (180 20 jsmol/liter; P <
0.05) and no changes were observed after hemofiltration with any of the
membranes employed. The clearance values were as shown in the table:
Cuprophan PAN Polysulphon
Mean SD Mean SD Mean SD
CIw 1/hr 0.54 0.09 (a) 1.5 0.30 (b) 2.9 0.68 (c)
CIp 1/hr 0.01 0.005 (d) 0.04 0.01 (e) 0.05 0.02 (f)
Zinc HF total jsmol 0.55 0.18 (g) 2.11 0.44 (h) 2.34 0.38 (i)
P < 0.05 between a-b, a-c, b-c, d-e, d-f, g-h, g-i.
A direct correlation was observed between the ZnHF total, in the three
hours, and the Ciw (r = 0.8; P = 0.0001) and CIp (r = 0.77; P = 0.0001).
A negative correlation was observed between plasma Zn levels and age (P
= 0.0006), the time on dialysis (r = 0.8; P = 0.0001), and the dose of
calcium carbonate (P = 0.0002). The amount of zinc hemofiltered was low,
owing the strong affinity of the element for plasma proteins, although
important differences were observed between the low permeability mem-
brane (Cuprophan) and the high permeability ones (Polysulphone and
Polyacrylonitrile). Clearance calculations are useful for estimating the
losses of Zn owing to the close correlation with the true values of Zn in the
ultrafiltrate.
Kinetics and balance of iron in anemic patients on hemodialysis
subjected to treatment with erythropoietin (rHuEPO). J. Nunez, J. Deira,
A. Gascón, J.L. Lerma, and J.M Tabernero, Nephrology Service, University
Hospital, Salamanca, Salamanca, Spain. Iron metabolism, together with its
modifications by rHuEPO, were studied in 17 patients with CRF on
hemodialySis with the aim of predicting iron requirements in these
patients. Hb, VH, MCV and reticulocytes were measured basally and
monthly in all patients: blood iron levels, CTF, IS, transferrin and ferritin
were measured basally and at 4 months. Iron kinetics were studied with
Fe59 in 11 patients basally and at 4 months, evaluating the plasma Fe T112,
plasma Fe turnover, and erythrocyte FE uptake. Reserve Fe and the
predictive iron deficit were evaluated according to the Van Wyck calcu-
lations in order to reach the desired Hb. The patients received: (500
mg/day/orally iron sulfate) after the basal study and until 15 days before
the last study; EPO at a dose of 50 lU/kg post-HD iv., modified according
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to the Hb. Results: Basal, normocytic normochromic anemia with sider-
emia (tg/dl) 111.6 40.8; CTF (sg/dl) 275.6 51.5; IS 42.5 16.6%;
transferrin (mg/dl) 216.2 45; ferritin 9 ng/dl) 284.7 191.5. The
predictive balance of iron was negative in 11 patients and was only positive
in 6. Apart from the logical increases in Hb, VH and reticulocytes, etc., a
decrease in ferritin to 185.8 168 (ng/dl; P < 0.05), was observed
accompanied by an increase in transferrin to 243 69.5 (mg/dl; P < 0.05).
Iron kinetics: a decrease in the plasma Fe T112 131 49.1 vs. 88 32.3
(mm) P < 0.05; an increase in Fe turnover 0.7 0.3 vs. 0.85 0.3 (mg/100
cc P/24 hr), and an important increase in the uptake of Fe59 by erythro-
cytes were observed. On the 6th day, all patients but 1 had incorporated
80% of the iron administered. An inverse correlation was observed
between basal ferritin levels and Fe59 uptake by erythrocytes (r = 0.568;P
< 0.05). Iron reserves were calculated in each patient at the end of the
study, and when the values were added to the predictive balance to reach
the final Hb, the absorption of Fe was obtained; this was very high (mean:
3.8 mg/day; range 0.2—4.8 mg/day). Conclusions: (1) The patients showed
a deficit in Fe in reaching the desired Hb. (2) EPO strongly enhances
erythropoiesis as demonstrated by the study of iron kinetics. (3) Oral Fe
absorption was good and sufficient for obtaining an adequate Hb.
Platelet aggregation in patients with advanced chronic renal failure
(CRF) on hemodialysis (HD). J.L. Deira, J.L. Ler,na, L. Vdzquez, F.
Valcárcel, A. GascOn, B. De Leon, and J.M Tabernero, Hospital ClInico,
Universitario de Salamanca, Servicio de Nefrologla, Salamanca, Spain.
Alterations in homeostasis have been described in uremic patients.
Decreased platelet aggregation is one of the pathogenic factors involved,
and the results of preliminary studies are controversial. The aim of the
present work was: (1) to make an in depth study of platelet aggregation
and its mechanisms; (2) to evaluate the effect of uremia, age, etiology,
PTH, Htc, platelet counts and treatments with Vitamin D, and rHuEPO
on aggregation; (3) to quantify the possible alterations elicited by dialysis
and biocompatible or cellulose membranes. Material and methods: The
patients were divided into 3 groups: (A) 15 healthy patients; (B) 10 with
advanced CRF (Car < 15 mI/mm); and (C) 18 patients on periodic HD
over more than 6 months with a pattern of adequate dialysis. Blood
samples were withdrawn pre-HD (Cl) and at 2 hours after the sessions
had begun (C2). None of the patients was receiving antiaggregants or
NSAID. Five and 1 sM ADP, 5 j.g/ml collagen, 10 LM epinephrine, and 10
sg/ml ristocetin, measured by a lumiaggregometer, were used as agonists
(Aggrecorder II). Results were aggregation in %.
Group ADP 5 ADP 1 Collagen Epinephrine Ristocetin
A 94±9 43±32 94±9 86±25 97±11
B 69 24 47 33 71 24 69 25 83 iia
C 75 iia 46 25 70 21 64 22 78.5 ioa
a P < 0.02 (ANOVA and t-test)
No differences were found between the patients older or younger than 65.
Using 5 M ADP, the patients with immune diseases showed a decrease in
aggregation (P < 0.02). With this agonist, using simple regression, a
relationship was observed between Htc and the % of aggregation: P
0.013; r2 = 0.362. This was not seen in patients treated with rHuEPO as
compared with those not receiving any agonist. In group C, there were no
significant differences between the Cl and C2 values, or when these were
studied according to the membrane used, although with biocompatible
membranes, a tendency for improvement appeared in C2. Using ADP 5,
collagen and ristocetin, the patients with PTH values below 65 showed a
significant improvement in C2 independent of the membrane. There was
no correlation between those receiving Vitamin D (25 .rg/24—48 hr) with
respect to those who did not. Conclusions: (1) In advanced CRF platelet
aggregation is decreased regardless of age, which is not corrected by
hemodialysis; (2) Platelet aggregation is improved in patients with high
Htc levels while this is not seen in patients treated with rHuEPO.
Functional activity of natural killer cells in patients on hemodialysis
with different types of membrane. IL. Lerma, A. Gascón, D. Hernández, A.
Orfao, I. Deira, and J.M Tabernero, Services of Nephrology and Flow
Cytometiy, Hospital ClInico, Universitario de Salamanca, Salamanca, Spain.
The activity of natural killer (NK) cells was studied in 27 patients on
hemodialysis (HD), 14 with Cuprophan membranes and 13 with biocom-
patible membranes (Polyacrylonitrile and Polysulphone). These patients
were compared with 15 controls in an attempt to evaluate whether the
function of these cells was altered in renal failure and whether the dialysis
membranes might affect their functional activity. All patients had been on
the HD program for more than 6 months; their parameters showed that
dialysis was adequate for them. The results of NK activity were given in
relation to the following parameters: age, CRF etiology, time on HD, PTH
serum levels, Beta2 microglobulin and whether or not the patient was
receiving oral treatment with 1.25 vitamin D 3. NK activity was evaluated
according to a cytotoxicity assay based on the release of 51Cr by the K562
cell line on interaction with NK cells. Results: NK activity (% of
cytotoxicity): controls 26.5 5; Cuprophan 14.2 2.8 (P < 0.05 vs.
control); biocompatible membranes 27 5.2 (P < 0.05 vs. Cuprophan).
Patients older than 60 showed less NK activity (P < 0.05) than those under
60. Most of the patients older than 60 (12/15) were on dialysis with the
Cuprophan membrane. The remaining parameters studied were not
discriminatory. Overall, the CRF patients on HD showed no significant
changes in NK activity as compared with the controls. However, a specific
analysis of the NK activity of the patients dialyzed with the Cuprophan
membrane, disclosed a significant decrease in this activity as compared
with the patients dialyzed with biocompatible membranes and the control
subjects. Previously we have reported that patients on HD with Cu-
prophan showed, in peripheral blood, a significantly stronger expression of
antigens associated with NK activity (CD 16+/HLA—DR+). The present
findings are consistent with this and indicate, as has been observed in
other types of immune cells, that HD with cellulose membranes would
elicit chronic stimulation of NK cells, leading to stronger antigen expres-
sion by these cells, although with less functional activity.
Expression of antigens associated with natural killer activity during
hemodialysis with different membranes. IL. Lenna, A. Gascon, A. Orfao,
J. Ciudad, and J.M Tabemero, Services of Nephrolo.gy and Flow Cytometty,
University Hospital, Salamanca, Spain. In previous studies our group
analyzed the CD3+, TCR a/n, TCR g/day, CD16+/HLA—DR+, CD3+/
CD25 + lymphocyte subsets in patients on periodic hemodialysis, compar-
ing them with a group of healthy controls. The findings revealed a
decrease in CD3 + (P < 0.003), secondary to the decrease of CD3 +/TCR
a/ (P < 0.05) and an increase in TCR g/day and in CD16+/HLA—DR+
(P < 0.05), CD3+/CD25 being normal. Material and Methods: In order
to accurately determine the effect of the different hemodialysis mem-
branes on cellular immunity a random study of 23 patients (8 W, 15 M)
with an average age of 56.8 16.3 was made; 11 were on Cuprophan and
12 on Polyaciylonitrile (PAN) and were clinically stable, were not suffering
from infections or neoplasms, and had not undergone kidney transplant or
chronic rejection in the previous six months. None of them had analytical
data pointing to inadequate dialysis and those with Kt/v - PCR below 1
were excluded. Peripheral blood samples were withdrawn during the
second hour of hemodialysis in order to avoid possible interference in the
results arising from low complement levels-leukopenia induced by Cu-
prophan in the first 30 minutes. Flow cytometry and double labeling with
direct immunofluorescence were used, employing a panel of monoclonal
antibodies against CD3+, TCR a/fl, TCR g/day, CD16+/HLA—DR+,
CD3+CD25+, CD3/CD56+, CD3—/CD56+, CD4, CD8. Results: the
CD16+, CD16+/HLA—DR+ and TCR g/day lymphocyte subsets were
significantly elevated in the group dialyzed with Cuprophan (Table). The





TCR y/b 10.7 5.8 <0.05
CD16+ 16 8.3 <0.006
CD16+/HLA DR+ 15.3 8.9 <0.02
Conclusions: In the patients dialyzed with Cuprophan, a significant
increase was observed in the expression of antigens associated with natural
killer activity (CD16+) as well as activation of these cells (CD16+/
HLA—DR+). Additionally, a significant elevation in the CD3+ lympho-
cyte subset expressing TCR g/day was detected. Finally, no increases were
observed in the activation of CD3 + lymphocytes.
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Hemodialysis with and without acetate. A comparative study. X
Borrelias, J. Bartolome, J. Fort, MT Español, J. ramps, J.A. Rodriguez A.
Olmos, and L. Piera, Nephrology and Biochemist,y Departments, Hospital
General Universitari Vail d' Hebron, Barcelona, Spain. Aim: To compare
acetate free biofiltration with acetate hemodialysis in patients with
peripheral arterial insufficiency. Methods: We studied prospectively, dur-
ing 8 months (4 with each technique), 5 patients with peripheral arterial
insufficiency, mean age of 61 8 years and time on HD 10 6 years. The
following were studied: clinical tolerance, acid-base balance taking sam-
ples at 0, 30, 60, 120 and 180 minutes from afferent and efferent lines and
parameters of adequacy Kt/V, TAC, PCR monthly. We compared levels of
IL-i (ELISA) at 0, 60, 180 minutes, lipid, nutritional and calcium-
phosphorous metabolism before and after AFB. Results: Bicarbonate pre-
and post-AFB session (24.1 1.3 mEq/liter and 30.3 2.7 mEqlliter) was
higher than with HD with acetate (18 1.3 mEq/liter and 19.8 1.4
mEq/liter). Levels of PCO2 were within the normal limits with AFB. KTV
was augmented in 5 patients (1,046 vs. 1,138) and PCR increased slightly
in 4. Total cholesterol and LDL levels increased and serum phosphorous
decreased. Dialysis associated morbidity improved and IL-i levels were
lower with AFB and increased intradialysis with acetate. Conclusions:
AFB is an adequate model of dialysis in patients with vascular disease
since it completely corrects acid-base balance, improving clinical tolerance
and lowering catabolism.
Antineutrophil cytoplasmic antibodies, HLA class II and hemodialysis
(HI)). X. Borreilas, J. Fort, A. Segarra, J.C. Duran, J. Bartolome, J. Camps,
J.A. Rodriguez, A. Oimos, and L. Piera, Nephrology and Hematology
Departments, Hospital Vail d' Hebron, Barcelona, Spain. Aim: To evaluate
the prevalence of ANCA in patients treated chronically with HD, and to
evaluate its clinical meaning and association with the specificities of class
II HLA. Methods: We examined the prevalence of positive ANCA in a
cross-sectional sample of 93 patients with a mean age of 60 13 years and
time on HD S 4 years. Patients with RPGN and other autoimmune
disease were not included. ANCA were determined with indirect immu-
nofluorescence using ethanol fixed neutrophils as a substrate. In the
positive cases we did a second determination at 12 months. In 50 of these
patients we studied the HLA DR antigens evaluating its association with
ANCA. Results: Two patients had positive ANCA with cytoplasmic
staining and a 1/32 titer, 1gM isotype. The determinations at 12 months
were negative. The HLA DR antigens corresponded to DR2/DR4 and
DR3IDR7. Conclusions: We detected the presence of ANCA in patients
on HD with a prevalence of 2.1%, considering its presence as false positive
and without relation with HLA DR antigens.
Once weekly subcutaneous administration of recombinant human
erythropoietin (rHuEPO) in hemodialysis patients. M Lago, R. Perez-
GarcIa, MS. Garcia de Vinuesa, M Viilaverde, F. Anaya, and F. Valdeirá-
bano, Service of Nephrology, Hospital General Universitario Gregorio Mara-
ñón, Madrid, Spain. Recombinant human eiythropoietin (rHuEPO) offers
an effective treatment in the anemia of the patients on maintenance
dialysis. In this study, we assess the efficacy in reversing renal anemia of
once weekly subcutaneous administration of rHuEPO and we compared
this schedule with usual, three times a week administration. We studied 30
patients stable on maintenance hemodialysis treated with rHuEPO sub-
cutaneous, three times a week. Patients showed stable hematocrit, serum
ferritin higher than 100 ng/ml and they received iron supplementation, if
they required. The target hemoglobin was 10.5 mgldl. Twenty-one patients
(experimental group, EG) out of 30 patients were treated by their habitual
rHuEPO dose and rule during six months; then, they received once weekly
subcutaneous administration during the next six months. The other nine
patients (control group, GC) received three times a week subcutaneous
doses of rHuEPO for 12 months. Three patients in the EG, were excluded:
one for kidney transplantation, one for hemorrhage and the last one, for
his own choice. Hematocrit and hemoglobin did not change in the 18
patients in the EG, during the six months of once weekly subcutaneous
administration, with respect to the CG. No statistical significant decreases
were observed in hematocrit and hemoglobin from start to the finish of the
study, in both groups. rHuEPO doses did not change in the CG and
increased in EG, without statistical significant differences. There were no
differences between the EG and the CG in leukocytes, platelets, serum
iron, transferrin and ferritin values, during the twelve months of the study.
Once weekly subcutaneous administration of rHuEPO has technical and
comfort advantages. A small decrease of hematocrit and hemoglobin has
been observed in these patients, during six months. An increase of
rHuEPO doses has been required.
Human immunodeficiency virus (HIV) infection in patients on main-
tenance dialysis. M. Lago, K Perez-Garcia, MS. Garcia de Vinuesa, F.
Anaya, M Goicoechea, and F. Valderrábano, Service of Nephrology, Hos-
pital General Universitario Gregorio Marañón, Madrid, Spain. Nine patients
with HIV infection were treated on maintenance dialysis (D), between
June 1987 and June 1993, in the Gregorio Marañón Hospital in Madrid.
In five of them, HIV antibodies (Ab) were detected in June 1987, the first
time we tested for HIV Ab. All patients were on D and had a functioning
kidney allograft. Since 1987, only four patients who were HIV seropositive
before developed renal insufficiency, were included into the D program.
Access to dialysis treatment has not been limited for these patients.
Initially, we indicated continuous ambulatory peritoneal dialysis (CAPD)
as the first choice of renal replacement therapy for end-stage renal disease
in these patients; 2 of them underwent CAPD, but they transferred to
hemodialysis due to peritonitis. The proportion between HIV+/HIV—
patients, who began D during last six years, was 1.14%. Ab screening for
HIV infection by standard ELISA sometimes yields false positive results in
patients with renal failure; therefore, it is especially important to confirm
HIV+ with the Western blot test. The percentage of HIV+ patients who
underwent D, with respect to all HIV+ patients of our hospital, was 0.2%.
The prevalence of HIV seropositive patients on dialysis has decreased
from 2.1% in 1987 to 0.34% in 1993. The high mortality rate after AIDS
diagnosis of these patients, 63% annually, explains that decrease. All of
them developed Acquired Immunodeficiency Syndrome (AIDS), with
constitutional syndrome and diarrhea. All patients, except the last one,
died during follow-up. Five of the deaths were due to infections. The
possibility of nosocomial transmission appears unlikely when routine
precautions are followed. HIV screening for blood and organ donors is
necessary to avoid this method of transmission. Patients with clinical HIV
infection have been considered as contraindications to transplantation.
Nutritional factors affecting survival and morbidity of hemodialysis
patients. K Perez-Garcia, R. Gonzalez, M Lago, F. Anaya, MS. Garcia
Vinuesa, and F. Valderrabano, Servicio de Nefrologia, Hospital General
Universitario Gregorio Marañon, Madrid, Spain. The objective of this study
was to analyze nutritional risk factors affecting mortality and morbidity
rates in hemodialysis patients. Nutritional status was established on a
clinical, anthropometrical, biochemical and urea kinetic basis. We ana-
lyzed those longitudinal data obtained, every four months, from Septem-
ber 1990 to March 1993, of all hemodialysis patients in a hospital dialysis
unit. Over the 30 month period, 131 hemodialysis patients [79 males and
52 females, aged between 24 and 80 years, 55.4 15 (M SD) years old]
were studied. Primary renal diseases were: 15.7% primary glomerulone-
phritis (GN); 3.9% secondary GN; 20.5% interstitial nephritis; 10.2%
polycystic kidneys; 7.9% nephrosclerosis; 13.4% diabetes mellitus; 11% all
others. All patients were dialyzed with bicarboiate as buffer; 17% were on
acetate free biofiltration; 47.2% with cellulosic membranes; 30.2% AN69;
12.2% Polysulphone; 7.5% cellulose triacetae; 2.8% Polyamid. Usual
blood flow range was between 350—400 mi/mm and dialysis time was
around 180 minutes. Mean KT/V and PCR in males were 1.05 and 1.13
g/kgfday, and 1.05 and 1.25 in females, respectively. Males were 2.1%
under their ideal weight, and females 7.2% over, as mean. The number of
patients dying, undergoing kidney transplantation, or being transferred
was 28, 16 and 2, respectively. To evaluate death risk, logistic regression
analysis for ten variables was applied: age, sex, dialysis length, weight/
height2, triceps skinfold, mid-upper arm muscle circumference (MAMC),
serum albumin, creatinine and transferrin, TAC, PCR, and KT/V. This
analysis produced a highly statistically significant model to predict mor-
tality, P < 0.001. Low serum creatinine and albumin were associated with
high death risk. MAMC was the most significant anthropometric param-
eter and TAC, not PCR, between urea kinetic parameters. During the
follow-up period biochemical factors did not change significantly, while
MAMC was lower at the beginning and decreased significantly more in
patients who were dead than the others. Hospitalization rates directly
correlated with a decrease of anthropometric parameters. Low PCR is a
cause for hospitalization, but not an independent risk factor. Protein-
caloric malnutrition in the chronic hemodialysis population is associated
with high death risk.
Peiitoneal clearance of intact PTH (iPTH) in chronic ambulatory
peritoneal dialysis. R. Lopez Menchero, R. Garcia Ramon, A. Miguel, J.
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Moreno, J.C. Alonso, and J.L. Olivas, Valencia, Spain. Introduction: Renal
osteodystrophy presents certain characteristic features in CAPD patients
such as peritoneal elimination of PTH. Purpose: To determine the value
of peritoneal clearance of IPTH and related factors. Methods: In 34
patients on CAPD for more than three months (20 males and 14 females,
age 60.6 9.9 years, months on CAPD 22.5 14.5) the value of PTH in
blood and in peritoneal fluid over 24 hours was calculated by IRMA; the
iPTH peritoneal clearance was calculated (dxvol.d/p). The results are
expressed as medians (percentage 25 and 75), and the relations between
variables were established by means of simple regressions models. Results:
(1) iPTH in blood: 103.6 pg/mI (43.7—205.6); iPTH in peritoneal fluid: 26.7
pg!ml (10.5—159.7); total amount of iPTH eliminated in 24 hours (mean
SD): 0.26 0.15 mg/24 hr; iPTH PCL: 1.49 mI/mm (0.61—3.5). (2) No
significant differences in these values were observed either between anuric
patients and those with residual renal functions nor between those who
received 6 liters or 8 liters/day of treatment. (3) There exists a linear
correlation between iPTH in blood and iPTH in peritoneal fluid (r =
0.72). An inverted correlation described by a multiplicative model was
observed between the values of iPTH in blood and iPTH C. (r = 0.90). No
relation between iPTH and iPTH or drained volumes was found, nor
with the PDCr and the peritoneal KT/V. Conclusions: (1) The higher the
level of iPTH in blood, the higher its peritoneal elimination. (2) The only
variable related to iPTH C, is the level of iPTH in blood.
Evolution of the CAPD register in the regions of Valencia Murcia and
Albacete. A. Miguel, R. Garcia, J. Alvariño, E. Andrès, J. Contreras, J.
Olivares, M Lanuza, and the Multicentric Group of Levante, Levante, Spain.
We present the evolution of the CAPD register that was initiated in 1991
(the data in parentheses refer to 1991). During 1992 the total number of
patients was 241 (243), of those 184 (172) remained in the program. There
was a higher prevalence of males 52% (53%). The age group with the
highest percentage was the elderly (65—74), 36% (30%) of the total group,
and 10% (5.5%) of the patients stayed in the program 5—10 years. The
etiology of renal failure was: unknown 32% (32%), followed by diabetes
13% (19%). Residual renal function (RRF) was present in 88 patients
32% (38%) of the total (Cr < 5 ml in 5 patients, 5—10 ml in 48 patients,
and >10 ml in 5). PET was carried out on 95 patients, and the D/PCr was
within normal limits in 71 patients (64), <0.81 in 16 (13) and <0.50 in 8
(6). We should underline the fact that 20% of the patients had been on
HD. The catheter used more frequently was the Tenckhoff 2-C 51%
(45.8%), and was the disconnecting system in 54% (46%). Peritonitis:
incidence of 1.2 episodes/patients/year, 227 cases (1.3 episodes/patients!
year); gram-positive 56% (62%); gram-negative 24% (18.4); fungal 2%(5%); sterile culture 18% (14.6%). Permanent exclusion: 55 patients in
1992 (64); 27 due to death (24); 13 for transplant (13); 15 switched to HD
(27). Conclusion: The evolution is similar to that of 1991 except: (1) There
was a decrease in diabetic patients. (2) The disconnecting system is the
most used and this may explain the decrease in gram-positive peritonitis.
(3) There was a high percentage of patients who had been on HD.
Characteristics of patients (Pts) who had peritonitis (P) and were on
continuous ambulatory peritoneal dialysis (CAPD). R. Garcia, A. Miguel,
J. Olivares, J. Contreras, M. Lanuza, E. Andrés, and J. Alvariño, Grupo
Multicéntrico Levante, Spain. A retrospective study was carried out on a
group of 241 Pts on CAJ'D who had P, and dialysis characteristics and
systems of those Pts who, in 1992, presented episodes of P were evaluated.
Peritonitis: The occurrence of P was 227 with an incidence of 1.23 p/p/a.
Out of the 241 pts, 117 were affected: 66 (1 episode); 26 (2 episodes); 10
(3 episodes); and 15 (more than 3). The isolated germ was: gram+ in 127
cases (56%); gram— in 55 (24%); fungal in 5 (2%) and sterile culture in
40 (18%). In 86% of cases the evolution was favorable and in 11% of cases
the catheter had to be withdrawn. Characteristics of Pts: Age: 75% of
affected pts were aged between 55 and 74 years; nevertheless the
prevalence of age in this range was 62%. Causal nephropathy: 38 cases of
unknown etiology (32%); 21 diabetes (18%); 20 interstitial nephritis
(17%). (These percentages are similar to those of prevalence). Time of
permanence: The highest percentage (46%) referred to pts who had been
1—2 years on the system (this being percentage similar to that of
prevalence). Systems: 58% of affected pts used a connection system;
nevertheless, the prevalence percentage was 48%. Conclusion: With
respect to the studied parameters only the type of system used and, to a
lesser degree, the age of pts show evident significance.
Complications in continuous ambulatory peritoneal dialysis (CAPD).
Five years of experience. E. Garrigos, A. Miguel, R. Garcia, J.C. Alonso, and
R. Lopez, Hospital Clinico Universitario, Valencia, Spain. We present the
complications experienced in our CAPD unit over five years. We have
classified them in three groups: (A) technique-related proceedings; (B)
infectious processes; (C) quitting the program. Patients: There were 76
patients (pts) studied, 46 males and 30 females with a mean age of 59.3
years (28—84). The average time of permanence on the program was 18.1
months (1—49), and 86 catheters were implanted using open (Ma) and
closed (Mc) methods. During the break-in period of 10 days, small
volumes were perfused and, in pts who needed HD, DPI with cycler.
Results: Group A: (1) During the initial period we had 14 cases (16%) of
leakage; in 6 the CT was implanted by Ma and in 8 by Mc. There were two
cases of hemoperitoneum and one of intestinal puncture. (2) There were
four cases of late leakage; 9 had difficulties in catheter drainage (5 due to
fibrin, 3 migrations and 1 trapping). (3) There was late hemoperitoneum
in 7 cases, 3 of which coincided with menstruation and the rest due to basic
pathology (Rendu Osler, Angiomyolipoma, PQR). (4) There were 13
cases of hernias, 10 of which were umbilical. (5) There was one case of
hydrothorax. Group B: (1) Exit orifice infection occurred 61 times in 23 pts
(30.2%), 0.53 e/p/y. In 52% of cases the germ was Pseudomona SP; 18%
St epidennidis and 6.5% StAureus. (2) Peritonitis: The incidence was 136
episodes in 48 pts (63.1%), which is equal to 1.19 e!p/y; gram+ in 42%;
gram— 35%; fungal 5%; and 18% sterile. In 20 cases the catheter had to
be withdrawn. Group C: (1) Death 56.7%; (2) Fungal peritonitis 13.5%;
(3) Catheter malfunction 10.8%; (4) Transplant 10.8%; (5) Peritonitis
8.1%.
Influence of residual renal function (RRF) on the correlation between
PCR and KTV on continuous ambulatory peritoneal dialysis (CAPD)
patients. A. Miguel, R. Garcia, J.C. Alonso, R. LOpez-Menchero, E. Garri-
gos, MP. Laporta, and A. Abarca, Hospital Clinico Universitario, Valencia,
Spain. Purpose: To determine the degree of correlation existing between
PCNR and KTV on CAPD patients (pts) and to evaluate the influence of
RRF in this respect. Material and methods: We carried out a retrospec-
tive study on 45 CAPD patients with a continuous permanence of between
3 and 46 months, 27 males and 18 females aged between 30 and 79 years
(x = 59.6). Three groups of study were established: Group A which
included the total number of pts (45); Group B: pts who presented RRF
(27); and Group C: pts with no RRF (18). There were 85 determinations
of weekly KTV (V according to Watson's formula) carried out; PCR
(based on the generation of urea, Randerson) and these were normalized
according to body weight (PCNR); total C. of Cr (peritoneal + urinary)
(CcrT). Results: The mean amounts of KTV were: 2.14 0.55 in group A;
2.41 0.61 in B; and 1.62 0.40 in C. CarT was 60.33 6.39 (A); 84.38
19.21 (B); and 60.30 6.40 (C). The correlations obtained were:
A: PCRn = 0.61 KTV + 0.10k = 0.79;P <0.0001);
B: PCRn = 0.58 KTV + 0.21 (r = 0.76; P <0.0001);
C: PCRn = 0.43 KTV + 0.37 (r = 051;P <0.0005).
The correlation between PCR and CarT was similar in groups A and B,
whereas group C presented no correlation. Conclusions: (1) There exists
a positive correlation between PCR and KTV in CAPD pts. (2) The lower
correlation of group C suggests that the variations of PCR bear a stronger
relation with urinary K'FV than with peritoneal KTV. (3) PCR is also a
good dialysis index.
Influence of nasal Staphylococcus aureus carriers on continuous ambu-
latory peritoneal dialysis (CAPD) over exit site infection (ESI) and
peritonitis (P). R. Garcia, A. Miguel, R. Lopez Menchero, E. Garrigos, J.C.
Alonso, and E. Millos, Hospital Clinico Universitario, Valencia, Spain.
Purpose: To determine whether CAPD SA nasal carrier (NC) patients
(pts) present a higher number of ESI and later on develop tunnel infection
(TI) produced by S. aureus. Patients: 58 patients were studied between
1989 and 1992. There were 35 males and 23 females (28—84 years x =
59.3). Mean permanence in the program was 18.80 months. Methods: At
the beginning of dialysis and every six months thereafter, samples of nasal
exudate were collected. Those with two consecutive positive results were
defined as chronic nasal carriers (CNC), and those with isolated positive
results as occasional nasal carriers (ONC). The exit site was studied
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according to infection criteria (erythema, suppuration, etc.); if ESI was
present a sample was sent for culture. Results: Of 174 cultures from 58 pts,
21(12.06%) were positive in 12 pts (20.68%), 7 were ONC (12.06%), and
12 CNC (8.62%). ESI were detected on 5 occasions in CNC (2.87%). The
organism was £ aureus in 2 cases (1.14%) and Pseudonzona species in 3
cases (1.72%). In the 2 cases where S. aureus was isolated neither TI nor
P developed. Conclusion: (1) There was a relatively low frequency of
chronic nasal carriers. (2) The relationship between nasal carriers and ES!
was not seen in this follow-up. (3) Specific treatment for S. aureus nasal
carriers may be questionable.
Causes for including patients in a continuous ambulatory peritoneal
dialysis (CAPD) multiceater registry. J. Contreras, J. Olivares, A. Miguel,
R. GarcIa, J. Alvarino, F. Andrés, and M. Lanuza, Grupo Multicéntrico
Levante, Comunidades Valenciana, Murciana y Albacete, Spain. During
1992, 66 new patients (35 male and 31 female) were included in a CAPD
multicenter registry that included a total of 241 patients treated with this
technique. Sixty-one (92.4%) of these new patients were still on CAPD at
the end of the year. The age distribution was as follows: 7 patients (11%)
between 15—34 years, 14 (21%) between 35—54 years, 19 (29%) between
55—64 years, and 26 patients (39%) older than 65 years. The etiology of
the chronic renal failure was unknown in 18 cases (27%), diabetes mellitus
in 12 (18%), 11 interstitial nephritis (17%), 9 glomerulonephritis (14%), 8
vascular nephritis (12%), 6 adult polycystic disease (9%), and other causes
in 2 cases (3%). The election of CAPD as the treatment technique was due
to patients' wishes in 29 eases (44%), while it was secondary to medical
indications in 33 cases (50%). There were 4 eases (6%) included for other
factors. The medical reasons for beginning CAPD were lack of vascular
access for hemodialysis (HD) in 20 patients, associated pathology in 11
cases (7 diabetes mellitus and 4 isehemie heart disease), and intolerance to
HD in 2 patients. Conclusions: CAPD is still being used as a "rescue"
technique for a high number of patients with advanced age, associated
pathology and/or discharge from HD. This situation no doubt affects the
possible results of the technique and must be kept in mind when
comparing CAPD with HD.
Exit site infection in CAPD: Incidence, complications and therapeutic
approaches. A. Gándara, L. Palomares, fri Moreiras, I Sobrado, I.
Gonzalez DIaz, and L. Gonzalez, Nephrology Service, Complexo Hospitalario
Xeral-CIes, Pizarro, Vigo, Spain. The episodes of exit site infection (ES!)
occurring in our CAPD program during the last 3 years were reviewed to
evaluate the incidence, the associated complications, and to assess the
results of a procedure used in our unit to treat the persistent ES!, thus
avoiding peritoneal catheter removal. We designate this technique as
"mixed" because it combines the removal the external cuff and the
creation of a new subcutaneous tunnel (SCT). Basically this consists of: (1)
the excision and drainage of SC'!' with removal of the portion of the
catheter staying inside the tunnel with the external cuff included; (2) the
creation of a short new tunnel and a new exit site distant to the previous
one. Immediately before the performance of this procedure, peritoneal
dialysis must be interrupted and the patient is transferred to interim
hemodialysis for 2 weeks, while antibiotic therapy is maintained. At the
end of this period of time, after correct healing is observed, CAPD is
resumed. During the last 3 years, we registered 41 episodes of ES!
occurring in 30 patients. The mean incidence was 0.8 episodes/patient/
year. The frequency was higher in diabetic patients, (80% vs. the non-
diabetics 48%, P < 0.05). There were no differences related to the number
of cuffs of the catheters. The most frequently isolated organisms were S.
aureus (33%) and gram-negative enterobacteria (30%). Extensive SC'!'
infection was present in 2 patients, Associated peritonitis occurred in 5
cases and this association was more frequent in diabetics (21% vs.
non-diabetics 7%, P = 0.08). The previously described mixed procedure
was successfully performed in 2 patients with persistent ESI episodes,
resulting in the eradication of the infection in both cases. Conclusions: (1)
Tbe most frequently isolated organisms were S. aureus and enterobacteria.
(2) The frequency of ES! and associated peritonitis was significantly
higher in diabetics. (3) A mixed procedure to treat persistent ES! avoiding
catheter removal, with satisfactory preliminary results, is described.
Urea and creatinine kinetics obtained by a 4 hour exchange or by a 24
hour balance In CAPD. J. TeiridO, F. Cofan, AL Ruiz, F. Castellote, J.C.
Martinez-O, R. Ro,nero, and A. Caralps, Hospital "Germans Trias i Pujol'
Badalona, Barcelona, Spain. In peritoneal dialysis, nitrogen bal-
anee, protein catabolic rate and creatinine generation are normally
measured from the simultaneous recollection of 24—72 hour peritoneal
effluent and urine, together with a blood sample. This study compares
BUN generation (mg/m) and creatinine generation (mg/m) obtained from
24 hours balance (24HB) with that from the calculation of the mass
transfer coefficient (MTC) in a 4 hour test in CAPD patients in 2
situations: (A) when 24HB and MTC are measured consecutively, and (B)
when each was evaluated on different days. Results were expressed by
linear correlation and paired t-test. Twenty-two tests of 24HB and MTC
were carried out in 18 patients with a mean age of 59.66 15.51 years and
time in CAPD of 23.11 20.90 months.
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Paired t-test: NS, not significan, ap < 0.01, Up < 0.001.
In group A, for urea and ereatinine generation, there is a good relation-
ship between 24HB and MTC in 4 hours. But the comparison of the means
of urea generation shows a significant difference. In group B there is a
weak relationship. Conclusions: (1) In urea and creatinine generation
there is an excellent correlation between the 24HB and MTC in 4 hours
when determined in the same day. (2) The results of these two methods
are not interchangeable. (3) If the 24HB and MTC are measured on
different days there is a weaker correlation.
Calcitriol treatment in post-transplant hyperparathyroidism. I Bor-
rego, R. Perez, D. Castillo, M. Rodriguez, A. G. Pantaleon, S. Tallón, A.
MartIn, F. Moreno, G. Hernendez, and P. AIjama, Hospital Reina Sofia,
Cordoba, Spain. Secondary hyperparathyroidism (HPTH) may persist
after renal transplantation (RT). This may be due to inappropriately low
levels of calcitriol (C'FR) relative to the degree of HPTH. Administration
of CTR may improve HPTH; however, it could impair renal function via
an increase in serum calcium (Ca) and phosphorus (P). The aim of this
study was to evaluate in RT (>2 years post-transplant) the effect of CTR
replacement therapy on PTH and creatinine levels (Cr). Five RT were
treated with oral CTR (0.25 rg >< 6 months and then 0.5 csg during 3
additional months). Controls were 5 RT with similar degree of HPTH, Cr




9 months0 months 6 months 9 months
iPTH 104±21 106±9 48±18a 118±35 141±68
Ca 8.4±0.8 8.8±0.2 9.6±0.6 9.6±1 9.0±1
P 3.7 0.5 3.4 ±0.6 3.4 0.3 33±0.4
Alk.P 115±42 73±2V 70±3fr 88±32 81±23
Cr 1.6 0.3 1.7 0.5 2.1 0.4a 1.7 03 1.8 0.5
ap < 0.05 vs. 0 months
The administration of CTR 0.5 .rg increased CTR levels from 11 4 to 16
2 pg/mI, a value significantly greater than that observed in the control
group (12 4 pg/mI). IPTH decreased only with 0.5 rg of CTR and
despite no change in Ca. Although Cr was increased after CTR treatment,
the slope 1/Cr versus time was similar in both groups. Daily oral 0.5 .rg of
CTR is effective in the treatment of HPTH post-transplant, though close
monitoring of renal function is advisable.
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Value of dietary interview carried out by dietitians in CAPD patients. J.
Teixidó, S. Johston, M. Cachero, M Ruiz, J. Bonet, E. Castellote, J. Bonal, R.
Romero, and A. Caralps, Hospital Badalona "Germans Trias i Pujol",
Badalona, Barcelona, Spain. The evaluation of dietary intake by interview
in dialysis patients, compared with the protein catabolic rate (PCR), has
given such various degrees of correlation by different authors that some
consider this method of little use in clinical practice. For others it must be
done by specialists. We studied the correlation between the index of
dietary protein intake (IDPI = DPI/weight) and the PCR in CAPD over
2 time periods. During period A dietary intake was evaluated by dialysis
staff, and in period B it was carried out by qualified dietetic staff. Methods:
The patients recorded the weight and volume of food and drink consumed
over the previous 24 hours. Simultaneously 24 hour peritoneal effluent and
urine plus a blood sample were analyzed to calculate the 24 hour balance
of urea and creatinine kinetics. Results:
Period A Period B Student's t-test
Patients 13 13
Male/female 10/3 7/6
Age 63.3 12.2 65.2 4.5 NS
Time in D.P. months 22.3 17.6 27.7 34.8 NS
Weekly KT/V 1.94 0.34 2.19 0.77 NS
Weekly KCr (L/w) 46.6 6.44 76.3 40.1 P < 0.05
IDPI (DPI/wt) 1.31 0.49 0.89 0.39 P < 0.05
nPCR 0.73 0.26 0.83 0.30 NS
Correlation between r = 0.529 r = 0.919
IDPI and nPCR
P = 0.063 P < 0.0001
We confirm: (1) That the protein intake, determined by dietary interview
carried Out by specialists, correlates very well with the results of urea
kinetics in CAPD patients; (2) the dietary interview is a good tool in
evaluating the efficacy of the dietary changes recommended to these
patients.
Lipoprotein alterations in CAPD patients. T Donate, R. Llopart, F.
Roussaud, M Rodá, P. Barceló and J. Pedreña, Nephrology Service,
FundaciOn Puigvert, Lipid Unit, Service BioquImica, Hospital San Pau,
Barcelona, Spain. We know that patients with chronic renal disease (CRD)
undergoing continuous ambulatory peritoneal dialysis (CAPD) have the
risk of presenting cardiovascular disease. Abnormalities in the lipoprotein
metabolism are risk factors explaining the mortality and morbidity in these
patients. Hypertrigliceridemia is the most frequent alteration in CAPD
patients. There doesn't exist any study about the composition of different
lipoprotein families in patients with CRD. The aim of this study was to
define the alterations in the lipoprotein composition and evaluate the
contribution in the high cardiovascular risk of these patients. We studied
15 patients (11 males and 4 females) aged 37—66 years and 20 healthy
control subjects (12 males and 8 females) aged 32—55 years. We isolated
the different lipoprotein fractions (VLDL, IDL, LDL and HDL) by an
ultracentrifugation method. Cholesterol, triglycerides, phospholipids, and
protein in the isolated lipoprotein fraction were determined by standard
colorimetric method. The composition, structure, and weight of VLDL,
IDL and HDL were significantly different than the control group (P <
0.05). We observed an important increase in the VLDL and IDL weight(VLDL: 559 mg/liter vs. 2013 mg/dl; IDL: 49 mg/dl vs. 177 mg/dl), and all
of their constituents were increased. The HDL weight decreased (3198
mg/dl vs. 2699 mg/dl) and they were rich in triglycerides. In LDL we only
observed a very important increase in triglyceride content. In summary, we
describe new data about lipoprotein metabolism in CAPD patients and we
conclude that this therapy produces important lipoprotein alterations.
Study of hematological parameters in patients with renal post-trans-
plant erythrocytosis (RXT). L. Horta4 A. Fernández, N. Vega, A. Losada,
J.C. RodrIguez, C. Tenreiro, T Molero, C. Plaza, E. Baamonde, M. Perdomo,
and L. Palop, Servicios de NefrologIa, A. ClInicos y Hematologla, Hospital
del Pino, Las Palmas de Gran Canaria, Spain. We have selected 15 renal
transplanted patients (PAT) with HCT > 50% out of 130 (11.5%) (GI),
comparing them to 15 non-polycythemic PAT (GIL), of similar age, sex,
previous dialysis technique, post-renal transplantation duration and renal
function. A hemogram was determined, as well as populations and other
erythrocytic parameter analyses, percentage corpuscular volume distribu-
tion and corpuscular hemoglobin concentration, erythropoetin (EPO),
iron (Fe) and ferritin (FER) levels, total iron binding capacity (TIBC),
reticulocytes and reticulocyte production index (RPI). The results are
shown in the table:
Parameters G.I G.II Significance
HCT. 53.6 3.8 41 5.4 P < 0.001
HB. 17.3 0.9 13.9 1 P < 0.001
M.C.V. 91.4 5.1 91.8 5 NS
M.C.H. 29.5 1.9 31 1.3 P < 0.05


























T.I.B.C. 273 53.7 272 67.8 NS
%Satura 14 9.4 19.7 9.7 P = 0.078
Ferriti 60.9 100 150 130 P < 0.05
Csa-Mn 124 32.9 140 56.8 NS
Csa-Pol 361 101 381 117 NS
Creatin 1.41 0.5 1.34 0.3 NS
Conclusions: (1) PAT with eiythrocytosis have a significantly greater
percentage of normocytic and hypochromic red blood cells and lower
MCH and MCHC. (2) PAT from GI present a significantly greater RPI
with a lower EPO. (3) GI have Fe deposits significantly lower and a minor
transferrin saturation index. These data could suggest that a major marrow
answer to the EPO stimulation might contribute to the renal transplant
erythrocytosis.
OKT3 treatment induces higher prevalence and greater severity of
cytomegalovirus (CMV) disease in renal transplant (RT). F. Tejada, E.
Gomez, S. Aguado, E. Gonzalez, S. Melon, K Marln, F. Fernandez, M de
Ona, and J. Alvarez-Grande, Service of Nephrology and Microbiology,
Hospital Covadonga, Oviedo, Spain. From February 1987 to December
1992 we have studied prospectively 206 consecutive RTs for CMV disease
(CMVD) or infection (CMVI). Virological studies included conventional
and shell-vial cultures in blood and urine, indirect immunofluorescence
with monoclonal antibodies in bufii coat (antigenemia), and detection of
IgG and 1gM antibodies (FC and EIA assays). The virological protocol
consisted of collecting peripheral blood leukocytes, urine and serum
samples pre-transplant, weekly during the first 3 post-transplant months,
and then in each clinical revision during the first year. CMVI was defined
by the appearance of at least one positive test. CMVD was defined by the
appearance of at least two positive tests with at least two of the following
symptoms: fever, leukopenia, hepatitis, pneumonitis or intestinal damage
without other etiology. CMVD was considered mild if there were fever,
leukopenia and/or hepatitis. CMVD was considered severe with pneumo-
nitis, intestinal damage and/or death. All patients were treated with triple
therapy (prednisone, azathioprine and cyclosporine); 31 patients were also
treated with OKT3 due to corticoresistant rejections or initial non-
functioning graft. There were no differences between patients with and
without OKT3 with respect to age, sex, incidence of rejections or
serological status of donor/recipients. There were forty-two patients whose
grafts survived less than 3 months and who were rejected for analysis; the
remaining 164 were available for the study. The prevalence of CMVD was
higher in the group treated with OKT3, 10/31 (32%) versus 17/133 (13%)
untreated group (odds ratio = 3.2 95% CI: 1.8—3.8). CMVD was
considered severe in 7/10 (70%) patients treated with OKT3 versus 5/17
(29%) in the untreated group (P = 0.04). In conclusion, OKT3 therapy
increased not only the prevalence but also the severity of CMV disease.
Does donor's age modi1y graft survival in renal transplant? J. Buades,
C. Vazquez, L. Mesa, J. Lavilla, M Martin, P. Errasti, and A. Purroy, Renal
Unit, University of Navarre, Navarre, Spain. It is well known that aging is
associated with progressive glomerular sclerosis. It has been suggested
that kidney donor's age may influence graft survival. We have evaluated
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our retrospective experience with 344 consecutive cadaveric transplants
performed in our unit (1978—1992). Recipients were grouped according to
donor's age: group A (<15 years old), group B (16—55 years old), and
Group C (>55 years old). To evaluate graft losses and renal function in
the remaining kidneys, we have considered three different time intervals:
less than 1 year, between 1 and 5 years, and more than 5 years, We have
also analyzed the effects of CsA treatment. Comparisons of percentages






Group A% B% C%
Working grafts 40 (72.7) 190 (69.09) 9 (64.29) 239
Lost grafts 15 (27.3) 85 (30.91) 5 (35.71) 105
Total 55 275 14 344
Lost grafts
Group A Group B
N % N %
Group C
N %
<1 year 7 47 46 54.2 3 60
1—5 years 5 33 30 35.3 2 40
>5 years 3 20 9 10.5 0 0
Total 15 100 85 100 5 100
Working grafts
Group N Cr/s (X + DS)
A 40 1,578 + 0.707 0.8—4.2
B 187 1.495 + 0.479 0.7—3.9
C 9 2.1 + 1.27 1—4.9
Conclusions: (1) As a whole we didn't find any significant difference in the
percentage of graft losses related to donor's age. (2) However, it seems
that grafts from younger donors (<15 years old) tend to have a longer
survival time. (3) Grafts from older donors (>55 years old) tend to have
higher creatinine levels. (4) Cyclosporin doesn't seem to modify the above
trends.
initial and rescue treatment of rejection in renal transplantation with
OKT3. B. Aurrekoetxea,
.1..!. Amenabar, P. Gómez-Ullate, M Riñón, I.
Minguela, J. Gainza, and I. Lampreabe, Servicios de Nefrologia e Inmuno-
logia, Hospital de Cwces, Bilbao, Spain. Aim: To evaluate the efficacy and
tolerance of OKT3 in the treatment of acute renal allograft rejection.
Material and methods: In our center during the period 1989—1993, 285
cadaver renal transplantations were performed, 124 (43%) of which
included treatment of acute rejection. Out of 24 (8.4%) patients who were
administered OKT3, 7 received it as initial treatment (group I) and 17 as
rescue treatment (group R) for steroid-resistant rejection to 250—500 mg
of 6-methylprednisolone (3 i.v. doses). OKT3 was administered in bolus of
5 mg/day for 10 days, except for two patients (one per group) who received
6 doses. The percentage of patients with panel-reactive antibody (PRA)
levels greater than 50% was higher in group I (57%) than in group R
(12%). A similar trend was observed for histologic lesions of vascular
rejection (80% vs. 69%). For patients in group R periods of 5 to 12 days
elapsed between the beginning of the steroid treatment and the adminis-
tration of OKT3. In all cases (with two exceptions, both in group R), the
rejection diagnostic was established during the two months immediately
after transplantation. A series of lymphocytes and T cell marker controls
was performed. Results: Efficacy. Agood recovery of renal function (Cr <
2.5) was observed in group I for 4 (57%) patients while 3 failed to show
any improvement. Likewise, in group R the treatment was successful in 12
(70%) cases, unsuccessful in 3 (18%), and partially successful in 2 (12%).
Both groups showed a stable renal function in patients with a good
response to treatment. There was only one case of rejection relapse.
Efficacy predictive factors. A late occurrence of rejection as well as of
infarction lesions in the allograft biopsy (43% vs. 7%, P 0.16) were
related to a bad response to treatment. Furthermore, no other clinical
difference was found. While the number of CD8 lymphocytes was higher
in patients who failed to respond to treatment, the serial evolution of the
rest of the T cell markers (CD3, CD4, CD2, and CD 19) was similar for all
of the patients. Adverse events. CMV asymptomatic activation 11 (46%),
CMV disease 2 (8%), herpes simplex virus infection 3 (12%), 1 B cell
lymphoma with EBV activation, and 1 aseptic meningitis. Conclusions:
The use of OKT3 as treatment of acute rejection has been efficient for
57% and 70% of the cases in groups I and R, respectively. The occurrence
of a late rejection, infarct lesions or high levels of CD8 has been associated
with a bad response to treatment. Additionally, a frequent and occasion-
ally symptomatic activation of CMV has been observed,
ALG versus OKT3 prophylaxis in kidney transplantation. A. Osuna,
f.M Osorio, M Biechy, M Palomares, .1. Bravo, A. Rubert, and C. Asensio,
Servicio de Nefrologia, Hospital Virgen de las Nieves, Granada, Spain. We
have performed a prospective randomized comparison of prophylaxis with
antilymphoblast globulin (ALU) and OKT3 in order to assess their
efficacy, results and complications in renal transplantation. From Decem-
ber 1990 to September 1992, 65 cadaver kidney allograft recipients were
treated with six doses of either ALG (10 mg/kg/48 hr, N = 33) or OKT3(5 mg/48 hr, N = 32) as part of a cyclosporin A and steroid low-dose
protocol. There were no significant differences between the groups in
terms of age, sex, number of HLA mismatches, or number of pre-
sensitized or regrafted patients. Patient and graft survival, rejection and
complications rates were:
ALG OKT3
First rejection 33% 22%
2nd rejection 9% 6%
Graft loss rejection 12% OP < 0.05
Graft survival
1 year 87% 86%
2 years 79% 67%
Symptomatic CMV infection 0 9%
Bacterial infection 33% 28%
Malignancy 0 6%
Patient survival
1 year 96% 92%
2 years 96% 81%
We conclude that incidence of allograft rejection and similar patient and
graft survival are achieved with both anti-lymphocyte therapies, but there
is a trend to a better response to rejection treatment and higher incidence
of CMV infection and malignancy in the OKT3 group.
Influence of cyclosporin on the induction of fibrogenesis of cellular
lines of renal origin. MT. Medina Cano, C. Ram frez Tortosa, J. Lopez
Hidalgo, M Andüjar Sanchez, M. Bustos de Abajo, A. Pelegrina Jimenez,
MD. Caracuel Ruiz, E. Vergara, and D. Aguilar Pena, Dept. of Pathology,
Faculty of Medicine, Granada, Spain. Background: CsA is the drug
generally used to induce tolerance in organ transplants. Nevertheless, its
secondary effects, mainly nephrotoxicity and gingival hyperplasia, make up
some of the most important complications experienced by the patient. In
the pathogenesis of both lesions the induction of fibrogenesis may occur,
either secondary to vascular alterations or due to the drug's direct
fibrogenetic effect. Experimental design: CsA's influence on collagen
synthesis and its proliferative capacity on different transformed cellular
lines of renal origin were studied, with the aim of testing the direct
fibrogenic action of CsA. Material and methods: The fibrogenesis and
proliferative capacity of CsA on the (fibroblastic) VERO cellular lines and
the MDCK (epithelial) were evaluated by measuring the incorporation of
timidine and proline labeled with tritium (activity 1 iCi/ml) on plates with
96 wells (4 X io cells/well) after 7 and 60 days after incubation with CsA
(base substance) at concentrations of 0.5 and 1 j.sg/ml. Secretion of type III
and IV collagen in these lines was determined by flow cytometly. Results:
After incubating the cultures with CsA there were no significant changes
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in the incorporation of labeled timidine and tritium labeled proline at 7
days. However, after an incubation period of 60 days we observed the
following: (a) the timidine reserve decreases [Vero cell line 2619 vs. 1960
counts/mm (cpm) at 1 g/ml, and MDCK cell line 1528 vs. 1276 cpm at 1
g/ml, P < 0.01 Student's t-test]; (b) Similarly, the proline reserve
decreases (Vero cell line 401 vs. 327 cpm at 1 .tg/ml, P < 0.001, Student's
t-test). After a 15 day incubation with CsA (0.5 g/ml), collagen IV
secretion decreases (Vero cell line 28.3 vs. 17.2 and MDCK line 27.1 vs.
5.4). Conclusions: (1) CsA does not produce a direct fibrogenetic stimulus
in vitro. (2) Its effect on the cell lines would be almost halved by
interruption of the nucleocytoplasmic signal restraining the incorporation
of labeled timidine in the nucleus and decreasing the incorporation of
labeled proline in the cytoplasm; the in vivo fibrogenic action of CsA could
be related to: (a) the inhibition of the synthesis of cytokinins such as
gamma-interferon, the principal regulator of collagen synthesis; and (b) an
ischemic vascular factor, probably dependent on the increased endothelin
secretion.
ALG versus OKT3 prophylaxis in renal transplant patients with high
immunological risk. J.M. Osorio, M Biechy, A. Osuna, E. Martinez, C.
Soriano, and C. Asensio, Servicio de Nefrologia, Hospital Virgen de las
Nieves, Granada, Spain. Introduction: Because of the higher incidence of
acute rejection (AR) and the lesser graft survival which occurs in
pre-sensitized and regrafted patients we have studied comparatively the
efficacy of prophylaxis with polyclonal (ALG) versus monoclonal (OKT3)
antilymphocyte therapies in 22 high immunological risk patients (HIRP)
who were grafted in our center from June 1988 to September 1992.
Material and methods: 15 patients were treated with ALG (6 doses, 10
mg/kg/48 hr) and 7 patients with OKT3 (6 doses, 5 mg/48 hr). Low doses
of cyclosporin A (8 mg/kg/day p.o.) and steroids were simultaneously
administered in both groups; 4 ALG patients and 3 OKT3 patients were
also treated with azathioprine (P = 0.46). Results: We did not find any
differences between groups in terms of age, sex, HLA matching, cold
ischemia time or the proportion of presensitized or regrafted patients.
Graft and patient survival, AR and other complications rates are summed
up as follows:
ALG (N = 15) OKT3 (N = 7)
AR incidence 5 (33%) 2 (28%) NS
AR appearance 62 56 days 14 0.7days
Steroid sensitivity 1(20%) 2 (100%) NS
Graft loss rejection 1(6%) 0 (0%) NS
Graft survival
1 year 86% 100% NS
2 years 86% 85.7% NS
CMV(+) culture 2 (13%) 4 (57%) P < 0.05
Symtom. inf. CMV 0 0
Bacterial inf. 7 (46%) 3 (43%) NS
Malignancy 1 (6%) 1(14%) NS
Pat, survival
1 year 100% 100% NS
2 years 100% 85.7P <0.05
Conclusions: There is not any difference between ALG and OKT3 in their
efficiency of preventing AR in our HIRP population. Similar rates of
infections and neoplastic complications are found in both groups, but the
patient survival decreases significantly in the OKT3 group after a period of
2 years.
Effect of pravastatin in the treatment of hypercholesterolemia after
renal transplantation under cyclosporin immunosuppression. A.M.
Castelao, J.M Gnñó, S. Gil Vemet, C. Fiol, M.J. Casteiñeiras, D. Serdn, J.
Torras, R. Garcia, and J. Alsina, Nephrology, URE and Biochemistiy
Departments, Hospital de Bellvittge, University of Barcelona, Barcelona,
Spain. We have studied the effect of the hydrophilic HMGCoA reductase
inhibitor pravastatin in our patients with persistent hypercholesterolemia
above 6.5 mmol/liter after 3 months of cholesterol diet restriction. All the
patients received cyclosporin A (C5A) and prednisone immunosuppres-
sion. Thirty-one patients (20 male, 11 female, 20 to 60 years old, average
age 46 9 years), received oral pravastatin (20 mg/day) in an evening
dose. Six patients were not included due to steroid diabetes or proteinuria
>3 g/day.
Before 6 months 12 months
P1. creatinine junollliter 147 48 141 53 131 71
Proteinuria glday 0.75 0.89 0.68 0.46 0.81 0.7








Triglycerides mmol/liter 2.38 1.47 2.46 1.84 2.18 0.13
Atherosclerotic index 0.17 0.05 24 0.12c 25 005d
HDL cholesterol mmol/liter 1.35 0.4 1.67 0.4 1.45 0.3
HDL2 cholesterol mmol/liter 0.91 0.02 1.25 0.3a 1.14 0.2
HDL3 cholesterol mmol/liter 0.91 0.02 1.25 0.3a 1.14 0.2
LDL cholesterol mmol/liter 5.04 0.53 9 1.2c 3.8 0.7e
VLDL cholesterol mmol/liter 0.76 0.4 0.55 0.5 0.58 0.4
Apo A 1 glliter 1.37 0.2 1.69 0.2a 1.63 0.2
Apo B g/liter 1.23 0.2 1.00 0.3 1.09 0.2
BMI (Quetelet index) 26.1 0.37 26.6 0.47 25.7 3.2
= 0.0001; bp < 0.001; P = 0.04; dp = 0.03; P = 0.009
No changes in CsA levels were seen, and one patient abandoned treat-
ment.
Influence of sodium ingestion on cyclosporin A induced chronic neph-
rotoxity: An experimental model in rats. A. Montes Puerta, M Anddjar
Sanchez, C. Ram frez Tortosa, C. Alemán Romero, MJ. Garcia Chicano, F.
O'Valle Ravassa, A. Gamdo Torres-Puchol, L. Lara Fortis, J. Rodriguez Gil,
J.L. Santos Perez, and R. Garcia del Moral, Dept. of Pathology, University
Hospital, Granada, and Nephrology Service and Clinical Analysis Service,
Virgen de las Nieves Hospital; Granada, Spain. Background: The chronic
nephrotoxicity (CNT) induced by cyclosporin A (CsA) causes progressive
deterioration of renal function and increases interstitial fibrosis (IF). The
influence of sodium levels on CNT is controversial. It has been suggested
that renal perfusion decreases on depletion of plasmatic volume in a
sodium-free diet, thus producing an increase in lesions. Experimental
design: The sodium-free diet catalyzed action (on CsA-induced CNT in
rats) has been evaluated. Material and Methods: Ninety Sprague-Dawley
male rats [30 control animals, 30 with a normal salt level diet, and 30 with
a sodium-free diet (Diet UAR 212)] were treated with CsA (8 mg/kg/day
in Alzet-2ML4 osmotic infusion pumps) for a three month period. The
animals were kept in metabolic cages and their weight, diuresis, blood
pressure, and plasmatic and urine biochemistry were determined every 15
days. Autopsies were carried out on batches of 10. Conventional histolog-
ical studies were undertaken and automatic quantification of IF by digital
image analysis (Visilog software) was carried out. Results: (1) The
glomerular filtrate in rats fed a sodium-free diet was less than in those fed
a normal diet (Cr = 0.69 0.27 mg% vs. 0.85 0.10 mg%; P < 0.05,
Student's t-test; control Cr = 0.61 0.02 mg%). (2) Blood pressure in rats
fed the salt diet became worse compared to the other animals (mean AT
of 152 12 mm Hg vs. 139 28 mm Hg in rats without salt and 121
9 mm Hg in the controls). (3) Similar results were observed for interstitial
fibrosis (6180 1407 mm2 versus 5625 1062 and 4360 362 per
microscopical field in the animals without salt and the control, respec-
tively; P < 0.05 ANOVA test). Conclusions: (1) A salt-free diet prevents
the development of CsA induced CNT in rats; (2) This effect is probably
related to the lower increase of blood pressure in these animals; (3) Those
animals fed a hyposodic diet and administered almost pharmacological
doses of CsA did not show any defect in secondary renal perfusion, or
depletion of the plasmatic volume as a result of hyponatremia.
Endothelin secretion by renal tubule MDCK cell line and cyclosporin A
induced modulation. K Garcia del Moral; M Aguilar Pena, M. Lucena
Rob/es, M Gómez Morales, M. T. Medina Cano, T. Caballero Morales, and
F. Revel/es Mann, Dept. of Pathology, Faculty of Medicine, Granada, Spain.
Background: Cyclosporin A (CsA) is potentially nephrotoxic. Increased
endothelin secretion by the kidney's endothelial cells has been shown to be
involved in the lesional pathogenesis of endothelin mechanisms. The
potent endothelin, vasoconstrictor action has been demonstrated by
clinical and experimental models, and its persistent release in subjects
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treated with CsA has been verified. It is known that endothelin is
synthesized and liberated by other cellular elements (epithelial cells,
mesangial cells, etc.). Experimental design: Endothelin secretion in the
dog permanent tubule kidney cell line (MDCK) and the changes induced
by the CsA were studied. Material and methods: Endothelin concentra-
tions in the MDCK cell line were determined by flow cytometry (Ortho
Cytoron Absolute) with an indirect immunofluorescence technique after a
30-day incubation with CsA. Monoclonal antibodies were used for N-type
endothelin (these recognize the common aminoterminal fragment for
both active endothelin and big-endothelin) and C-type endothelin (which
specifically recognizes the C terminal fragment of active endothelin).
Endothelin determinations were simultaneously carried out on culture
supernatants by RIA (Amersham Kit, UK). Results: A basal secretion of
endothelin was observed in 40.1% of the MDCK cells which went up to
79.9% and 73.7% in those treated with (1 g/ml) and (0.5 .rg/ml),
respectively. The modifications induced by both CsA concentrations were
similar, causing a simultaneous increase of in culture supernatants free
endothelin (206 pg/mi in control cultures vs. 497 pg/mI in cells treated with
CsA at 1 rg/m3 days). Conclusions: (1) There is a significant endothelin
secretion from the MDCK cell line of the renal tubule in basal conditions.
(2) CsA induces the secretion of this substance and its release into the
medium. This suggests the possible collaboration of this mechanism in the
genesis of interstitial ischemic phenomena in chronic nephrotoxicity
secondary to CsA.
Serologic and genomic markers of hepatitis C virus in renal transplan-
tation. J.L. GOrriz, L.M. Pallardó, A. Sarrión, J. Córdoba, J. Sanchez, D.
Gómez, and P. Sanchez, Departments of Nephrology and Microbiology,
Hospital Universitario La Fe, Valencia, Spain. Renal transplant patients are
a population at risk for hepatitis C virus infection. We have determined
the prevalence of hepatitis C virus antibodies (HCV-Ab) with ELISA 2
(Ortho') and INNOLIA (Innogenetics'), and the virus genoma (RNA-
HCV) with PCR technique, as well as its relation to the presence of
hepatitis. We determined HCV-Ab in 310 patients. RNA-HCV was
performed in 46 patients; 28 of them showed non-A, non-B hepatitis
(NANBH). ELISA screenings were positive in 138 patients (44%),
negative in 170 (55.9%) and indeterminate in 2 (0.6%). Patients with
ELISA 2 positive HCV-Ab were screened with INNOLIA test. Ninety-
nine (71.8%) were positive, 16 (11.6%) negative, and it was indeterminate
in 23 patients (16.6%). The prevalence of HCV-Ab was 31.9%. Sixty-four
(64.6%) of the 99 patients with HCV-Ab showed persistent elevation of
ALT/AST (P < 0.0001). The analysis of the different antigens in the
INNOLIA test showed that the reactivity with NS4 antigen (c-100) was
related to the presence of hepatitis (P = 0.012). RNA-VHC: Nineteen
patients (66%) with NANBH showed HCV-Ab. RNA-HCV was detected
in 14 of them (48.2%) and in 4 patients without HCV-Ab. In seventeen
patients without hepatitis, HCV-Ab was detected in 12 (70.5%), and
RNA-HCV in 9 of them (75%). Using serological and genomic markers,
80% of the NANBH were filiated as hepatitis C virus. In conclusion, we
observed a high prevalence of HCV-Ab in our series. PCR improved the
detection of hepatitis C virus and permits a better understanding of
hepatitis C virus infection in renal transplanted patients.
Hepatitis C virus in renal transplantation: Risk factors and prognostic
significance. J.L. Górriz, L.M. Pallardó, M Ba/lester, P. Sanchez, J. Sanchez,
E. Orero, and A. Rochera, Department of Nephrology, Hospital Universita,y
La Fe, Valencia, Spain. Hepatitis C virus (HCV) is believed to be the most
important cause of liver disease in recipients of a renal transplant. There
is not enough information about the risk factors and prognostic signifi-
cance in renal transplantation. We have analyzed the prevalence of HCV
in 454 patients transplanted from February 1980 to May 1992. HB5Ag,
toxic hepatitis and other etiologies were excluded. HCV was diagnosed in
95 (21%) in the presence of ALT/AST elevation twice what is normal in
addition to HCV antibodies (HCV-Ab; ELISA 2 plus INNOLIA). In 15
patients histological diagnosis was obtained. When HCV patients were
compared to the 264 patients without hepatitis, HCV patients were
characterized by more pretransplant blood transfusions (P = 0.0014), a
longer time on chronic dialysis (P = 0.0002), a more frequent diagnosis of
non-A, non-B hepatitis in dialysis (P < 0.0001), and azathioprine treat-
ment (P < 0.0001). Stepwise logistic regression showed that HCV
correlated with non-A, non-B hepatitis in dialysis (P < 0.0001) and with
azathioprine treatment (P < 0.0001). Histological diagnosis included 2
cirrhosis, 3 active chronic hepatitis, 3 hemosiderosis, and 3 minimal
change. HCV did not influence graft survival (P = 0.24), but it was
associated with a reduced patient survival (P = 0.0030, log rank test). In
conclusion, HCV was the most frequent cause of transplant-associated
liver disease. It was correlated with pretransplant risk factors and was
followed by an increased mortality rate.
Changes in the profile of the renal transplant recipients since intro-
duction of cyclosporin. L.M. Pallardó, P. Sanchez, J. Sanchez, I. Beneyto, F.
Ros, J. Crespo, and A. Rochera, Nephrology Dept., Hospital Universitario La
Fe, Valencia, Spain. In order to analyze the pattern of renal transplant
recipients since the introduction of CsA treatment in our unit, we have
studied the clinical, immunological and evolutive characteristics of 432
patients treated with a single protocol of CsA during the last seven years,
comparing the transplants performed from 1986 to 1989 (227 transplants)
and those performed between 1990 and 1992 (205 transplants). Transplant
recipients in the second period were characterized by an older age (P =
0.015). A greater percentage of recipients were considered moderate or
poor candidates for transplantation due to associated diseases (P =
0.0077), and because they had received less pretransplant blood transfu-
sions (P = 0.0000). The grafts came more frequently from multiorgan
donors (P = 0.0000), but less commonly the brain donor deaths were due
to trauma (P = 0.013). There were not significant differences in HLA
matching (P = 0.54), HLA sensitization (P = 0.052), percentage of
retransplants (P = 0.80), incidence of post-transplant renal failure (P =
0.12), and acute rejection (P = 0.31) episodes in the two periods analyzed.
Graft survival (P = 0.25) and patient survival (P = 0.45) were not different
in the two periods. In conclusion, in the CsA era we have not observed in
the second period analyzed a change in the immunological profile of the
patients in the presence of an increase in the recipient age, and with more
frequently associated diseases, without negative effects on transplant
results.
Prevalence and factors associated with normalization of arterial hyper-
tension in renal transplant patients. J. Sanchez Plumed, L.M Pallardó, P.
Sanchez Perez, I. Beneyto, F. Ros, J. Crespo, and A. Rochera, Nephrology
Dept., Hospital Universitario La Fe, Valencia, Spain. Arterial hypertension
constitutes a common complication in renal transplant recipients, and the
factors associated with it are well-known. However, the circumstances in
which hypertensive transplant recipients normalize their high arterial
pressure, without antihypertensive treatment, are less known. We have
analyzed the prevalence of normalization of post-transplant arterial
hypertension and the related factors in 243 renal transplant recipients.
The actuarial probability (Kaplan-Meier) to become normotensive in
hypertensive patients was 5% at one year, 10% at three years, and 15% at
five years. The probability of becoming normotensive was related to the
degree of HLA-DR+B compatibilities (P = 0.0058), immunosuppression
with CsA (P = 0.026), and trauma brain death of the donor, in front of
vascular death, (P = 0.045). There were no significant differences between
patients who normalized the arterial blood pressure and those who
remained hypertensive, in body weight, daily and cumulative doses of
steroids, serum creatinine levels, proteinuria, and doses and blood levels
of CsA (P> 0.050). In conclusion, renal transplanted patients with arterial
hypertension can normalize their arterial blood pressure, and this is
related to the degree of HLA compatibility, the immunosuppressive
treatment, and the etiology of donor brain death.
Analysis of the prognostic factors associated with late survival in renal
transplantation. P. Sanchez, L.M Pallardó, J. Sanchez, J. Garcia, I.
Beneyto, E. Orero, and J.M Cruz, Nephrology Dept., Hospital Universitario
La Fe, Valencia, Spain. The efficacy of the current immunosuppressive
protocols with cyclosporin (CsA) has been followed by a significant
increase in graft survival in the first year following renal transplantation,
but doubts persist about its benefits compared to azathioprine (Aza)
treatment, in the mean and long-term follow-up. The aim of this study was
to analyze the factors related to graft survival after the first post-transplant
year in 455 recipients of kidney transplants performed from February 1980
to December 1991. Late graft failure (52 cases) was related to acute
rejection episodes early post-transplant (P = 0.0000), immunosuppression
with azathioprine (P = 0.0001), and HLA-DR incompatibilities (P =
0.023). The presence of arterial hypertension and serum creatinine levels
higher than 2 mgJdl six and twelve months post-transplant was followed by
a reduced graft survival (P < 0.010).When deaths after the first year were
also considered as graft failures (29 cases), the pre-transplant clinical
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evaluation of the recipient, as a moderate or poor candidate due to
associated diseases, was associated with an increased risk of transplant
failure (P = 0.0013). In conclusion, acute allograft rejection early post-
transplant was the strongest factor associated with late graft failure, and a
persistent beneficial effect of CsA treatment in comparison to Aza
treatment was observed. A reduced allograft function and arterial hyper-
tension in the first year increased the risk of late failure. Mortality
contributed significantly to late transplant failure.
Prognostic significance of IgG flow cytometric cross-match in renal
transplantation. N Puig, L.M Pallardó, P. Sanchez, .1. Sanchez, I. GOmez,
A. Rochera, and J.A. Montoro, Nephrology Dept., Hospital Universitario La
Fe, and HLA Laborato,y, Centro de Transfusiones, Valencia, Spain. We
have evaluated the prognostic significance of the flow cytometric cross-
match (FCXM) in a series of 106 cadaveric kidney allograft recipients. The
transplants were performed in the presence of a negative T and B
lymphocytotoxic cross-match, with both current and historic sera (NIH).
The FCXM was made after transplantation using the same current sera
and separated T and B lymphocytes. We used Fab fragment anti-IgG
conjugated fluorescein, and the FCXM was considered positive when the
fluorescence values (mean, mode and % positive cells) were higher than
negative controls (X 3 SD). Acute rejection episodes (biopsy proven)
were diagnosed in 25 patients (23.5%), and after a follow-up of 12.0 6.1
months there were eight immunological losses (7.5%). The T FCXM was






T+ 6 3 (59) 1(16.6)
B+ 26 8 (30.7) 2(7.6)
T— 100 22(22.0) 7(7.0)
B— 61 13(21.3) 4(6.5)
Conclusions: In the presence of a negative T and B lymphocyte cross-
match (INH), the positivity of FCXM was not followed by a worse
prognosis.
The influence of acute rejection in lymphocyte subsets and activation
antigens in kidney transplants. J. Martin, A. Gascón, A. Orfao, and J.
Tabernero, Services of Nephrology and Hematology, University Hospital,
Salamanca, and Insalud Hospital, Avila, Spain. Twelve kidney transplant
patients were subjected to a sequential study on days 0, 3, 5, 15, 45 and 100
post-transplant, through direct IF and flow cytometry on different periph-
eral blood lymphocyte subsets and activation antigens using simple and
double labeling with monoclonal Ac against CD3, CD25, CD56, CD8,
CD4, CD11b, CD38, CD45RO, CD16, HLA-DR, TCRab and TCR.gs.
The patients were treated with OKT3 (5 mg i.v.) during the first 5 days,
CsA at adjusted dosage as from the 3rd day and prednisone as from day
0. Three patients suffered acute clinical rejection on days 21, 45 and 80
post-transplant. The study of the lymphocyte subsets and the activation
antigens were analyzed using analysis of variance for two factors (time and
rejection), verifying in these patients: (A) an increase in T lymphocytes
(CD3%) in patients with rejection all the days studied, (63.2 23.6% vs.
52.1 24.1%; P < 0.01), with an increase in the TCR-ab% most
pronounced on day 15 (71.1 5.7% vs. 55.2 16.4%); (B) an increase in
the TCR-gs cells, especially on days 45 and 100 [4.2 4.4% (135 179 X
106/ml vs. 2.6 2.3%; 75 81 x 106/ml; P = NS]. (C) a decrease in the
expression of the CD11b antigen as from day 15 (48 37% vs. 59.6
33.8%; P = NS); NA: 532 314 vs. 1258 856 x 106/ml; P < 0.01), with
a decrease in the CD8/CD11b lymphocytes at NA (148 85 X 106/ml vs.
403 279 x 106/ml; P < 0.01). (D) an early increase (days 3 and 5) of the
CD4 (day 3: 39.3 30.8% vs. 18.2 11%; day 5: 27.3 8.6% vs. 18.6
9.5%; P < 0.01); with an increase of the CD4/CD45RO (day 3: 14.3
8.5% vs. 7.4 3.1%; day 5: 19.6 8.7% vs. 12 7.6%; P < 0.05). (E) The
expression of the NK antigens was smaller as from day 15 (CD56: 191
166 X 106/ml vs. 330 246 x 106/ml; P < 0.1) and CD16 (147 90 X
106/ml vs. 406 316 x 106/ml; P < 0.05); with less activated NK
(CD16/HLA-DR: 47 52 >< 106/ml vs. 146 195 x 106/ml; P = NS).
Paradoxically, we also observed a slight decrease in the expression of
HLA-DR: 132.8 11.3% vs. 41.2 15.9% (NA: 464 476 X 106/ml vs.
663 615 x 106/ml; P = NS)]. No variations were found in the expression
of the activation antigens CD25 and CD38. Conclusions: Acute rejection
elicits increased T lymphocyte levels in peripheral blood, with an early rise
in the CD4 subset accompanied by a decrease in CD4/CD45RO (memosy)
and a decrease in the CD8/CD11b (suppressor) subset; no alterations are
seen in CD8. The lower late expression of NK and HLA-DR antigens may
be affected by the i.v. injections of MP. The monitoring in peripheral blood
of CD4/CD45RO and CD8/CD11b may be of greater clinical value than
that of HLA-DR and CD25.
Formation of anti-OKT3 antibodies (IgG) in patients receiving kidney
transplantation and its effect on peripheral blood lymphocyte subsets. J.
MartIn, A. Gascón, A. Orfao, J. San Miguel, and J.M. Tabernero, Services of
Nephrology at the Hospital of Nuestra Sra. de Sonsoles, Avila, and The
University Hospital in Salamanca, Salamanca, Spain. Anti-OKT3 antibody
levels were determined in 12 patients receiving cadaver kidney transplan-
tation using the following immunosuppressor protocol: OKT3 (days 0 to
+5), cyclosporin A (from day +3), and prednisone (from day 0). Periph-
eral blood samples (PB) were obtained for the determination of levels of
anti-OKT3 antibodies (using an ELISA technique) on days +5, +15, +45
and + 100 post-transplantation. On the same days, the distribution of
different lymphocyte subsets and activation antigens was studied by direct
immunofluorescence and at flow cytometry. Five patients had elevated
levels of anti-OKT3 antibodies. In three cases, the titers were higher than
100 ng/ml. Upon analyzing the different lymphocyte subsets with respect to
the pre-transpiantation period, an increase was observed in T CD3+
lymphocytes (70.4 12.1%; 2010 1.554 vs. 56.4 22.8%; 1160 952;
P NS) which was more marked on day +5 in the two patients with the
highest titers. The expression of the TCR a/ receptor was also higher (60
15%; 1648 1369 vs. 48,7 29%; 1001 900 X 109/liter; P = NS). The
TCR g/d subset was significantly more elevated both in percentage and in
the absolute number of lymphocytes (2.6 2.9%; 101 129 vs. 1.8
2.4%; 38 69 x 109/liter; P < 0.01). Other subsets, such as that of CD4+
and CD4/CD45RO+ lymphocytes, were also elevated (41.5 9%; 1045
698 vs. 30.6 14%; 586 534 X 109/liter; P < 0.05, and 27.6 8.9%; 747
670 vs. 20.2 9.9%; 374 320 x 109/liter; P < 0.05), respectively.
Finally, a slight increase was observed in CD8+ lymphocytes (NS) and
cells expressing the CD25+ antigen (20.7 10.3%; 546 579 vs. 16.4
11.5%; 285 273 x 109/liter; P < 0.01). No differences were seen in the
rest of the subsets analyzed (CD3/CD25, CD9/CD11b, CD8/CD38, CD16/
HLA-DR, CD3/CD56). In summaly, our findings suggest that anti-OKT3
antibody levels are associated with an early rise in the T-CD3+ lympho-
cyte subsets, both TCR a//3 and TCR g/day mainly due to an increase in
CD4+ and CD4+/CD45RO+ cells.
Effect of i.v. bolus injections of MP on different lymphocyte subsets and
activation antigens in renal transplantation patients. J. MartIn, A. Gas-
con, A. Orfao, J. Ciudad, and J. Tabernero, Services of Nephrology and
Hematology, University Hospital, Salamanca, and Insalud Hospital, Avila,
Spain. Five patients who had undergone cadaver renal transplantation
were treated with 7 series (4 on day 15 and 3 on day 45th) of 3 bolus MP
(500 mg i.v.) injections, due to a rise in their serum Cr levels and the
suspicion of acute rejection. The rejection was not confirmed, because the
rises in Cr levels were due to other causes. A sequential study was carried
out on days 0, 3, 5, 15, 45, and 100 post-transplantation, by direct
immunofluorescence and at flow cytometry of lymphocyte subsets and
activation antigens in peripheral blood using simple and double labeling
with monoclonal antibodies against: CD3, CD25, CD56, CD8, CD4,
CD11b, CD38, CD45RO, CD16, HLA-DR, TCR-a13 and TCR-gb. The
following immunosuppressive treatment was employed: OKT3 on the first
5 days, cyclosporin A from the 3rd day, and prednisone from day 0.
Another five patients who did not receive bolus injections of MP served as
a control group. The study revealed the following: (A) a slight increase in
T lymphocytes (CD3) on day 45 (79 3.8 vs. 66.6 10.4%, P = NS),due
to an increase in the CD3/FCR-a13 (2502 327 vs. 1570 1644 X 106/ml,
P = NS). (B) A greater expression of CD11b on day 45 (70 10.7 vs. 35.2
26.9%; 2433 404 vs. 680 411 X 106/ml; P < 0.01) with an increase
in CDS/CD11b suppressor T cells (704 273 vs. 257 185 X 106/ml; P <
0.05). (C) An increase in CD4 (45.3 7 vs. 29.6 7.6%; P < 0.05; 1565
190 X 106/ml vs. 795 875 X 106/ml; P = NS), with no variation in
CD4/CD45RO cells. (D) A clear decrease in antigens defining NK cells on
days 15 and 45: CD56 (8.4 4.8 vs. 14.7 7.3%; 175 70 vs. 300 77
x 106/ml; P < 0.01); CD16 (10.4 6.9 vs. 19.5 9.9%; 213 218 vs. 454
355 X 106/ml; P < 0.01), with a decrease in CD16/HLA-DR activated
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NK cells (3.1 2.1 vs. 8.3 7.7%; 79 78 vs. 234 285 x 106/ml; P <
0.01). (E) A decrease in TCR-g/d cells (1.3 1.8 vs. 2.8 2.6%; 12 62
vs. 83 85 X 106/ml; P = NS). Conclusions: i.v. bolus injections of MP
lead to the following: (1) an increase in T lymphocytes with a greater
expression of antigens linked to suppressor activity and of CD4 inducing
suppression; (2) a weaker expression of NK antigens with fewer activated
NK cells; (3) fewer TCR-gd cells.
Effect of immunosuppressor treatment on peripheral blood lymphocyte
subsets in kidney transplantation: A sequential study. A. Gascón, J.
MartIn, A. Orfao, J.L. Lerma, B. Leon, and J.M Tabernero, Nephrology
Service of the 55 Hospital, Avila, and Services of Nephrology and Flow
Cytomet,y, The University Hospital of Salamanca, Salamanca, Spain. The
present study reports a sequential analysis of the phenotype of T and
natural killer (NK) lymphocyte subsets from peripheral blood (PB) in a
group of 12 patients with terminal chronic renal failure on hemodialysis
who had undergone renal transplantation (RT). The patients were treated
uniformly with OKT3 (from day 0 to day +5), cyclosporin A (from day
3+), and prednisone (from day 0). Lymphocyte subsets (LS) were studied
at flow cytometry prior to and after kidney grafting on days 0, +3, +5,
+ 15, +45 and + 100. The immunosuppressor treatment was seen to elicit
a decrease in the total number of PB lymphocytes, affecting T and NK cells
(P < 0.0001 and P < 0.01, respectively) and the main LSs were: CD4+ (P
< 0.001), CD8+ (P < 0.001), CD4+/CD45RO+ (P < 0.001), CD8+/
CD38+ (P < 0.01), CD8+/CD11b+ (P < 0.005), CD3+/CD56+ (P <
0.05), TCR a/j3 (P < 0.001) TCR gld (P < 0.01). However, it should be
noted that this effect was more pronounced in T CD3+ lymphocytes (1168
vs. 109 x 109/liter) than in NK cells (283 vs. 70 x 109/liter). On day +5
post-RT, a discrete increase in the antigen expression of the different LSs
was observed, this being more evident on day + 15. At this time, some LSs
had reached levels similar to those observed pre-RT, such as CD4+,
CD8+/CD11b and CD4+/CD45RO+. However, the expression of acti-
vation antigens such as CD3+/CD25+, CD25+ alone and CD16+/
HLA-DR was more marked on day + 15 than pre-RT. On day +45, most
of the LSs were observed to have recovered normal values and there was
even a slight increase in T CD3+ (P < 0.05), and in CD3+1CD56+ (NS),
TCR (a/f3) (NS), TCR gld (NS), CD8+/CD38+ (NS), CD8+ (P < 0.05)
and HLA-DR+ (P < 0.05). Finally, on day + 100, with respect to pre-RT
there was an increase in the PB lymphocyte counts and in CD3+/CD25+
(NS), CD25+ (NS), CD3+/CD56+ (P < 0.05), CD3—/CD56+ (P <
0.05), TCR a/j3+ (NS), TCR g/d+ (NS), CD8+ (P < 0.05), CD8+/
CD38+ (NS), CD16+ (P < 0.05), CD4+/CD45RO+ (NS), HLA-DR+
(P < 0.05) and CD16+/HLA-DR± (NS), whereas CD11b and CD8+/
CD11b+ were discretely decreased and there were no appreciable
changes in CD4+. Our results show that the recovery times of the different
LSs analyzed are different and should be taken into account when this
methodology is applied in immunological evaluation of graft rejection.
Effects of i,2-dimethyl-3-hydroxipyrid-4-one (Li) on cell proliferation.
R. Elorriaga, P. Menéndez Fraga, M.L. Naves, and J.B. Cannata, Bone and
Mineral Research Unit, Hospital Central de Asturias, Oviedo, Spain. Several
studies have shown that desferrioxamine (DFO), a chelating agent with
some similarities to Li, inhibits cell proliferation, and the effect is iron
dependent. Li has been shown to be as effective as DFO in removing iron
and aluminum. Thus, the aim of this study was to evaluate the effect of LI
on osteoblast proliferation using the cell line MG-63. The cell prolifera-
tion was measured after 24 hours by adding different concentrations of Li
(1, 2, 20, 100, 120, 150, 180, 200 and 300 /.tM) and DFO (1, 2, 5, 10, 20, 40,
100 sM) to the cultured medium. The decrease in the cell proliferation
began with 2 sM of Li and 5 rM of DFO. With 150 M of Li and 20 j.M
of DFO the inhibition was about 50%, whereas with 300 tM of Li and 100
sM of DFO the inhibition was 98%. The decrease in cell proliferation was
present with iron incubations in equimolar concentrations. The results
demonstrate that Li induces a reduction in osteoblast-like cell prolifera-
tion. As with DFO the effect is iron-dependent.
The dialysis fluids as a source of aluminum in hemodialysis: influence
in serum aluminum levels. W. Douthat, G. Acufla, J.L. Fernández MartIn,
M Se,rano, and J.B. Cannata, Bone and Mineral Research Unit, Hospital
Central de Asturias, Oviedo, Asturias, Spain. Although there are many
sources of aluminum exposure in dialysis patients, the high aluminum
levels in dialysis fluids due to poor water treatment still remains the most
dangerous source of aluminum contamination. The aim of this study was
to evaluate throughout 5 years from October 1988 to May 1993 the
concentration of aluminum in dialysis fluids and serum in 12 dialysis units.
During that period the units studied regularly sent 2546 samples of serum,
69 of untreated water, 111 of treated water (reverse osmosis) and 179
samples of the final solution of dialysis (treated water + concentrate). We
found that the serum aluminum concentration decreased from 1988 to
1992, parallel to the reduction in the concentration of aluminum in the
final solution for dialysis. The mean serum aluminum achieved in 1992 was
39.1 jg/liter and the mean value of aluminum in the final solution for
dialysis was 1.1 pg/liter. In the first quarter of 1993 the concentration of
aluminum in the final solution for dialysis increased to a mean value of 4.6
1.5 .rg/liter. This small increment in the final solution for dialysis was
enough to induce increments in serum aluminum levels. These results
confirm the fact that the aluminum concentration in the final solution for
dialysis must be maintained under 4 j.g/liter. Due to effective measures of
prevention of aluminum toxicity, the mean serum aluminum found in most
patients is close to 40 .tg/liter. In these circumstances, as only 10% of the
total serum aluminum is dialyzable, if the fluids exceed this limit (4
jsglliter), there is a real risk of aluminum transfer from the fluid to the
patient. Therefore, a frequent and rigorous water and fluid monitoring is
mandatory to prevent aluminum exposure through dialysis fluids.
Aluminum (Al) removal with a hemoperfusor (HP) containing desfer-
rioxamine (DFO). G. Acuna, W. Douthat, fL. Fernández MartIn, and J.B.
Cannata, Bone and Mineral Research Unit, Hospital Central de Asturias,
Oviedo, Spain. Previous studies have shown controversial results in Al
removal using charcoal cartridges and HP. The HP used in this study
(Al/Fe Clark specific) has a hydrogel which contains DFO. Since DFO is
already in the HP it would not be necessary to infuse DFO into patients
to remove Al. The aim of this study was to evaluate the Al removal using
this device. We simulated a dialysis perfusing the DFO-HP (N = 10) with
plasma in biological conditions (37°C, pH 7.38—7.40) with a known
concentration of Al (starting with 150 zWliter). In the first phase the Al
removal was evaluated after a single pass and in the second phase after
recirculating the plasma through the DFO-HP during 105 minutes (flow of
60 and 120 mI/mm). In the third phase we recirculated the plasma during
the same period but without a DFO-HP on the circuit (N = 3). Plasma Al
was measured before and after, 30, 60, 90, and 105 minutes of using the
DFO-HP. Plasma Al did not decrease using DFO-HP; by contrast the final
plasma Al increased significantly (P < 0.003). The recirculation with no
DFO-HP showed no changes in plasma Al. Iron parameters did not show
any changes. The content of Al of the DFO-HP was investigated, finding
691.76 sg/g of Al (about 7 mg of Al on each DFO-HP). In this study
DFO-HP did not extract Al from the plasma; on the contrary, it seems to
release Al to the plasma, likely due to the high affinity of plasma protein
for aluminum.
Ultrafiltrable aluminum in human serum: An in vitro comparative
study between desferrioxamine and a new chelator i,2-dimethyl-3-hy-
droxypyrid-4-one (Li). fL. Fernández MartIn, J. Perez Parajon, P. Menén-
dez Fraga, R. Elorriaga, and J.B. Cannata, Bone and Mineral Research Unit,
Hospital Central de Asturias, Oviedo, Spain. Ultramicrofiltration tech-
niques were used to study the binding of aluminum to heavy molecular
weight proteins in the presence of different concentrations of desferriox-
amine and 1,2-dimethyl-3-hydroxypyrid-4-one (Li) and the kinetics of
aluminum release from human serum proteins. Human serum from
healthy volunteers was used in all studies. The serum was spiked with
aluminum (100 jig/liter) and different concentrations of chelators. Ultra-
microfiltration was performed using Amicon YMT membranes which had
a nominal cutoff of 30,000 Da. Aluminum was measured by graphite
furnace atomic absorption spectrometry in total serum and ultrafiltrated
fluid. Li shows a higher capability to displace aluminum from serum
proteins (80%) than desferrioxamine (60%). The kinetics of the release
were also faster for Li, taking 20 minutes to achieve its maximum effect,
whereas desferrioxamine achieved only 80% of its maximum effect after
two hours. Thus, Li could be an attractive alternative to desferrioxarnine
as an aluminum chelator agent.
Aluminum histomorphometric effects in rats with normal renal func-
tion. C. Gómez Alonso, P. Menéndez RodrIguez, MJ. Virgós Soriano, P.
Menéndez Fraga, M. Naves DIaz, and J.B. Cannata Andla, Bone and Mineral
Research Unit, Hospital Central de Asturias, Oviedo, Spain. In previous
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studies a different effect of aluminum (Al) on bone metabolism in animals
with chronic renal failure (osteomalacia, aplastic bone) and in animals
with normal renal function (positive osteogenic effect) has been demon-
strated. The aim of this study was to evaluate the aluminum histomorpho-
metric effects (structural and functional parameters) in osteoporotic rats
with chronic aluminum administration. In 18 male Wistar rats we induced
osteoporosis administered during 6 months NH4C1 (2%) in the drinking
water. After this period the rats were divided in three groups (G) and
followed during 4 months. Gi continued with NH4 Cl oral administration
(N = 5); in 02 we stopped NH4CI administration and they received
intraperitoneal AId3 (10 mg/kg/S days per week) (N = 8); in G3 we
stopped the NH4CI administration and they did not receive any compound
(N = 5). In all animals we investigated biochemical markers (serum Ca, P,
Cr, Al, osteocalcin, hydroxyproline) as well as bone mineral density
measurements and bone histomorphometric studies in tibiae, femur and
lumbar and caudal vertebrae [trabecular bone volume (TBV), cortical
thickness (CT), formation area (FA), osteoid thickness (OT), and osteo-
clastic index (01)1. We observed significant differences in the bone
formation in the aluminum overloaded group (G2) compared with the
others groups, such as an increase in TBV and in CF with a moderate
increment of the osteid thickness as well as changes in other parameters.
Tibiae Gi G2 03
TBV 7.28 3.80 18.59 5.66a 7.69 3.08
CT 0.23 0.04 0.52 0.06 0.36 0.07
FA 1.01 0.037a 3.79 2.58 2.04 0.11
OT 3.50 0.64a 14.05 4.72 5.25 0.90
0! 3.65 1,93 2.44 0.52 1.30 0.01
<0.05
These findings indicate that Al induces, in rats with normal renal function,
trabecular bone formation even when osteopenia is present.
